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ABSTRACT 
The present invention involves methods and devices which 
enable discrete objects having a conducting inner core, 
surrounded by a dielectric membrane to be selectively 
inactivated by electric fields via irreversible breakdown of 
their dielectric membrane. One important application of the 
invention is in the selection, purification, andlor purging of 
desired or undesired biological cells from cell suspensions. 
According to the invention, electric fields can be utilized to 
selectively inactivate and render non-viable particular sub- 
populations of cells in a suspension, while not adversely 
affecting other desired subpopulations. According to the 
inventive methods, the cells can be selected on the basis of 
intrinsic or induced differences in a characteristic electropo- 
ration threshold, which can depend, for example, on a 
difference in cell size andlor critical dielectric membrane 
breakdown voltage. The invention enables effective cell 
separation without the need to employ undesirable exog- 
enous agents, such as toxins or antibodies. The inventive 
method also enables relatively rapid cell separation involv- 
ing a relatively low degree of trauma or modification to the 
selected, desired cells. The inventive method has a variety of 
potential applications in clinical medicine, research, etc., 
with two of the more important foreseeable applications 
being stem cell enrichmentlisolation, and cancer cell purg- 
ing. 
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(57) 
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A number of cell isolation, cell separation, and cell 
purging strategies have been employed in the prior art for 
purifying or removing cells from a suspension. Prior art cell 
separation methods used to isolate cells or purge cell sus- 
s pensions typically fall into one of three broad categories: 
physical separation methods typically exploit differences in 
a physical property between cell types, such as cell size or 
density (e.g. centrifugation or elutriation); chemical-based 
methods typically employ an agent that selectively kills or 
10 purges one or more undesirable cell types; and affinity-based 
methods typically exploit antibodies that bind selectively to 
marker molecules on a cell membrane surface of desired or 
undesired cell types, which antibodies may subsequently 
enable the cells to be isolated or removed from the suspen- 
1s sion. While physical separation methods can be advanta- 
geous with regard to their ability to separate cells without 
causing undo damage to desired cells, current physical 
separation methods typically have relatively poor specificity 
and do not typically yield highly purified or highly purged 
20 cell suspensions. While many chemical and affinity methods 
have better selectivity than typical physical methods, they 
can often be expensive or time consuming to perform and 
can cause considerable damage to, or activation of, desired 
cells, for example stem cells, and/or can add undesirable 
2s agents to the purified or isolated cell suspensions (e.g. 
toxins, proliferation-inducing agents, and/or antibodies). An 
additional potential problem with antibody-based cell sepa- 
ration techniques typically employed for purification of stem 
cells, is that they select stem cells solely on the basis of cell 
30 surface markers (e.g., CD34) and will not select cells lacking 
such markers. 
In addition to cancer therapy, there are a number of other 
important medical therapies which exist, or are under 
development, that are based on cells derived from a variety 
3s of different types of stem cells. Examples include pre- 
exposure prophylaxis or post-exposure therapies under 
development for a variety of biological exposures that may 
occur naturally (e.g., viral exposure for example with Ebola, 
etc.) or be inflicted by mankind (i.e., biological warfare 
40 agents). A variety of gene therapies involving genetically 
manipulated stem cells, are being contemplated or are under 
development for treating a variety of blood-related diseases 
(e.g., AIDS, leukemia, other cancers, etc.). Gene therapy 
techniques based on genetically manipulated stem and/or 
4s germ cells may also be useful in cloning organisms, such as 
animals. However, genetically manipulating stem cells using 
many current technologies is difficult, typically employing 
viruses or gene carriers that can be time consuming and 
expensive, or may be dangerous to perform and may not 
SO have high yields. Current research findings also suggest that 
the practical implementation of animal organ transplants 
into human recipients also may require procedures involving 
stem cells from both the donor and recipient. Many of these 
promising therapies would require cryopreservation and 
ss storage of donor specimens including human stem cells, for 
example, as derived from the stem cell-rich umbilical cord 
blood of newborns, which can provide such donors with a 
therapeutic basis for hematopoietic reconstitution or gene 
therapy should a health emergency occur later in life. If such 
60 storage demands are to be realistically met, the specimens 
will need to have minimal volume, and, therefore, successful 
implementation of such technologies may rest on the devel- 
opment and availability of effective methods for isolating 
trace numbers of stem cells from sources such as umbilical 
65 cord blood and the fetal liver. In order to achieve broad 
implementation of the therapies discussed above and others, 
rapid and cost effective methods are needed to isolate, with 
1 
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This application is a division of U.S. application Ser. No. 
091148,620, filed Sep. 4, 1998, now issued as U.S. Pat. No. 
6,043,066 granted Mar. 28,2000, which claims priority from 
provisional specification 601057,809 filed Sep. 4, 1997, the 
subject matter of which is incorporated herein by reference. 
This invention was made with government support under 
subcontract no. 04027 awarded the National Technology 
Transfer Center at Wheeling Jesuit University supported by 
the Ballistic Missile Defense Organization, Technology 
applications Program-NASA Cooperative Agreement no. 
NCC W-0065. The government has certain rights in the 
invention. 
FIELD OF THE INVENTION 
This invention relates to methods and apparatuses for 
selecting specific cell types from cell suspensions, specifi- 
cally those employing applied electric fields. 
BACKGROUND OF THE INVENTION 
The ability to isolate specific sub-populations of cells 
from cell suspensions is of critical importance to many 
applications in the biological sciences as well as to many 
therapies in clinical medicine. For example, the basis of 
many medical therapies for treating a variety of human 
diseases and for countering the effects of a variety of 
physiological injuries involves the isolation, manipulation, 
expansion, and/or alteration of specific biological cells. One 
particularly important example involves the reconstitution 
of the hematopoietic system via bone marrow or progenitor 
cell transplantation. More specific examples include: 
autologous, syngeneic, and allogenic stem cell transplants 
for immune system reconstitution following the myeloabla- 
tive effects of severe high dose chemotherapy or therapeutic 
irradiation; severe exposure to certain chemical agents; or 
severe exposure to environmental radiation, for example 
from nuclear weapons or accidents involving nuclear power 
generators. 
Intensive chemotherapy and/or irradiation for the treat- 
ment of a variety of cancers, including breast cancer, has 
become a commonly used approach in cancer care centers. 
Such treatments are associated with severe ablation of the 
bone marrow cells required for function of the blood and 
immune systems. Such bone marrow cells are derived from 
a small number of progenitor cells known as hematopoietic 
stem cells in the normal bone marrow. Therefore, patients 
receiving such therapies require life-saving transplants of 
stem cells in order to survive the effects of the treatment. 
Stem cell containing tissue for transplant may be derived 
from donor marrow (allogeneic transplant) or from the 
patient’s own bone marrow or peripheral blood after mobi- 
lization (autologous transplant). In both instances, there is a 
need for effective cell separation methods to enrich the 
transplant tissue in stem cells and reduce the number of 
undesirable and deleterious cells (e.g. mature T cells for 
allogeneic transplants and residual cancerous cells for 
autologous transplants). For example, for autologous adju- 
vant stem cell transplant therapy following myeloablative 
cancer treatments, it is believed that reinfusion of residual 
tumor cells is a major cause of post therapy relapse. Clearly, 
removing such cells from transplanted tissue would be 
beneficial to the patient. 
US 6,589,786 B3 
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high purity, desired target cells from suspensions having a 
diverse mix of cell types and concentrations. 
The use of applied electric fields to physically manipulate 
cells is known. Applied electric fields have been employed 
in the prior art for cell inactivation and sub-lethal cell 
membrane electroporation. For example, U.S. Pat. 5,048, 
404 to Bushnell discloses a system and method for steriliz- 
ing liquid foodstuffs by killing microorganisms with expo- 
sure to pulsed electric fields. 
Sale and Hamilton (“Effects of High Electric Fields on 
Microorganisms I. Killing of Bacteria and Yeasts,” Biochim 
et Biophys Acta, 148:781 (1967); and “Effects of High 
Electric Fields on Microorganisms 11. Mechanism of Action 
of the Lethal Effect,” Biochim et Biophys Acta, 148:789 
(1967)) studied the effect of pulsed electric fields on sus- 
pensions of bacteria or suspensions of yeasts. Specifically, 
they investigated the effect on the degree of cell kill by the 
field as a function of field strength and exposure time. The 
effect of pulsed electric fields on the killing of bacteria was 
also studied by Hulsheger et al. (“Lethal Effects of High- 
Voltage Pulses on E. Coli K12,” Radial Envivon Biophys, 
18:281(1980); and “Killing of Bacteria with Electric Pulses 
of High Field Strength,” Radial Envivon Biophys, 20:53 
(1981)). Hulsheger et al. studied the effects on bacterial cell 
death of a variety of experimental parameters and were able 
to demonstrate a 99.9% reduction in the number of living 
bacterial cells in suspensions after exposure to certain pulsed 
electric field parameters. 
The lysis of erythrocytes in erythrocyte suspensions by 
pulsed electric fields has also been studied both for bovine 
(Sale and Hamilton, “Effects of High Electric Fields on 
Microorganisms 111. Lysis of Erythrocytes and Protoplasts,” 
Biochim et Biophys Acta, 163:37 (1967)) and human 
(Kinosita and Tsong, “Voltage-Induced Pore Formation and 
Hemolysis of Human Erythrocytes,” Biochim et Biophys 
Acta, 471:227 (1977); and Kinosita and Tsong, “Hemolysis 
of Human Erythrocytes by a Transient Electric Field,” Pvoc 
Nut1 Acad Sci. 74:1923(1977)) erythrocytes. Knowledge 
derived from the studies above indicates that applied electric 
fields resulting in cellular transmembrane potentials on the 
order of 1 Volt can result in colloidal osmotic lysis of the 
erythrocytes. 
Electric fields have also been used to sublethally porate 
the plasma membrane of nucleated cells, such as leukocytes 
and Chinese Hamster Ovary (CHO) cells (Sixou and TeissiC, 
“Specific Electropermeabilization of Leukocytes in a Blood 
Sample and Application to Large Volumes of Cells,” Bio- 
chim et Biophys Acta, 1028:154 (1990)). Sixou and TeissiC 
investigated electropermeabilization conditions to enable 
reversible poration of cell membranes, while maintaining 
long-term cell viability, for the purpose of enabling the 
reversibly porated cells to uptake drugs and act as immu- 
nocompatible drug delivery vehicles within the body. Sixou 
and TeissiC studied the effect of pulsed electric field param- 
eters on the reversible poration of suspensions comprising 
single cell types and suspensions comprising mixtures of 
two cell types (e.g. CHO cells and erythrocytes, and leuko- 
cytes and erythrocytes). The authors showed that reversible 
electropermeabilization is a function of the cell size and that 
large cells are reversibly porated at lower electric field 
strengths than small cells. 
While the above mentioned methods and systems for cell 
separation and cell electropermeabilization represent, in 
some cases, valuable and useful techniques for some 
applications, there remains a need in the art for simple, fast, 
and clean methods to selectively isolate or remove specific 
4 
cell sub-populations from cell suspensions without causing 
undo damage or activation to the remaining cells and 
without employing undesirable or toxic agents. 
5 SUMMARY OF THE INVENTION 
Accordingly, the present invention can provide relatively 
simple, fast, and clean methods for cell isolation or purging 
based on physical differences between different cell types 
present in a suspension. Furthermore, the invention provides 
lo systems and methods that enable selective isolation of viable 
cells, selective cell inactivation, as well as stem cell 
electropermeabilization, using applied electric fields. 
In one aspect, the invention provides a method for crest- 
ing from a biological sample having a given cell population, 
a suspension of cells that contain a selected viable subpopu- 
lation of the given cell population. The method is based on 
a characteristic electroporation threshold of the cells. The 
subpopulation of cells selected by the method is substan- 
tially limited to cells that have a characteristic electropora- 
tion threshold that is greater than a predetermined electropo- 
ration threshold. The selected suspension of cells is 
produced from the biological sample by first subjecting the 
sample to an electric field that has a magnitude that is 
sufficient to porate a substantial fraction of the cells in the 
sample that have a characteristic electroporation threshold 
less than the predetermined electroporation threshold. The 
electric field, however, does not porate a substantial fraction 
of cells that have a characteristic electroporation threshold 
3o greater than the predetermined electroporation threshold. 
Essentially, all of the porated cells in the sample that is 
subjected to the electric field are also inactivated. 
In another aspect, the invention provides a method for 
creating a selected subpopulation of discreet objects from a 
3s sample having a given population of discreet objects. A 
discreet object comprises an inner conductive core which is 
surrounded by a dielectric membrane. The method is based 
on a characteristic electroporation threshold of the discrete 
objects. The subpopulation of discrete objects selected by 
4o the method is substantially limited to discrete objects that 
have a characteristic electroporation threshold that is greater 
than a predetermined electroporation threshold. The selected 
suspension of discrete objects is produced from the sample 
by first subjecting the sample to an electric field that has a 
4s magnitude that is sufficient to cause irreversible dielectric 
breakdown of the dielectric membrane of a substantial 
fraction of the discrete objects in the sample that have a 
characteristic electroporation threshold less than the prede- 
termined electroporation threshold. The electric field, 
so however, does not cause irreversible dielectric breakdown of 
the dielectric membrane of a substantial fraction of cells that 
have a characteristic electroporation threshold greater than 
the predetermined electroporation threshold. 
In yet another aspect, the invention provides a method for 
5s porating cells. The method includes supplying a suspension 
of cells in a treatment volume, where the treatment volume 
includes at least two electrodes that are in fluid contact with 
the suspension. The method further involves applying a time 
varying bi-polar electrical potential across the electrodes 
60 that is sufficient to create an electric field that is sufficient to 
porate at least one cell in the suspension. The bi-polar 
electrical potential is varied so that the average current 
across the sample over the entire treatment time is essen- 
tially zero. 
In another aspect, the invention provides the method for 
reversibly porating stem cells. The method involves supply- 
ing in a treatment volume a suspension of cells including a 
1s 
20 . 
2s 
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plurality of stem cells, which stem cells have a characteristic In another aspect, the invention provides a cell suspension 
size, a characteristic shape, a plasma membrane, and a comprising a plurality of non-cultured biological cells, 
nuclear membrane. A pulsed electric field that has a pulse including a plurality of viable stem cells that have a given 
duration and magnitude sufficient to Porate the Plasma characteristic size, suspended in a liquid. The cell suspen- 
membrane of a cell having a characteristic size and shape s sion further includes a plurality of irreversibly porated cells, 
essentially identical to the stem cells, but having an effective essentially all of which irreversibly porated cells have a 
membrane thickness of the plasma membrane of the stem of the stem cells, 
cells is then applied to the suspension. 
In another aspect, the invention involves a system for 
creating from a biological sample having a given cell troporated stem cells. population, a suspension containing a selected viable sub- 
population of the given cell population. The selected cell a suspension 
population is substantially limited to cells that have a comprising human  p lu r ipo ten t  'ympho- 
characteristic electroporation threshold greater than a pre- hematopoietic stem cells, which are capable of differentiat- 
determined electroporation threshold. The system functions ing into members Of the lymphoid, erythroid, and mye1oid 
by inactivating a substantial fraction of the cells in the lineages. The suspension is essentially free of mature and 
sample not included in the selected subpopu~ation, The lineage committed cells and is derived from a precursor cell 
system includes a generating mechanism that generates an suspension comprising substantially viable cells. The sus- 
electric field of a magnitude and duration sufficient to pension is derived from the precursor suspension by sub- 
included in the selected subpopu~ation, while not irrevers- sufficient duration and magnitude to inactivate a substantial 
ibly porating a substantial fraction of the cells included in fraction of the mature and lineage committed cells in the 
the selected subpopulation. The system further includes a precursor suspension. 
treatment cell that is electrically connected to the generating 25 , Other advantages, novel features, and objects of the 
mechanism and is adapted to contain a cell suspension. invention will be become apparent from the following 
yet another aspect, the invention provides a system for detailed description of the invention when considered in 
selectively inactivating biological cells based on a difference conjunction with the accompanied drawings, which are 
in a characteristic electric poration threshold, The system schematic and which are not intended to be drawn to scale. 
includes a generating mechanism that generates an electric 3o In the figures, each identical Or nearly identical component 
signal constructed and arranged to create desired electric is illustrated in various figures is represented by a single 
field parameters. The system also includes a treatment cell numeral. For PuToses of clarity, not every component is 
that is electrically connected to the generating mechanism, labeled in every figure. 
membrane thickness substantiah' exceeding the average characteristic size that is greater than the characteristic size 
In another embodiment, the invention provides a cell 
10 suspension including a plurality of viable, reversibly elec- 
In yet another aspect, the invention 
irreversibly porate a substantial fraction of the cells not " jecting the precursor suspension to an field Of 
- - 
includes at least one electrode, and includes a treatment 
volume adaated to contain a cell susaension. The electrode x BRIEF DESCRIPTION OF THE INVENTION 
i d  
is in fluid contact with the cell suspension during operation 
material, which is sealed in order to reduce the release of 
gases from the electrode during operation of the system. FIG. l b  is a schematic illustration of a portion of the cell 
In another aspect, the invention involves a cell suspension 40 membrane from the cell in FIG, for an applied electric field 
comprising a plurality of biological cells suspended in a strength of zero; 
liquid. The suspension includes one population of cells, 
which have a maximum of characteristic size not than FIG. IC is a schematic illustration of a portion of the cell 
a predetermined value, that are viable, and membrane from the cell in FIG. 1 for an applied electric field 
another population of cells, having a maximum character- 45 strength less than the critical applied electric field strength; 
istic size greater than the predetermined value, that are FIG. Id is a schematic illustration of a portion of the cell 
non-viable, The cell suspension is obtained membrane from the cell in FIG. 1 for an applied electric field 
from a precursor suspension of substantially viable cells that strength approximately equal to the critical applied electric 
contains as subpopulations the two cell populations men- field strength; 
tioned above. The cell suspension is obtained by subjecting 50 FIG. l e  is a schematic illustration of a portion of the cell 
the precursor cell suspension to an electric field having a membrane from the cell in FIG. 1 for an applied electric field 
magnitude and duration that is sufficient to irreversibly strength exceeding the critical applied electric field strength; 
porate a substantial fraction of the cells in the precursor FIG, 2a is a schematic illustration showing a cross-section 
suspension that have a maximum characteristic size above of a typical stem cell; 
FIG. 2b is an electrical circuit diagram illustrating how a the predetermined value. 
In yet another aspect, the invention involves a cell sus- cell charges in response to an applied electric field; 
pension comprising a plurality of biological cells suspended FIG. 3 is a flow chart outlining the steps of certain in a liquid where each of the biological cells is enclosed by embodiments of the inventive method; a plasma membrane. The cell suspension includes a sub- 
popu~ation of biological cells that possess a maximum 6o FIG. 4 is a schematic illustration of a batch treatment 
characteristic size in excess of a predetermined value, system according to one embodiment of the invention; 
Furthermore, the cells in the subpopulation of cells having FIG. 5 is a schematic illustration showing a Cross- 
a maximum characteristic size in excess of the sectionalview of an electrode enclosure assembly according 
predetermined, value also have a maximum transmembrane to one embodiment of the invention; 
electrical potential that exceeds that required to cause irre- 65 FIG. 6 is a schematic illustration showing a perspective 
versible dielectric breakdown of the plasma membrane of view of a disassembled test cell according to one embodi- 
the cells. ment of the invention. 
FIG, la is a schematic illustration showing a cross-section 
of the system and is constructed of a porous, biocompatible of a cell suspended in an electric field between two elec- 
trodes; 
55 
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FIG. 7 is a schematic illustration of a continuous flow 
treatment system according to one embodiment of the inven- 
tion; 
FIG. 8 is a schematic block diagram showing the com- 
ponents of a pulse driver system according to one embodi- 
ment of the invention; 
FIG. 9 is a graph showing a bipolar electric field pulse 
according to one embodiment of the invention; 
FIG. 10 is a graph showing a unipolar electric field pulse 
according to one embodiment of the invention; 
FIG. 11 is a graph showing surviving cells as a function 
of PEF electric field exposure time and magnitude for cells 
treated according to one embodiment of the invention; 
FIG. 12a is a viability scatter plot derived from flow 
cytometry data for a control cell specimen; 
FIG. 12b is a viability scatter plot derived from flow 
cytometry data for a PEF-treated cell specimen for cells 
treated according to one embodiment of the invention; 
FIG. 12c is a viability scatter plot derived from flow 
cytometry data for a PEF-treated cell specimen for cells 
treated according to one embodiment of the invention; 
FIG. 12d is a viability scatter plot derived from flow 
cytometry data for a PEF-treated cell specimen for cells 
treated according to one embodiment of the invention; 
FIG. 13a is a scatter plot of data obtained with flow 
cytometry for a control cell suspension; 
FIG. 13b is a scatter plot of data obtained with flow 
cytometry for a PEF-treated cell suspension for cells treated 
according to one embodiment of the invention; 
FIG. 13c is a scatter plot of data obtained with flow 
cytometry for a PEF-treated cell suspension for cells treated 
according to one embodiment of the invention; 
FIG. 13d is a scatter plot of data obtained with flow 
cytometry for a PEF-treated cell suspension for cells treated 
according to one embodiment of the invention; 
FIG. 14 is a graph showing surviving cells as a function 
of PEF electric field exposure time and magnitude for cells 
treated according to one embodiment of the invention; 
FIG. 15a is a forward scatter histogram derived from flow 
cytometry data for monocytes in a control cell suspension; 
FIG. 15b is a forward scatter histogram derived from flow 
cytometry data for monocytes in a PEF-treated cell suspen- 
sion for cells treated according to one embodiment of the 
invention; 
FIG. 1% is a forward scatter histogram derived from flow 
cytometry data for monocytes in a PEF-treated cell suspen- 
sion for cells treated according to one embodiment of the 
invention; 
FIG. 15d is a forward scatter histogram derived from flow 
cytometry data for monocytes in a PEF-treated cell suspen- 
sion for cells treated according to one embodiment of the 
invention; 
FIG. 15e is a forward scatter histogram derived from flow 
cytometry data for monocytes in a PEF-treated cell suspen- 
sion for cells treated according to one embodiment of the 
invention; 
FIG. 15fis a forward scatter histogram derived from flow 
cytometry data for lymphocytes in a control cell suspension; 
FIG. 15g is a forward scatter histogram derived from flow 
cytometry data for lymphocytes in a PEF-treated cell sus- 
pension for cells treated according to one embodiment of the 
invention; 
FIG. 15h is a forward scatter histogram derived from flow 
cytometry data for lymphocytes in a PEF-treated cell sus- 
pension for cells treated according to one embodiment of the 
invention; 
8 
FIG. 15i is a forward scatter histogram derived from flow 
cytometry data for lymphocytes in a PEF-treated cell sus- 
pension for cells treated according to one embodiment of the 
invention; 
FIG. 15j is a forward scatter histogram derived from flow 
cytometry data for lymphocytes in a PEF-treated cell sus- 
pension for cells treated according to one embodiment of the 
invention; 
FIG. 16 is a graph showing lymphocyte enrichment as a 
lo function of electric field exposure time and magnitude for 
cells treated according to one embodiment of the invention; 
FIG. 17 is a bar chart showing surviving fraction of cells 
and stem cell enrichment as a function of electric field 
strength for cells treated according to one embodiment of the 
invention; 
FIG. 18a is a light scatter plot derived from flow cytom- 
etry data for input CMK cells to be treated according to one 
embodiment of the invention; 
FIG. 18b is a viability stain histogram derived from flow 
cytometry data for input CMK cells to be treated according 
to one embodiment of the invention; 
FIG. 18c is a light scatter plot derived from flow cytom- 
etry data for input PBMC cells to be treated according to one 
FIG. 18d is a viability stain histogram derived from flow 
cytometry data for input PBMC cells to be treated according 
to one embodiment of the invention; 
FIG. 18e is a light scatter plot derived from flow cytom- 
30 etry data for an input CMWPBMC cell mixture to be treated 
according to one embodiment of the invention; 
FIG. 18f is a viability stain histogram derived from flow 
cytometry data for an input CMWPBMC cell mixture to be 
treated according to one embodiment of the invention; 
FIG. 19a is a light scatter plot derived from flow cytom- 
etry data for a control cell specimen containing a CMW 
PBMC cell mixture; 
FIG. 19b is a bivariate plot derived from flow cytometry 
data for a control cell specimen containing a C M W B M C  
FIG. 19c is a viability histogram derived from flow 
cytometry data for a control cell specimen containing a 
CMWPBMC cell mixture; 
FIG. 19d is a light scatter plot derived from flow cytom- 
45 etry data for a PEF-treated cell specimen containing a 
CMWPBMC cell mixture for cells treated according to one 
embodiment of the invention; 
FIG. 19e is a bivariate plot derived from flow cytometry 
data for a PEF-treated cell specimen containing a CMW 
PBMC cell mixture for cells treated according to one 
embodiment of the invention; 
FIG. 19f is a viability histogram derived from flow 
cytometry data for a PEF-treated cell specimen containing a 
55 CMWPBMC cell mixture for cells treated according to one 
embodiment of the invention; 
FIG. 20a is a light scatter plot derived from flow cytom- 
etry data for a control cell specimen containing a CMW 
PBMC cell mixture; 
FIG. 20b is a bivariate plot derived from flow cytometry 
data for a control cell specimen containing a C M W B M C  
cell mixture; 
FIG. 20c is a viability histogram derived from flow 
cytometry data for a control cell specimen containing a 
FIG. 20d is a light scatter plot derived from flow cytom- 
etry data for a PEF-treated cell specimen containing a 
5 
2o 
25 embodiment of the invention; 
35 
40 cell mixture; 
so 
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CMWPBMC cell mixture for cells treated according to one 
embodiment of the invention; 
FIG. 20e is a bivariate plot derived from flow cytometry 
data for a PEF-treated cell specimen containing a CMW 
PBMC cell mixture for cells treated according to one 
embodiment of the invention; 
FIG. 20f is a viability histogram derived from flow 
cytometry data for a PEF-treated cell specimen containing a 
CMWPBMC cell mixture for cells treated according to one 
embodiment of the invention; 
FIG. 21 is a graph showing surviving cells as a function 
of PEF electric field magnitude for three types of cells for 
cells treated according to one embodiment of the invention; 
FIG. 22 is a graph showing surviving cells as a function 
of PEF electric field magnitude and pulse duration for cells 
treated according to one embodiment of the invention. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The present invention provides novel methods and sys- 
tems for selectively inactivating biological cells, or any 
discrete objects having an inner conducting core surrounded 
by a dielectric layer, for example a lipid bilayer membrane. 
Specifically the invention provides methods and apparatus 
for selectively inactivating such cells or discrete objects by 
subjecting a suspension containing such cells or discrete 
objects to an applied electric field of sufficient duration and 
magnitude to cause dielectric breakdown or electroporation 
of the dielectric layer. The methods provided by the present 
invention can be used advantageously to selectively inacti- 
vate subpopulations of cells or discrete objects from a 
precursor population that contains a mixture of different 
cells or discrete objects, or mixtures of cells and non-cell 
discrete objects, on the basis of a characteristic electropo- 
ration threshold, thus providing a means for selectively 
purging or isolating cells or discrete objects from larger 
populations. One embodiment of the inventive method 
involves subjecting a sample having a given population of 
cells or discrete objects to electric field conditions sufficient 
to porate a substantial fraction of cells or discrete objects 
that have a characteristic electroporation threshold below a 
selected predetermined value, while not simultaneously 
porating a substantial fraction of the cells or discrete objects 
having a characteristic electroporation above the predeter- 
mined value, and subsequently, or simultaneously inactivat- 
ing the porated cells or discrete objects. 
The term “biological cell” or “cell” as used herein has its 
commonly understood meaning and includes viable, poten- 
tially viable, or previously viable cells derived from a 
biological sample. Such cells include prokaryotic cells such 
as bacteria, and algae, and eukaryotic cells, such as yeasts, 
fungus, plant cells, and animal cells. Such cells typically 
have an inner, electrically conducting core comprised of 
cytoplasm, surrounded and enclosed by at least one dielec- 
tric membrane, for example the cytoplasmic or, equivalently, 
plasma membrane. Eukaryotic cells, in addition, typically 
also possess a dielectric nuclear membrane surrounding a 
conductive nucleus within the interior of the cell. 
The term “discrete objects having an inner conducting 
core surrounded by a dielectric layer” or simply “discrete 
object” as used herein refers to any object comprising a 
substance exhibiting a relatively low electrical resistivity 
surrounded and enclosed by a dielectric layer or dielectric 
membrane having a much higher electrical resistivity. Such 
discrete objects include biological cells as previously 
described, but also include objects such as certain viruses, 
10 
sub-cellular organelles, liposomes, micelles, and others. 
Throughout the remainder of this detailed description, many 
of the methods and apparatus of the invention are described 
in relation to biological samples comprising biological cells. 
5 It should be understood that the invention is not so limited 
and that the invention may similarly be applied to discrete 
objects, as defined herein, other than cells. Also, whenever 
the term “discrete object” is used herein, it should be 
understood that the term includes, as a subset, biological 
cells. The term “dielectric layer,” or “dielectric membrane,” 
or “membrane” as used herein refers to a continuous layer or 
coating having a finite thickness and having an electrical 
resistivity (Qcm) exceeding that of a conducting core which 
the membrane encloses. Typically, the electrical resistivity 
1~ of the dielectric layer will exceed that of the inner conduct- 
ing core by at least a factor of 10, and more typically, for 
example as is the case with most biological cells, by at least 
a factor of 104-109. In the context of biological cells, the 
dielectric layer is defined by at least one lipid bilayer 
2o membrane, together with any associated structures or sub- 
stances associated therewith which affect the effective mem- 
brane thickness or resistivity of the dielectric layer. 
“Effective,” as used herein in the context of membrane 
thickness or resistivity, refers to a thickness or resistivity of 
25 an equivalent membrane not possessing any associated 
structures or substances affecting its dielectric properties 
associated therewith that possesses the same dielectric prop- 
erties as the actual membrane having such associated struc- 
tures or substances. 
The term “inactivating” as used herein refers to destruc- 
tion of at least one property of a discrete object. In the 
context of biological cells, inactivating is equivalent to 
rendering unviable, or killing the cell. As applied to non-cell 
discrete objects, inactivate can refer to physical destruction 
35 of the object, or simply a destruction of the permi-selective 
diffusional barrier properties of the dielectric layer with 
respect to at least one molecular, ionic, or atomic species. In 
certain embodiments involving cells, inactivation may 
involve not only rendering the cells non-viable, but also 
40 irreparably lysing and physically disrupting and destroying 
the physical structure of the cell. 
The invention provides, in some embodiments, relatively 
fast and effective methods for purifying certain desired cells 
in a viable state from a suspension or eliminating certain 
45 undesired cells from a cell population. As mentioned, the 
methods involve exposing a suspension containing a popu- 
lation of cells to an applied electric field, which field has a 
magnitude and is applied for a duration selected to porate, 
and in some embodiments inactivate, a substantial fraction 
SO of certain subpopulations of cells based on their character- 
istic electroporation threshold. The term “suspension of 
cells” as used herein refers to a mixture of cells suspended 
in a carrier liquid. The carrier liquid may be naturally part of 
the biological sample from which the cells derive, for 
ss example blood is a suspension of blood cells suspended in 
plasma, or, for cells which are not normally present in a 
suspension, the carrier liquid can be any suitable diluent or 
medium. Preferred carrier fluids are non-toxic and physi- 
ologically compatible with the cells they suspend, at least for 
60 a time period equal to that of the electric field application 
procedure. Preferred carrier fluids are also electrically con- 
ductive. The electrical conductivity can be any value greater 
than zero, but preferably will range from about 10%-200% 
that of the conductive core of the cell. In certain 
65 embodiments, the conductivity or resistivity of the carrier 
fluid will be essentially equal to that of the conductive core 
of the cell. In other embodiments, in order to reduce the 
30 
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power consumption of the electric field generating apparatus discrete objects based on a characteristic size. “Character- 
and/or reduce the degree of heating of the cell suspension, istic size” or “size” as used herein with respect to dimen- 
as will discussed in greater detail herein, it can be preferable sions of cells or discrete objects, refers a linear dimension of 
to utilize a carrier fluid having a resistivity that is greater a cell or discrete object as measured in the direction of an 
than that of the conductive core of the cell. In order to 5 applied electric field to which the cells or objects are 
provide a more uniform electrical field throughout a cell subjected and from an external surface of the outermost 
suspension being treated according to the invention, the cell dielectric membrane on one side of the geometric center of 
suspension should be essentially free of gas bubbles. The the cell or object, through the geometric center of the cell or 
cells in the suspension should also be individually sus- object, to an external surface of the outermost dielectric 
pended and as free from clumping and aggregation as 10 membrane on the other side of the geometric center of the 
possible during application of the electric field in order to cell or object. For example, for a spherical cell or object, the 
provide the maximum resolution and selectivity attainable characteristic size would be the external diameter of the cell 
for a given set of electric field exposure conditions. The or object. Specifically, the method involves porating and 
concentration of cells in a cell suspension, as will be inactivating a substantial fraction of discrete objects above 
discussed in more detail, can also affect the selection and 1s a certain predetermined threshold size, which is a function 
performance of the applied electric field. Typically, for of the electric field and suspension properties as discussed, 
mammalian cells, the range of total cell concentrations in while leaving in an uninactivated state a significant fraction 
treated samples can range from about 102-1010 cellsiml, of discrete objects below the threshold size. The method can 
with preferred suspensions having from about 104-10s cells/ be used, for example, to inactivate cells present in viral 
ml. 20 preparations used in treatment, diagnosis, or research of 
The term “substantial fraction” or “substantially viral diseases such as AIDS. It is often desirable to obtain 
depleted” as used herein, in the context of discrete objects suspensions of pure virus that are essentially uncontami- 
having a characteristic electroporation threshold less than a nated with viable cells infected with such virus. Because 
predetermined value, refers to at least 25% of such cells virus-carrying cells will typically be substantially larger than 
being porated by the applied electric field and inactivated, 2s viruses, the inventive method can be use to selectively 
preferably at least 50%, more preferably at least 90%, in inactivate the cells without causing undue damage to the 
some embodiments preferably at least 99%, in some virus. Another application involves isolation of certain sub- 
embodiments preferably at least 99.99999%, and in some cellular organelles from cells. In this case, the cells can 
embodiments preferably essentially all of the discrete initially be porated using the inventive method in order to 
objects. The term “electroporation threshold” or “critical 30 liberate the intracellular contents of the cells into the sus- 
electroporation threshold” as used herein refers to the sus- pension. Subsequently, an electric field having different 
ceptibility of a particular cell or subpopulation to membrane parameters can be applied to the suspension to selectively 
poration by an applied electric field. As will be discussed in isolate one or more subpopulations of organelles on the basis 
greater detail herein, the characteristic electroporation of a difference in a characteristic electroporation threshold, 
threshold of a cell or subpopulation of cells is a function of 35 for example due to a difference in characteristic size. An 
the physical and chemical properties of the cell that influ- example of the inventive method as applied to a non- 
ence its interaction with an applied electric field. Differences biological sample is the selective disruption of liposomes on 
between one or more of these properties between different the basis of size. Liposomes are commonly used as vehicles 
cells or subpopulations may be advantageously exploited to for drug delivery or for transfection of genetic material into 
provide a basis for selective isolation and inactivation 40 cells. The performance of the liposome for its intended task 
according to the invention. Such properties include charac- and also potentially its pharmacokinetics within the body 
teristic cell size, effective dielectric membrane thickness, can be a function of the size of the liposome. Thus, the 
cell shape, cell and/or membrane morphology, cell mem- current invention can provide a relatively fast and easy 
brane capacitance, cytoplasmic electrical resistivity, etc. The means for performing a size selection of manufactured 
term “predetermined electroporation threshold” as used 45 liposomes. 
herein refers to a chosen value of electroporation threshold Two important applications where the present invention 
below which a significant fraction of cells having such has particular utility involve the purging of cancer cells from 
electroporation thresholds will be porated by the applied cell suspensions and the isolation and enrichment of stem 
electric field, and above which a significant fraction of cells cells or germ cells from cell suspensions. A “germ cell” as 
having such electroporation thresholds will not be porated. so used herein, refers to haploid cells, or gametes, such as 
The predetermined electroporation threshold, as will be sperm or egg cells. These applications are important corn- 
discussed in greater detail herein, can be a function of the ponents in many clinical treatment therapies involving, for 
parameters of the applied electric field (e.g. field strength, example, cancer treatment, organ transplant, and gene 
field duration, etc.) and the electrical properties of the cell therapy. The present method exploits a difference in a critical 
suspension (e.g. fluid carrier resistivity, total suspension ss electroporation threshold between the above mentioned cell 
capacitance, etc). An important feature of the invention is types and the other cell types present in the cell suspension 
the selection of such electric field parameters and suspension to effect a selection of desired cells and/or a purging of 
properties in order to provide conditions that selectively undesired cells. In particular, in particular embodiments, 
inactivate a significant fraction of one or more subpopula- differences in characteristic cell size (e.g. average cell 
tions of cells in a sample based on one or more differences 60 diameter) provide, at least in part, for the above mentioned 
in their properties that affect their characteristic electropo- difference in critical electroporation threshold. Cancer cells, 
ration threshold. for example, are often significantly larger than the desired 
The methods and apparatus provided by the present population of cells, for example stem cells, in a sample and 
invention can be applied to a wide variety of discrete object will generally have an electroporation threshold below that 
separation applications, and to a wide variety of biological 65 of the desired cells. Thus, by subjecting the suspension to a 
and non biological samples. One important embodiment of selected electric field having predetermined characteristics, 
the invention provides a method of isolating or inactivating a substantial fraction of the cancer cells can be inactivated 
US 6,589,786 B1 
13 14 
without inactivating the desirable cells. Preferably, when a Thus, it is apparent that the present invention provides a 
suspension initially containing such cancer cells is subjected novel method for cancer purging and stem cell isolation 
to the inventive cell selection method, the concentration of useful for a variety of medical therapies, an important one of 
viable cancer cells remaining is decreased by at least a factor which is stem cell transplantation for hematopoietic recon- 
of 10 (1 log reduction) and most preferably by at least a s stitution after myleoablative therapies. Aparticularly attrac- 
factor of 100,000 (5 log reduction). Similarly, because for tive application for the teachings of this invention is the 
many biological samples stem cells are the smallest cells isolation of hematopoietic stem cells from bone marrow, 
sample in viable stem cells by selectively inactivating non- liver tissue, which is a crucial first step in an protoco~ 
stem cells in the sample. Preferably, the concentration of for delivering genetically manipulated, stem-cell-based, 
viable stem cells, with respect to the total number of viable pathogen countermeasures that have the potential to provide 
present, the inventive method can be used to enrich such a mobilized peripheral blood, umbilical cord blood or fetal 
present in the is increased in the pre-exposure prophylaxes or post-exposure therapies, and 
through application of the inventive method by at least a immune system reconstitution, Isolation of stem cells to 
in certain preferred embodiments, by a factor of lo6 or more, while, correspondingly, the concentration of viable non- 1~ eliminating the interference and complications that occur 
stem cells in the sample is substantially depleted, One should other leukocytes be presenthiable during gene trans- 
cation and enrichment of stem cells, is that typical cell specimens will be required for large scale implementa- 
antibody-based stem cell isolation methods, isolation of tion of such stem cell-based-countermeasures. Efficient, 
stem cells using applied electric fields does not rely on the 20 Practical CrYostorage of large numbers of specimens 
presence of surface markers on the stem cells (e.g. CD34). demands small specimen volumes. Since the relative con- 
The most primitive stem cells may not possess the cell centrations of stem cells in bone marrow mononuclear cell 
surface markers targeted by typical antibody-based methods (BMMC) and mobilized peripheral blood mononuclear cells 
and thus, such cells will not be recovered by those methods. (MPBMC) specimens are approximately 1:105, stem cell 
Conversely, stem cells isolated by the present methods are 2s isolation and enrichment will be important for achieving 
selected on the basis of their critical electroporation thresh- small specimen volumes advantageous for efficient cryos- 
old. Therefore, the stem cell suspensions Provided according torage. To eliminate interference from non-stem cells during 
to the inventive methods, will include stem cells that do not expansion and gene transfection, and to reduce volume 
Possess the surface markers tYPicallY used requirements for cryostorage, isolation strategies should be 
based methods to select stem cells if such stem cells were 3o capable of enriching stem cell concentrations by up to 106 
initially present in the sample before application of the for BMMC and MPBMC specimens, 
inventive methods. Specifically, one embodiment of the Many presently available methods typically in use for present invention can provide a suspension enriched in stem 
stem 
mitted cells, and which includes as a subpopu~ation, stem binding to cell surface structures or toxin-based cell inacti- 
cells not expressing CD34 on their surface. 35 vation strategies. These strategies can be sub-optimal for 
me stem cell and/or cancer cell containing suspensions stem cell-enrichment because they provide in some cases 
can be derived from a variety of including, but not relatively low degrees of enrichment and can add detrimen- 
limited to, bone marrow, mobilized or unmobilized periph- tal substances to the suspension, such as exogenous anti- 
eral blood, umbilical cord blood, fetal liver tissue, other bodies or toxins, that damage or can activate the isolated 
organ tissue, skin, nerve tissue, etc. A variety of stem cells 40 stem cells or be detrimental to a patient upon reinfusion of 
may advantageously be isolated and enriched according to such cells. Other currently available stem cell isolation 
the invention including, but not limited to, hematopoietic strategies involve a culture-based protocol requiring a long 
factor Of more preferably by at least a factor Of five, and high purity prior to their genetic manipulation is essential for 
feature of the inventive method when applied to the purifi- fection and expansion. Cryostorage of large numbers of stem 
cells, which is essentially free of mature and lineage Or cancer purging depend On antibody 
stem cells, embryonic stem cells, mesenchymal stem cells, processing time, for example up to one week. In addition, 
epithelial stem cells, gut stem cells, skin stem cells, neural many currently available cell isolation methods do not easily 
stem cells, liver progenitor cells, and endocrine progenitor 4s scale, and, therefore, are not optimal for handling the large 
cells. One embodiment of the invention involves the isola- throughput required for a widespread implementation of 
tion of lympho-hematopoietic stem cells, which are capable many stem-cell-based therapies. Thus, in the prior art, there 
of differentiating into members of the lymphoid, erythroid, exists a need for stem cell isolation strategies for effective 
and myeloid lineages, from cell suspensions including implementation of the stem-cell-based countermeasures, 
mature and lineage committed cells to provide a suspension so which the present invention, in some embodiments, poten- 
of lympho-hematopoietic stem cells that is essentially free of tially can fill. 
mature and lineage committed cells. The enriched stem cell The methods and apparatus provided according to the 
suspensions according to the present method will also be present invention can provide significant improvements and 
advantageously enriched in pluripotent stem cells, which advantages over many prior art methods for performing cell 
have the ability to differentiate into the full complement of ss separations and isolations. The present method is based on 
mature cells derived from a particular type of stem cell. intrinsic differences between cell types, for example char- 
Also, in some embodiments, the enriched stem cell suspen- acteristic size and/or characteristics that effect the membrane 
sions produced according to the invention will contain, in breakdown voltage, such as the dielectric strength of the 
addition to pluripotent stem cells, stem cells which are membrane or the effective membrane thickness, and does 
committed colony forming cells. For example, for samples 60 not require, in many embodiments, the addition or use of 
including hematopoietic stem cells, the enriched suspen- exogenous agents, such as antibodies or toxins, which can 
sions can advantageously include viable colony forming adversely affect the viability or state of activation of the 
cells for granulocytes and macrophages (CFC-GM), colony isolated cell fraction. “Dielectric membrane breakdown 
forming cells for erythrocytes (BFU-E), colony forming voltage” or “membrane breakdown voltage” refers the volt- 
cells for eosinophils (CFC-Eo), multipotent colony forming 65 age across the dielectric membrane layer of a cell or discrete 
cells (CFC-GEMM), and immature lymphoid precursor object at the onset of poration of the membrane. In addition, 
cells. the present method is substantially faster than many prior art 
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cell separation techniques. Cell inactivation and isolation may include multiple treatment cells. For flow systems, 
using the inventive method can be performed in times multiple treatment cells can be arranged in a series or 
ranging from milliseconds to minutes. Finally, with appro- parallel configuration. 
priate selection of operating parameters, as discussed herein, The treatment cell will include at least one electrode in 
and routine optimization of the selected parameters and 5 electrical communication with the cell suspension to be 
method, the inventive method can potentially provide high treated. Preferably the treatment cell will include two elec- 
degrees of enrichment or purging of selected cell subpopu- trodes placed on either side of and in electrical communi- 
lations. cation with the cell suspension during operation to which an 
As discussed in more detail later herein, cell selection electric potential is applied to produce an electric field 
with electric fields according to the invention can be used as 10 within the treatment volume. In preferred embodiments, the 
a stand alone method or may be combined with one or more treatment cell and electrodes are constructed and arranged to 
other cell separation methods, such other methods being a impose an electric field that is substantially spatially uniform 
pre-treatment or post-treatment step. Also the method within the treatment volume SO that all cells in the suspen- 
according to the invention can be applied to a cell suspen- sion are exposed to similar electric field conditions. In some 
sion so that the applied electric field both porates and 15 embodiments, the electric field applied to the cell suspension 
step, or, alternatively, the applied field may porate Some or however, it is also contemplated that the electric field can be 
all of the cells to be inactivated without inactivating all of induced in the sample cell via induction by a magnetic field. 
such cells, with the inactivation step performed in a subse- In order to reduce the tendency for the electrical potential 
quent step. In the former case, the applied electric field is 20 applied to the electrodes to discharge by arcing, and in order 
sufficient, under the conditions of its application, to cause to reduce the degree of electrical heating that occurs in the 
irreversible breakdown or irreversible poration of the dielec- cell suspension, in certain preferred embodiments, the 
tric membrane of the cell. “Irreversible breakdown” or applied electric field is pulsed for short durations, such 
“irreversible poration” refers to poration that is sufficient to durations, except as otherwise described herein, being 
cause death, inactivation, and/or physical disruption of a 2s shorter than the residence time of the treated cell suspension 
discrete object without a need for a secondary inactivating in the treatment volume during the step of subjecting the 
step. Inactivation and cell death due to poration are believed suspension to the applied electric field. Such electric fields 
to be caused by a loss of the permi-selective nature of the are hereinafter referred to as “pulsed electric fields” or PEFs. 
membrane leading to cell death and/or membrane The shape of the electric field pulse is preferably substan- 
disruption, or a direct physical disruption of the membrane 30 tially rectangular in shape, thus providing very short voltage 
caused by extensive poration. In the case of a loss of the rise and fall times and a substantially constant magnitude 
permi-selective nature of the membrane, the inactivation or over the entire pulse length. Such rectangular pulse shapes 
cell death is ultimately caused by diffusion of previously yield the best performance and poration threshold resolution 
excluded molecular species, especially small ionic species obtainable with the inventive method. While rectangular 
such as Na+, K+, and Ca++, across the membrane followed 35 pulses are preferred, any pulse shape known in the art may 
by an uptake of water across the membrane into the cell in be employed in performing the methods of the invention, 
an attempt to achieve osmotic equilibrium with the suspend- especially when high resolution is not required, as, for 
ing fluid medium, which can lead to colloidal osmotic lysis example, when inactivating a cell type that is substantially 
and irreparable (fatal) cell lysis, or to a lethal disruption of larger than the desired cell type. 
cellular metabolism. For embodiments involving a method 40 As described previously, the electric field parameters 
where the applied field pra tes  some or all of the cells to be required to effect a desired cell inactivation or isolation 
inactivated without inactivating all of such cells, where the depend upon the nature of the cells, the suspension and 
inactivation step is performed in a subsequent step, the suspending fluid, and the characteristics of the electric field 
poration induced by the applied field is typically less exten- application apparatus. The exact parameters for any given 
inactivates one or more subpopulations of cells in a single is created by an electric signal applied to the electrodes; 
sive and not irreversible, at least for a certain portion of the 45 sample that will yield desired results must be found in 
porated cells. Given sufficient time, the reversibly porated practice via routine experimentation. What follows herein is 
cells in such samples could seal their pores and retain a theoretical development and description of the inventive 
long-term viability if left in the same fluid carrier or sus- method, apparatus for performing the method, and important 
pending media in which they were subjected to the electric parameters affecting the performance and selectivity of the 
field. The reversibly porated cells may, however, be effec- so method to provide guidance to those of skill in the all in 
tively inactivated by resuspending them in a different post- selecting parameters to develop successful cell or discrete 
poration media, adjusting the temperature of the poration 
media, and/or adding a supplemental agent to the poration The Fundamental Basis of Electric Field Cell Isolation 
media which accelerates cell death, colloidal osmotic lysis, The mechanism by which electric fields, and particularly 
or prevents the resealing of membrane pores. More specific 5s pulsed electric fields (PEFs), isolate cells can be best under- 
techniques and conditions are discussed later herein. stood by examining the response of a single discrete object, 
The electric field is preferably applied to the cell suspen- as exemplified by a biological cell, to an externally applied 
sion within a spatially defined treatment cell. The treatment electric field. Aschematic illustration of such a system 50 is 
cell can be designed as a static non-flow volumetric con- shown in FIGS. la+. The externally applied electric field 
tainer in which the cell suspension to be treated is placed, or 60 57 can be established by applying a constant voltage or 
more preferably, the treatment cell will include an inlet and voltage pulse across a pair of electrodes 55 and 56 that are 
an outlet constructed and arranged to enable a cell suspen- in electrical communication with, and preferably in physical 
sion to continuously flow through the treatment volume. contact with, a cellular suspension containing a plurality of 
Systems including flow-through treatment cells may be cells, one of which 51 is shown in FIG. la. Alternatively, the 
arranged so that the cell suspension passes through the 65 electric field 57 can be applied inductively by creating a 
treatment cell only once (one pass) or a plurality of times time-varying magnetic field throughout the cellular suspen- 
(recirculating). In addition, either the flow or static systems sion. To preserve the viability of the desired target cells, the 
object isolation and inactivation strategies. 
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carrying fluids in which the biological cells are suspended there are two, are defined as the two points formed on the 
are typically buffered saline solutions having, in some surface of the cell 51 by the intersection of a ray parallel to 
embodiments, a standard physiological osmolality (e.g. the electric field direction passing through the center of the 
275-300 moskg-water for most mammalian cells), and a cell, then application of an external electric field causes one 
PH in the PhYsiological range (e& about 7.0-7.6 for most s half of the pole-to-pole potential drop outside of the bio- 
mammalian cells). The ionic strength of the solutions in logical cell 5 1  to develop the membrane 52 at each 
certain embodiments is essentially the same as the ionic pole of the cell, mat is, the externally applied electric field 
strength of the intracellular fluid 53 (e.g. about 0.15 M NaCl 57 produces a maximum transmembrane potential, v,, at 
equivalent for most mammalian cells). As such, these are each pole of the cell 51 that scales as 
conducting solutions. Electric field effects on cells can be 
estimated from the potential theory developed by Coulson 
(Coulson C A  Electricity, Oliver and Boyd, London, Chap- 
ter 9, 1951) incorporated herein by reference. This theory 
implies that induced transmembrane potentials depend on 
induces a potential across the cell 51, Vcell, given by 
V,=Vced~ (2) 
or equivalently 
Vm=3dE14 cell size and shape. Formally, the external electric field (3) 
15 
for a spherical cell. 
Since, in response to an externally applied electric field 
57, the potential drop, Vcell, that develops over a cell’s 
diameter 54 or projected length is transferred approximately 
20 equally across the two poles of the cell’s membrane 52, the 
ik- 8 Vcen - flE where f = 1 
and where E is the field strength of the imposed electric maximum electric field thereby imparted to a cell’s mem- 
field; d is the cell diameter 54,l  is the projected length of the 
cell in the electric field direction 57; and f is a form factor, 
d) and is approximately unity for large aspect ratio cylin- 25 
drically shaped cells (where l>>d). In the development to 
follow, the cells of interest will be assumed to be spherical 
will be set equal to 1.5. For a more detailed discussion on the 
effects of non-spherical cell shape and angular orientation 30 
(6) 
Kinosita and Tsong (Kinosita K and Tsong TY, Voltage- 
induced pore formation and hemolysis of human where E, is the electric field imparted to the membrane 52 
erythrocytes, Biochim et BiophysActa. 471:227-242, 1977). for an externally applied electric field 57 of strength E; d is 
Biological cells have an outer, semipermeable plasma 35 the diameter 54 of the biological cell 51; and t, is the 
membrane 52 that allows the cell to control its internal thickness of the membrane. Thus it is apparent from equa- 
environment by its selective permeability. The proper func- tion 5, that the imposed electric field within the cell mem- 
tion of this membrane is crucial to the viability of the cell. brane is directly proportional to cell size and applied electric 
If the function of this membrane is altered or destroyed, cell field strength and inversely proportional to the thickness of 
death often follows. Plasma membranes are typically lipid 40 the cell membrane. Since the size of many typical biological 
bilayers which behave electrically as dielectrics, i.e., they cells falls within a range of lede50 pm and a typical 
behave as electrical insulators. For eukaryotic cells, as thickness of cell membrane 52 lipid bilayer is approximately 
shown in FIG. la, the cell nucleus 68 and accompanying 5 nm, the electric field strength imparted to the membrane 52 
nuclear membrane 69 reside within the outer membrane 52, can be two to three orders of magnitude greater than the 
with cytoplasm 53 filling the gap between the nuclear and 45 strength of the externally applied electric field 57. More 
outer membranes. For prokaryotic cells, there is no nucleus specifically, for a typical lipid bilayer membrane thickness 
or nuclear membrane, so the cytoplasm, which supports the of about 5 nm, a transmembrane potential, V, of approxi- 
cell’s genetic information (one or more DNA molecules in mately one Volt will impart a 2 MVicm electric field, E,, to 
the form of nucleoids) fills the entire intracellular volume. the lipid bilayer membrane 52. So for a 10 pm diameter 
Cytoplasm, which refers collectively to the substance filling SO spherical cell, which, for example, is about the mean size of 
the gap 53 between the outer and nuclear membrane for peripheral blood cells, a 2 kVicm externally applied electric 
eukaryotic cells, or the entire intracellular volume for field E would generate the 2 MVicm electric field, E,, in the 
prokaryotic cells, is mainly composed of cytosol, which is a lipid bilayer membrane. Since the dielectric strength of 
semifluid concentrate having an electrical resistivity that is many polymers, in response to electric fields, is in the range 
similar to that of aqueous solutions having a standard 55 0 .14 .5  MVicm, it is reasonable to expect that a 2 MVicm 
physiological ionic strength. As such, the cytosol is electri- electric field imparted to the membrane 52 of a 10 pm 
cally conductive, which dictates that the intracellular vol- diameter cell by an externally applied 2 kVicm electric field 
ume of both eukaryotic and prokaryotic cells is electrically 57 would produce membrane pores by dielectric breakdown. 
conductive. Thus, biological cells can be viewed as a con- Thus, the electric field magnification provided by the elec- 
ducting intracellular region surrounded by a dielectric 60 trical behavior of biological cells can lead to the dielectric 
(insulating) membrane 52. With this conceptual view of breakdown of a cell’s membrane 52 when the externally 
biological cells, application of an external electric field 57 applied electric field has sufficient strength, thereby forming 
causes charge separation to occur inside the biological cell irreversible pores in the membrane which lead to cell death. 
51 resulting in a nearly constant intracellular potential that From equations 1 and 5, it is apparent that the susceptibility 
has a value corresponding to the boundary average of the 65 of a given cell to poration by an applied electric field 57 is 
potential established on the outer surface of the cell’s proportional to the magnitude of the applied electric field, E, 
dielectric membrane 52. If the poles of the cell 51, of which that is required to produce a given electric field, E,, in the 
brane 52 is 
which is equal to 1.5 for a spherical cell (where 1 is equal to E,=Vceii12t,, (4) 
Or, for 
so that d will be used for 1 in the following equations and f 
with the applied electric field, the reader is referred to 
Em=3Edl4t, (5) 
or equivalently 
E,=V,lt, 
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lipid bilayer membrane (which is directly related to mem- be much more insensitive to electric fields and appear to be 
brane poration) and is related to the size of the cells, the sensitive only during germination and outgrowth when the 
thickness of the dielectric membrane, the dielectric strength cortex disappears and the spore coat layers dissolve as the 
Of the membrane (v/m), the and the cell swells (Husheger H., hotel J., and Niemann E-G. 
orientation of non-spherical cells in the applied electric field. 5 Electric Field Effects on Bacteria and yeast cells, ~ ~ d i ~ ~ ,  
Thus, a difference in one or more of these properties between Environ, Biophys, 22:149-162,1983,; (hereinafter “Hulshe- 
different cell types can lead to a difference in their charac- ger 1983,,) and Grahl T,, Sitzman w,, 11, Killing of teristic electroporation threshold and can potentially be Microorganisms in Fluid Media by High-Voltage Pulses, 
Presented at 10th Dechema Annual Meeting of Biotechnolo- exploited to effect a selective cell isolation or inactivation using an applied electric field, as described in greater detail 
10 gists. Karlsruhe, Germany, Jun. 1-3, 1992.). This behavior to follow. These relations are rigorously valid when the cell 
required in embodiments for the inventive method to effective dielectric membrane thickness due to the presence 
be functional. of the coat layers. Thus for a given critical transmembrane 
For lipid bilayer membranes, which are typical of many electric field strength, E,,, which is a function of, for 
mammalian cells and bacterial cells, the onset of membrane 15 example the resistivity and material properties of the dielec- 
Of the 
is immersed in a conducting fluid, but such fluid may not be may be due to the quiescent ’pores having a much thicker 
dielectric breakdown in response to an externally applied 
electric field has been relatively consistently observed in the 
prior art when the transmembrane potential, V,, reaches a 
particular critical value, namely V,=V,,, where V, is the 
critical transmembrane potential for dielectric breakdown, 20 
or, equivalently, the dielectric membrane breakdown volt- 
age. Table 1 summarizes data from cell poration experiments 
assembled by Castro, et al. (Castro A J, et al: Microbial 
tric layer, a larger effective membrane thickness would, 
according to Eq. 6, yield a larger V,,, and would thus 
require a larger critical applied electric field, E,, for cell 
inactivation (see Eq. 3). 
As shown in FIGS. l k e ,  when V, achieves the critical 
value V,,, membrane dielectric breakdown results in the 
formation of pores in the cell membrane 52, Some of which 
may reseal upon removal of the externally imposed electric 
Inactivation of Foods by Pulsed Electric Fields. Washington field. FIG. 1b illustrates the condition of a section of cell 
State University, Department of Food Science and Human 25 membrane 52 from near one pole of the cell with no external 
“castro”)showing the critical dimensions of various viable that is below the critical field strength required for poration 
Nutrition, Pullman, Wash., 99164-6376, 1993) hereinafter 
cells and their critical membrane potentials for cell mem- 
brane poration. The critical dielectric membrane breakdown 
applied electric field (E=()). When an external field is applied 
@<E, FIG. 1.) there is a separation of charge across the 
membrane 52 and a resulting transmembrane potential v, 
voltage v,, for these cells were obtained by using Eq. 3 30 but no pore formation. This situation for the condition E=E,, 
together with results from cell inactivation experiments is shown in FIG. Id, where E is the strength of the externally 
which measured the critical threshold applied electric field, applied electric field and, from Eq. 3: 
E,. E,=4VmJ3d (7) 
TABLE 1 35 which is the critical electric field strength for spherical cells 
that defines the onset of membrane pore 58 formation for a 
V, is less than V, (i.e., when E<E, in FIG. lc), pore 
Microorganism Ocm) Ocm) Oc& formation, or at least irreversible pore formation, does not 
40 occur. As V, is increased beyond V, (i.e., when E>>E, in 
E. coli (4 hr) 1.15 6.9 72 o.26 FIG. le), membrane pores 59 become more numerous, 
o,83 3,2 1,7 1,09 1,26 larger, and irreversible. Thus, application of sufficiently 
l? aeruginosa 0.73 3.9 1.6 1.07 1.26 strong electric fields, or PEFs to cellular suspensions can 
S. aureus 1.08 nia 0.6 1.50 1.00 result in the inactivation of cells by the formation of irre- 
L. monocytogenes I 0.76 45 versible pores which can destroy the function of the semi- 
permeable cell membrane 52. As noted earlier, the proper 
function of a cell’s semipermeable membrane is required to 
In the table, v, is the volume of the cells. With the important control a cell’s intracellular environment and, therefore, to 
exception of young cells (e.g., E. c o s  4 hr culture, in the maintain its viability. The critical applied electric field, E,, 
logarithmic growth phase), the critical membrane potentials SO necessary to form irreversible pores is thus, as is apparent 
V, of cells in their stationary phase is approximately 1 Volt. from Eq. 6, directly proportional to the critical transmem- 
A variety of parameters can effect dielectric membrane brane potential V,,, and thus membrane thickness, and 
breakdown voltage, Vmc. Such parameters include, but are inversely proportional to cell diameter d for spherical cells. 
not limited to, the membrane thickness, the dielectric PEF Parameters for Cell Purging and Cell Isolation 
strength of the membrane, the dimensional and chemical ss As noted above, the lethal effect of pulsed electric fields 
uniformity of the membrane, etc. Since, for a given dielec- on biological cells is caused by irreversible electroporation 
tric material, the threshold transmembrane electric field of their semipermeable membranes or reversible poration 
strength, E,,, for dielectric breakdown is often similar, and followed by a subsequent treatment to prevent membrane 
since most of the cells in Table 1 have similar dielectric repair or accelerate colloidal osmotic lysis and thereby cause 
membranes (lipid bilayers together with any associated 60 cell inactivation. An electric field applied across the cell 
protein and/or carbohydrate components), Eq. 6 would sug- electrically polarizes the cell membrane causing charge 
gest that the electrical properties, specifically the membrane separation and build up of a transmembrane potential. The 
thickness, of the membranes having similar V, are similar. critical transmembrane potential required for membrane 
In addition to rapidly growing cells, another important poration will be a function of the nature and thickness of the 
exception to the general rule of 1 Volt being a critical 65 membrane, as previously mentioned, and must be deter- 
transmembrane potential for cell poration and inactivation mined experimentally for any given system; however, as 
are spores in their quiescent state which have been shown to previously discussed and illustrated by the data in Table 1, 
Cell size and induced membrane potential for several microorganisms. specific cell size and critical transmembrane potential, When 
d 1 v m c  
E. coli (30 hr) 0.88 2.2 1.4 1.15 1.05 
K. pneumoniae 
0.99 
C. albicans 4.18 nia 38.0 1.50 2.63 
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for a wide variety of biological cells the critical transmem- 
brane potential associated with an externally applied field is 
approximately V,,=l Volt. The pores resulting in the mem- 
brane structure of the cell due to exposure to field strengths 
above the critical value can, in certain cases, irreversibly 
increase cell membrane permeability leading to cell death. 
The dielectric membrane breakdown concept of cell inacti- 
vation is illustrated in FIGS. l&e. 
Electric field strength, total exposure time, and pulse 
duration, for PEFs, can be selected to preferentially inacti- 
vate biological cells in a suspension which are more sus- 
ceptible to electric fields due, for example, to their having 
one or more or a combination of the following properties 
with respect to other cells in the suspension: a larger average 
size; a thinner effective dielectric membrane thickness; a 
more spherical shape, etc. Of particular importance for many 
biological samples, especially those having cells with simi- 
lar shapes, such as roughly spherical, and similar dielectric 
membrane thickness, is selective inactivation of cells based 
on a difference in characteristic size. Typically, the threshold 
electric field required for cell inactivation is inversely pro- 
portional to the characteristic size of the cell, i.e., from Eq. 
7, E,(d)=4 V,,/3d, where V m C d  Volt is the critical trans- 
membrane potential for the onset of irreversible pore for- 
mation for a wide variety of cell types and d is the diameter 
or characteristic size of the cell. If the undesirable cells are 
larger in diameter than the desirable cells, then the pulsed 
electric field method can be used to selectively inactivate the 
larger cells. By operating at electric field strengths just 
below the characteristic electroporation threshold for inac- 
tivation of the desirable cells, yet above the characteristic 
electroporation threshold for the undesirable cells, a sub- 
stantial fraction of the undesirable cells can be preferentially 
inactivated while leaving a substantial fraction of the desir- 
able cells (primitive stem cells for example) essentially 
unaltered and still viable. To further illustrate the utility of 
the concept, a specific example related to cell isolation from 
hematopoietic cell suspensions will be illustrated. Table 2 
lists the types of blood cells that typically will be present in 
bone marrow specimens during tumor cell purging and stem 
cell isolation processing. The cell diameters, relative 
abundance, and projected threshold electric field strengths 
(E, as calculated from Eq. 7 assuming V,$ volt) for the 
onset of membrane damage are also provided in the table. 
Similar cell sizes as those listed would be expected for 
hematopoietic cells derived from mobilized peripheral 
blood, umbilical cord blood and fetal liver tissue, although 
the relative abundance of each may differ. Table 2 clearly 
shows that the electric field damage threshold for stem cells 
can be significantly greater than for the other leukocytes 
present in bone marrow specimens. Furthermore, the electric 
field threshold for stem cells can be more than a factor of two 
greater than for breast cancer cells. Since, as will be dis- 
cussed below, the fraction of cells inactivated by an applied 
electric field scales exponentially with electric field strength 
(Hulsheger 1983) the factor of two difference in the critical 
electroporation threshold should allow essentially complete 
inactivation of breast cancer cells with preservation of the 
viability of the cells crucial for autologous transplantation 
(stem cells). 
5 
10 
1s 
20 
2s 
30 
3 s  
40 
4s  
so 
5s 
60 
65 
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TABLE 2 
Electric field damage thresholds for leukocytes and stem cells. 
Projected Electric 
Characteristic Relative Field Damage 
Size Abundance Threshold 
Cell Type ocm) (%I (kVlcm) 
Stem 
Lymphocyte (resting) 
Lymphocyte (active) 
Neutrophil 
Eosinophil 
Basophil 
Monocyte 
Breast Cancer 
0.001a 
nla 
21c 
73c 
4c 
0.1c 
2c 
nla 
2.2 
1.9 
1.1 
1.1 
1.0 
0.9 
0.9 
<0.9 
aBerardi AC, et al: Functional isolation and characterization of human 
hematopoietic stem cells. Science, 267: 104-108,1995. 
bZipori D, et al: Introduction of Interleukin-3 gene into stromal cells from 
the bone marrow alters hematopoietic differentiation but does not modify 
stem cell renewal. Blood 71:586,1988. 
Vandl JH, Blood: Textbook of Hematology, Little, Brown and Company, 
BostonIToronto, 1987. 
dHenry JB: Clinical Diagnosis and Management by Laboratory Methods, 
16th Ed., W.B. Saunders Company, Philadelphia, PA, Vol. 1, 1979. 
efrom observations by inventors 
Another feature which, in the present example, further can 
enhance the ability to perform preferential electric field 
isolation of stem cells and/or to purge relatively large tumor 
cells, such as breast cancer cells, involves the quiescent 
nature of stem cells. As discussed in Berardi, et al., stem 
cells are quiescent and are unaffected by an anti-metabolite 
treatment, whereas rapidly proliferating cells are inactivated 
by an anti-metabolite treatment. A similar phenomenon has 
been observed (Hulsheger 1983) with PEF inactivation of 
Escherichia coli (E. coli). The observations of Hulsheger 
1983 indicate that the stationary growth phase E. coli cells 
(quiescent cells) are much less vulnerable to the lethal 
effects of PEF’s than are the larger, rapidly dividing E. coli 
cells that are in the logarithmic growth phase. Based on 
these considerations, it is expected that stem cells, due to 
their quiescent nature and smaller size, will be much less 
vulnerable to the lethal effects of electric fields and PEFs and 
that electric field strength can be used to preferentially 
inactivate a substantial fraction of non-stem cell leukocytes 
and tumor cells while leaving a substantial fraction of the 
stem cells unharmed. Thus, it is expected that the inventive 
methods will be an effective approach for purging tumor 
cells from autologous transplant tissue. Similarly, the inven- 
tive methods may be applied to other cell suspensions or 
suspensions on non-cell discrete objects having differences 
in characteristic size between subpopulations in order to 
selectively isolate or inactivate selected subpopulations. 
In addition to performing a selective cell isolation or 
inactivation on the basis of a difference in characteristic cell 
size by selecting an appropriate applied electric field 
strength, the method can also be employed to select cells that 
can be similar in size based on a difference in dielectric 
membrane breakdown, voltage, for example, due to a dif- 
ference in effective membrane thickness. For example, a 
variety of cells, such as some epithelial cells and cancer 
cells, can have a layer of mucopolysaccharide coating asso- 
ciated with their plasma membrane which may increase the 
effective thickness of the membrane and make the cells less 
susceptible to an applied electric field than would be pre- 
dicted by Eq. 7 with V, assumed to be 1 Volt. In fact, 
assuming that the critical electric field imparted to the 
membrane required for poration, E,,, is similar for the cells 
present in the suspension, Eq. 6 indicates that the critical 
transmembrane potential V, will be directly proportional to 
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the effective thickness of the dielectric layer, and, therefore, strength using any suitable regression analysis apparent to 
from Eq. 7, the critical applied electric field strength, E,, for one of skill in the art. 
poration will also be directly proportional to the effective The equation for surviving fraction s can be utilized as a 
membrane thickness. Thus, an applied electric field strength tool to analyze data collected for the surviving fraction of a 
may be chosen that is sufficient to inactivate a substantial 5 particular cell population vs. applied electric field strength 
fraction of cells having an effective membrane thickness and exposure time, generated for a given cell suspension, 
below a certain predetermined threshold without inactivat- and as a guide for selecting the field strength and duration 
ing a substantial fraction of the cells having an effective required to achieve a desired survival fraction for cells 
membrane thickness above the threshold. which are to be porated and inactivated. By prescribing 
Although the threshold electric fields for the cells com- appropriate values for the electric field strength and total 
prising harvested human bone marrow, as exemplified exposure time, required reductions in populations of cells of 
above, were theoretically estimated based on their size (see electroporation threshold below a critical value, for example 
Table l) ,  the critical threshold electric fields for the cells having sizes larger than a critical diameter, can be achieved. 
listed in Table 1 have been previously measured. In addition Eq 8 indicates that s is a strong exponential function of 
to the importance of the magnitude of the applied electric 15 electric field strength E and a weaker power law function of 
field strength, total exposure time of the cells to the electric total electric field exposure time t. 
field is also an important parameter in determining the Thus, isolation and inactivation of cells or discrete objects 
degree of inactivation of a given population of cells. In by size differences according to the present invention pro- 
general, for cells that are selectively inactivated by electric ceeds by selecting an appropriate applied electric field 
fields on the basis of cell size, the electric field strength 2o strength E, so that cells of size greater than (from Eq. 7), d=4 
determines the size below which cells are preserved, and V,J3 E, will be inactivated and then applying an appro- 
total electric field exposure time determines the relative priate number of electric field pulses and/or total electric 
reduction in cells having sizes above the critical size. field exposure time to reduce the viable fraction of cells 
Experiments in the prior art have been conducted over a above the critical size to the desired level. 
wide range of pulsed electric field strengths and number of 25 Table 3 presents the results of cell inactivation experi- 
applied pulses and have led to an empirical model developed ments assembled by Castro on a variety of microorganisms 
by Hulsheger 1983 herein incorporated by reference, for the using Hulsheger’s original form of Eq. 8, which is obtained 
surviving fraction of cells, s,  following electric field by removing the factor “+l”in Eq. 8 (Hulsheger 1983). The 
treatment, as a function of the peak applied electric field threshold electric field E, derived from lethality measure- 
strength, E, and the total time the cells are exposed to the 30 ments for E. coli in the logarithmic growth phase is shown 
electric field, t. The time t in the following model sums the in Table 3 to be 0.7 kV/cm, while the threshold field for E. 
on-time of the electric field over the total number of pulses, coli in the stationary phase is more than 10 times higher, i.e., 
so that t=NpTp, where N, is the number of applied pulses and 8.3 kV/cm. The lower threshold electric fields required to 
T, is the time duration of each pulse over which EZE,. H irreparably porate the membranes of growing cells are 
ulsheger 1983 demonstrated that bacterial cell surviving 35 related to the fact that growing cells are larger and must take 
fraction can be roughly modeled by an empirical expression in nutrients from the external environment, making them 
that is a power law function of time and an exponential more susceptible to electric fields. 
TABLE 3 
Experimental conditions, values, and confidence limits for model parameters. 
E t E, tc k 
Microorganism (kV/cm) (ms) (kV/cm) (ms) (kV/cm) 
E. coli (4 hr) 4-20 0.7-1.1 0.7 r 3.1 11 r 9.6 8.1 r 1.8 
E. coli (30 hr) 10-20 0.7-1.1 8.3 r 0.3 18 r 5.7 6.3 r 1.0 
K. pneumoniae 8-20 0.7-1.1 7.2 r 2.0 29 r 16 6.6 r 1.4 
l? aeruginosa 8-20 0.7-1.1 6.0 r 0.4 35 r 6.1 6.3 r 1.1 
S. aureus 14-20 0.7-1.1 13 r 0.9 58 r 17 2.6 r 0.7 
L. monocytogenes I 12-20 0.7-1.1 10 r 2.6 63 r 12 6.5 r 2.5 
C. albicans 10-20 0.7-1.1 8.4 r 7.5 110 r 33 2.2 r 0.9 
function of electric field strength. Equation 8 provides a 
variant of Hulsheger’s rough model that behaves correctly as 
the exposure time approaches zero for E>E,. 
One embodiment of the invention, involving cancer cell 
Purging and stem cell isolation by applied electric fields such 
55 as pulsed electric fields, is based on the observation that 
non-stem-cells are typically larger in size than stem cells; 
therefore, Eq. 7 and the observation that V, is typically 
about 1 Volt for a wide variety of cell types implies that an 
electric field strength, E,, can be selected that will inactivate 
a substantial fraction of cells larger than the stem cell, 
6o including contaminating tumor cells. After selecting an 
threshold value of the electric field strength for membrane (which can be approximate~y ~ = 2 - 2 , 2  kVlcm to preserve 
breakdown, tc is an exposure time ~ormalization constant, stem cell viability), total electric field exposure time, t, can 
and k is an electric field normalization constant. E,, t, and then be selected with guidance from Eq, 8, and routine 
k can be empirically determined for a given cell suspension 65 experimental optimization, in order to achieve the desired 
by fitting Eq. 8, to data taken relating fractional inactivation reduction in the unwanted, non-stem-cell populations, most 
as a function of exposure time and applied electric field importantly, tumor cell populations. Therefore, electric field 
W E , )  t ~~~~~ 
s = ( ; + l )  
where, is fraction (ranging from 0-1>, Eo is the appropriate predetermined critical electric field strength 
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conditions can be determined that lead to effective tumor cell 
inactivation and stem cell preservation, which is crucial for 
effective transplant tissue purging. 
Unlike stem cell isolation and purging strategies based on 
anti-metabolites, mechanical cell sorting, or antibody bind- s 
isolate stem cells without damage and without mutation of 
the basic genetic molecules (DNNRNA) within the cell. 
TABLE 4 
Parameters influencing PEF tumor cell purging and stem 
cell isolation efficacv. 
ing strategies, the present invention has the potential to Group Parameter Description Range 
- Electric field pulse shape “Rectangular” 
0.5-5 kV/cm 
4 0  ms 
2-20 ,us 
E Electric field strength 
PEF 
Most importantly, the genetic material is shielded from the 
pulsed electric fields by the conductivity of the cell nucleus i o  
and cytoplasm. Furthermore, at the electric field strengths of 
potential developed across critical bonds in these complex 
RNA/DNA molecules is generally not sufficient to break strength equivalent 
these bonds. Hence, stem cell isolation with pulsed electric IS 
within the cells. An additional advantage of using the 
electric-field-based tumor cell purging, stem cell isolation 
strategy is centered on the fact that toxic or potentially 
antibodies, are typically not placed in physical contact with 
the stem cells. residence time 
As previously mentioned, because of difficulties in apply- 
t Total electric field exposure 
T~ Electric field pulse duration 
time 
qps Initial leukocyte 106-108 cellsiml 
,u,. Pulsing medium ionic 
yps Pulsing medium osmolality 
- Agents for cell size 
- Agents for dielectric mem- 
concentration interest for isolating stem cells (about 1-3 kV/cm), the E:zm 
0.0154.15 M KC1 
5300 mOsm/kg-water 
modification 
brane breakdown voltage 
modification 
strength and composition lent Cap++ 
fields should not cause undo damage to the genetic material 
,ul, Inactivation medium ionic 
T~~ Inactivation medium 
- Collection protocol Gradient density 
Fp Electric field pulse rate 
0.15 M KC1 equiva- activating agents, such as anti-metabolites or exogenous 20 ~ ~ ~ ~ e s s i n g  
centrifugation 
Apparatus & pulsing 
medium dependent 
Tps Pulsing medium temperature 541” C. 
ing a continuous potential across electrodes without arcing Heat 
or discharge, electrochemical reactions, and excessive heat 25 Transfer 
generation, the applied electric field is preferably supplied to 
the suspension as a series of short pulses, i.e. as a PEF. The 
maximum electric field pulse duration is typically limited by rectan- 
electric breakdown due to arcing between electrodes in the gular electric field pulse shape is preferred for achieving 
treatment volume and by single Pulse heating effects. The 30 optimum size selectivity. Rectangular pulses are those that 
Pulse repetition rate is limited by the maximum temperature have rise and fall times that are short compared to the pulse 
rise that can be sustained without causing undo damage to duration, and preferably shorter than the charging time scale 
the sample. The minimum allowed pulse duration should be of the dielectric membrane of the cells or objects to be 
greater than the time constant at which the dielectric mem- inactivated (typically rise and fall times areS0.5 ps for most 
brane charges in response to the electric field, as will be 35 applications of interest in the present invention), have essen- 
discussed in greater detail herein. tially no overshoot during the rise- and fall-time transients, 
Thus far, the effect of applied electric field strength and and have a substantially constant electric field strength 
exposure time on the performance of the inventive methods between the rise and fall transients; preferably the difference 
have been discussed in detail. In addition, as mentioned in the maximum and minimum values in the substantially 
earlier, a variety of other parameters related to the PEF, 40 constant field strength region is less than 3%. Non- 
suspension, pulsing medium (fluid carrier), and other pro- rectangular-shaped pulses, such as half-sinewave shaped or 
cessing steps can affect the performance of the inventive exponentially decaying pulses may be employed for some 
method and should be considered when developing an embodiments but will not provide as clearly defined an 
effective isolation or inactivation protocol. What follows is electric field strength, which can broaden the electroporation 
a description of a number of what are believed are important 45 threshold demarcation line between uninactivated and PEF 
factors related to performance. Throughout the description, inactivated cells, thereby degrading the selectivity, 
reference will be made to one embodiment of tumor cell resolution, and efficiency of the PEF cell inactivation 
purging and stem cell isolation from suspensions of hemato- method. 
poietic cells in order to illustrate the concepts with a The range of electric field strengths given in Table 4 is 
concrete example. It should be understood that the particular SO based on the critical electric field strengths given in Table 2 
example chosen is purely exemplary, and the methods may and represents a reasonable range to employ for optimiza- 
be practiced on a wide variety of samples for a wide variety tion trials involving the inactivation of specific cell types 
of desired applications. Table 4 below summarizes some of listed in Table 2 as a function of electric field strength and 
the more important parameters (column 2) that can influence total exposure time. With this electric field range, the range 
PEF performance, particularly as related to tumor cell purg- ss of inactivation that can be expected would range from no 
ing and stem cell isolation, along with contemplated pre- lethal effects on any cells to essentially total inactivation of 
ferred ranges (column 3) of some chosen parameters for all cell types. Based on Eq. 8 ,  total electric field exposure 
tumor cell purging and stem cell isolation. The table will time t can be used to achieve a desired reduction in the 
serve as an outline for the discussion to follow. The “PEF” number of viable unwanted cells. The maximum total elec- 
group includes parameters related to the nature of the 60 tric field exposure time typically will be less than about 10 
applied electric field. The “Pulsing Medium” group includes ms for essentially complete inactivation of tumor cell popu- 
parameters related to the properties of the suspension. The lations. 
“Post Processing” group discusses optional treatments sub- For embodiments involving PEFs, the inactivation of 
sequent to electric field exposure that can, in some cases, biological cells involves multiple steps which are dependent 
enhance performance, and the “Heat Transfer” group 65 on the duration of the individual electric field pulses 5. 
includes parameters related to the heating effects of the Early in the pulse, the membrane of the cell charges, thereby 
applied PEFs. producing an elevated transmembrane potential. The mem- 
For embodiments involving PEFs, a 
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Q,=Jw wq .d2c,V,J4, and the performance of the inventive method, especially for 
isolations based on characteristic cell size. In some embodi- 
where vTvis the volume of the PEF treatment cell (cm3), q, ments however, it can be desirable to suspend a cell sus- 
is the concentration of cells in the PEF treatment volume pension in a somewhat hypotonic medium either prior to 
(cells/cm3), d is the average diameter of the cells in the PEF 60 pulsing, with subsequent pulsing performed in isotonic 
treatment volume (assume for purposes of illustration-10 medium, or during the PEF treatment itself. In these 
pm), c, is membrane specific capacitance (assume for embodiments, the suspending medium should have an ionic 
purposes of illustration-1 pficm’), and V, is the critical strength selected to enable at least one cell type in the 
transmembrane potential for the onset of irreversible pore suspension to undergo osmotic swelling, while not being 
formation (assume for purposes of illustration that V,,26 1 65 low enough to cause rupture or a substantial loss of viability 
Volt). Note that Q, is proportional to the cell concentration, to target cells within the time frame of the treatment. 
qc, Q, can be expressed as: Pre-treatment, or PEF treatment using a hypotonic suspend- 
brane charging time scale z, for spherical cells is given by 
(Lynch P T and Davey M R, Electrical Manipulation of 
Cells, Chapman and Hall, pp. 18-20,1996,; and TessiC J and 
Tsong TY, Electric field induced transient pores in phospho- 
lipid bilayer vesicles, Biochemistry 20:(6) 1548-1554, 
1981.): 
~,%c,d(Pc+Ppxi2)> (9) 
where c, is the membrane specific capacitance (typically-1 
pficm’ for biological cell membranes (see Schanne OF and 
P. Cerreti ER, Impedance Measurements in Biological Cells, 
John Wiley and Sons, New York, p. 331, 1978.)), d is cell 
diameter, p, is the resistivity of the intracellular fluid 
(typically, for cytosol-100 Q-cm), and p is the resistivity 
of the medium supporting the cells during PEF treatment 
(typical range of about 70-500 Q-cm depending on the ionic 
strength of the solution). For a typical cell as exemplified by 
a hematopoietic cell, the maximum charging time constant 
will be on the order of about 0.5 ps. In preferred 
embodiments, in order to achieve thorough membrane 
charging, the duration of the portion of the electric field 
pulse supplying an electric field strength greater than the 
critical field strength, E,, to porate the cell, for example the 
flat-topped portion of a rectangular field pulse, Should be at 
least three to four times the membrane charging time con- 
stant z,, (i.e., for z,-0.4 p, y 1 . 6  p). 
After membrane charging is complete, pore formation 
begins and transport of ionic species between the inside of 
the cell and the pulsing medium takes place. It is known 
(Kinosita K and Tsong TY, Voltage-induced pore formation 
and hemolysis of human erythrocytes, Biochim et Biophys 
Acta.471:227-242, 1977.) (hereinafter “Kinsota 1977”) that 
ion transport processes can enhance PEF cell lysis by 
disrupting the osmotic balance across the cell membrane, 
which, in turn, can lead to cell swelling and irreversible lysis 
due to the uptake of water. It is also known (Kinosita 1977) 
that the efficacy of inducing irreversible cell lysis by PEFs 
decreases for human erythrocytes when the electric field 
pulse length is decreased below about lops and improves as 
the pulse length is increased above 10 p. This phenomenon 
probably reflects the need for an electric field pulse duration 
that is sufficient to allow extensive pore development and 
time for ion species transport. Based on these observations, 
reasonable pulse durations for cells having a size range of 
between about 6 pm and 20 pm, typical for hematopoietic 
cells, can range from about a z,=2 ps to about so z, =20 p. 
PEF cell inactivation and isolation efficacy can also be 
affected by the total concentration of cells in the PEF 
treatment volume. The effect of total concentration can be 
understood by comparing the total electric charge (Q,) 
required to charge the membranes of all of the cells in the 
treatment volume to a transmembrane potential of V,=1 
Volt, with the charge (Q,) actually supplied to the test 
volume by the electric field pulse. Q, can be expressed as: 
P” 
Qp=TpvdlPpsW> (11) 
where z, is the electric field pulse length (sec), vTv is the 
PEF treatment volume (cm3), E is the electric field strength 
(Vicm), pps is the resistivity of the medium supporting the 
cells (typically about 70-500 Q-cm) in the PEF treatment 
volume, and w is the separation distance between the 
electrodes in the PEF treatment. Note that Q, is proportional 
to the electric field pulse length, z,, and inversely propor- 
tional to the pulsing medium resistivity, pps. If the ratio 
Q,/(Q,+Q,) is not small, then cell concentration effects can 
degrade PEF cell inactivation efficacy by significantly 
increasing the effective charging time scale, z, of the cells 
in the treatment volume, i.e., a significant amount of the total 
charge supplied to the treatment volume is required to 
simply charge the cells. In fact, as this ratio approaches 
unity, the cell membranes approach the situation where they 
have just achieved complete charging by the end of the 
electric field pulse, so there would be essentially no addi- 
tional time for pore development and transport of ionic 
species between the cell and the pulsing medium to take 
place. For best performance, the ratio Q,/(Q,+Q,) is pref- 
erably within the range of about 0.00045Qm/(Q,+Q,) 
50.74. The ratio Q,/(Q,+Q,) can be kept constant as the 
cell concentration (q) is increased by increasing the pulse 
length (z,) proportionally and/or by appropriately reducing 
the pulsing medium resistivity (p,) for example by increas- 
ing the ionic strength. The upper limit of cell concentration 
given in Table 4 (qc=lOs cellsiml) has significance relative 
to a clinical PEF tumor cell purging system embodiment. 
For example, one liter of bone marrow, which is the approxi- 
mate volume harvested for autologous transplants, contains 
approximately 10” mononuclear cells, which must be 
purged before transplantation. If PEF conditions can be 
defined that provide high PEF tumor cell inactivation effi- 
cacy for a treatment volume cell concentration of IOs 
cellsiml, then a 100 ml PEF treatment volume, or a flow- 
through system able to process 100 ml of cell suspension, 
can be used to process the entire bone marrow specimen, 
such a system is reasonable both in terms of system size and 
electric field pulse energy requirements. 
In addition to the nature of the applied PEF, the medium 
within which cells are suspended can be a significant factor 
in the performance and efficacy of the invention. The pulsing 
medium, in which biological cells are suspended, in some 
embodiments can have an osmolality that preserves the 
osmotic balance between the intracellular and intercellular 
fluids, in other words isotonic, where isotonic defines a 
solution with an osmotic strength (osmolality) similar to that 
of the suspended cells so that the cells do not undergo 
substantial osmotic pressure-driven cell volume regulation 
(-300 mOsm/kg-water for many mammalian cells, such as 
hematopoietic cells). If the osmotic strength of the pulsing 
medium differs substantially from that of the cytosol of the 
cell, the cell can undergo changes in cell volume, such as 
shrinkage or swelling that can be detrimental to cell viabilitv 
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ing fluid can potentially improve performance for certain 
cell isolations by causing cells to become larger and more 
spherical in shape, and thus potentially more sensitive to the 
effects of an applied electric field. Treating cell suspensions 
that are characterized by cells having a more uniform 
spherical shape can also improve performance by reducing 
the effects of cell orientation within the electric field on 
poration. 
The ionic strength of the pulsing medium can be altered, 
while preserving the desired osmolality, by combining a 
solution comprising one or more solubilized electrolytes 
having a desired osmolality (e.g. an isotonic saline solution) 
with a solution comprising one or more solubilized non- 
electrolytes having a desired osmolality (e.g. an isotonic 
sucrose solution). There are several reasons why, for some 
embodiments, it can be desirable to reduce the ionic strength 
of the pulsing medium from standard physiological condi- 
tions (e.g. equivalent to a 0.15 M NaCl aqueous solution for 
many mammalian cells, such as hematopoietic cells). One 
reason is that it has been shown (Kinosita 1977) that PEF 
treatment using a pulsing solution having a below- 
physiological ionic strength followed by resuspension of 
PEF-treated cells in a standard physiological ionic strength 
solution can enhance cell destruction by colloidal osmotic 
lysis and result in a more rapid and extensive irreparable 
lysis of erythrocytes (red blood cells). This phenomenon has 
also been observed in the context of the present invention 
with leukocytes (white blood cells), where the PEF porated 
cells were subsequently reduced to small cell fragments by 
PEF treatment in low ionic strength medium (e.g. 10 v % 
PBS, 90 v % isotonic sucrose) followed by exposure to a 
physiological strength medium (e.g., isotonic PBS or 
Iscove’s Modified Dulbecco’s Medium (IMDM)). For 
embodiments of the inventive method utilizing a relatively 
lower ionic strength pulsing medium followed by exposure 
to a relatively higher ionic strength medium, the particular 
ionic strengths chosen for the pulse and post-treatment 
medium, and the exposure time of the PEF-treated cells in 
the post-treatment buffer will be selected based on routine 
experimentation with the particular cell suspension of inter- 
est to determine the conditions that yield the highest levels 
of inactivation of undesired cells with the best preservation 
of the viability of desired cells. Typically, the post-treatment 
medium will have an ionic strength similar to the physi- 
ological ionic strength of the cells in the treated suspension 
and the pulse medium will have an ionic strength ranging 
between 10% and 90% that of the post-treatment medium. 
The exposure time of the cells to the post-treatment medium 
can vary from a few seconds to an essentially indefinite 
period. It is important, however, that sufficient time be 
allowed for adequate diffusion and colloidal osmotic lysis to 
take place. In addition to, or instead of, having an ionic 
strength that is higher than that of the pulsing medium, the 
post-treatment medium may for some embodiments, have a 
higher osmolality than the pulsing medium and/or contain an 
agent that causes or enhances irreparable lysis of porated 
cells, such as, in some preferred embodiments, calcium ions. 
For some embodiments including a post-treatment step after 
PEF treatment designed to enhance or cause irreparable cell 
lysis, the cells porated by PEF exposure undergo irreversible 
poration of the cell membrane during PEF treatment, and 
post-treatment, as described, functions to irreparably lyse 
the cells that have already been inactivated by the PEF 
exposure. In other embodiments, exposure to the PEF 
porates, but does not necessarily irreversibly porate, the 
membranes of the cells to be inactivated, with inactivation 
and/or irreparable lysis occurring during a post-treatment 
inactivation step. 
30 
For some embodiments, it may be desirable to remove any 
inactivated cells, lysed cells, and cellular debris from PEF 
treated specimens. Small cell fragments and debris gener- 
ated by cell rupture during irreparable cell lysis can be 
s separated from the viable cells using a variety of techniques 
known in the art, for example single- or multi-gradient 
centrifugation techniques. For embodiments where PEFs or 
post-treatment can fragment affected cells, it is possible to 
separate viable cells from cellular debris using standard 
i o  gradient density centrifugation techniques. For example, 
Ficoll-Paque gradient density centrifugation, which is a 
single gradient separation scheme can be used. Multi- 
gradient centrifugation can also be used for other applica- 
tions as apparent to one of skill in the art. For embodiments 
IS where inactivated cells also undergo irreparable cell lysis, 
characterized by cell rupture, it can also be advantageous to 
add to the suspending medium an agent that is able to 
degrade cellular debris. Avariety of such agents apparent to 
one of skill in the art can be employed to reduce the cellular 
20 debris to its molecular components. Particularly preferred 
are enzymatic agents, and especially preferred is DNase to 
breakdown DNA dispersed in the pulsing media, and trypsin 
digestion to breakdown cell membrane and proteinaceous 
material. Such agents may be present during the PEF 
zs treatment, or alternatively, may be added subsequent to PEF 
treatment. 
Other advantages to reducing the ionic strength of the 
pulsing medium for some embodiments are related to the 
increased resistivity and reduced conductivity of pulsing 
30 solutions having a reduced ionic strength. The power density 
W, (J/cm3) and total charge density Q (Coulomb/cm3) input 
into the PEF treatment volume are both functions of the 
resistivity of the pulsing medium: 
Q=E~,,lpps (13) 
where E is the magnitude of the applied electric field, T, is 
the pulse duration, and pps is the resistivity of the pulsing 
40 medium. The resistivity of the pulsing medium varies 
inversely with ionic strength. Thus, according to Eq. 12, 
energy and power requirements of a PEF treatment cell can 
be reduced by a factor of ten, for example, by using a 
mixture of 10% by volume aqueous isotonic phosphate 
4s buffered saline and 90% by volume aqueous isotonic buff- 
ered sucrose as a pulsing medium instead of a standard 
physiological ionic strength medium. Additionally, reducing 
the ionic strength of the pulsing medium increases the 
resistance of the PEF treatment volume, which, for a given 
SO electric field strength and pulse duration, reduces the elec- 
tron charge driven through the PEF treatment volume as 
shown by Eq. 13. Undesirable electrochemical reactions, 
such as free radical production, are typically proportional to 
the charge driven through the PEF treatment volume. Thus, 
ss reducing the ionic strength of the pulsing medium can 
proportionally decrease the production of free radicals, or 
other undesirable by-products of electrochemical reactions. 
Reduction of electrochemical reactions occurring in the PEF 
treatment volume during treatment can also reduce the pH 
60 swing of the pulsing medium during pulsing and also reduce 
the production of chlorine and hydrogen bubbles. Formation 
of bubbles during treatment is very undesirable, since the 
presence of bubbles can lead to non-uniform field distribu- 
tion within the treatment volume and locally elevated elec- 
65 tric field intensities, which can significantly reduce the size 
selectivity of the inventive cell isolation methods. In 
general, it is desirable to maintain the pH of the pulsing 
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medium relatively constant during PEF treatment and within 
a range that is not detrimental to the viability of the cells 
being treated (typically about pH 7-7.6). Avariety of buffer 
systems apparent to one of skill in the art for use in this range 
that are sufficiently non-toxic to cells can be employed 
including, but not limited to phosphate buffers, BES, MOPS, 
TES, HEPES, DIPSO, and TAPSO. Preferred for embodi- 
ments where precise pH control is especially important, are 
buffer systems including one or more strong organic buffers 
such as those referred to as "Good" buffers (Good, N. E., et 
al., Biochemistry, 5:467(1966); Good, N. E., and Izawa, S., 
Meth. Enzymol., 24(Part B):53(1972); Ferguson, W. J. and 
Good, N. E., Anal. Biochem., 104:300(1980)), and espe- 
cially N-[2-Hydroxyethyl]piperazine-N'-[2-ethanesulfonic 
acid] (HEPES). 
One important consideration in designing and implement- 
ing a PEF isolation or inactivation strategy is heat effects and 
temperature rise due to heat generated within the PEF 
treatment cell due to the energy deposited into the treatment 
cell by the electric field. One issue that depends heavily on 
heat transfer effects is whether the total exposure time of the 
treated suspension should be achieved with a single pulse or 
with a series of pulses. Since many biological cells can be 
non-selectively inactivated by overheating, which is not a 
function of electroporation threshold, and since a single long 
electric field pulse can, without sufficient heat removal, 
cause a greater amount of heating of the cells for a given 
total exposure time, it is preferable, for many embodiments, 
to apply the total electric field exposure time as a series of 
pulses, rather than as a single pulse of longer duration. Since 
cyclic heating and cooling is particularly destructive for 
blood cells, pulse duration should be kept short enough to 
minimize cell and cell suspension temperature excursions 
beyond the physiological range. The rate, or frequency, at 
which electric field pulses may be applied is related to the 
energy deposited in the pulsing medium per electric field 
pulse (Joule heating), the geometric shape and heat transfer 
characteristics of the particular PEF treatment volume and 
the density and thermal conductivity of the pulsing medium 
(which collectively dictate heat removal rates), and the heat 
capacity of the pulsing medium. There are two components 
to the total temperature rise in the PEF treatment volume as 
a function of the electrical energy input: the temperature 
jump ATj(" C.) that occurs for each individual electrical 
pulse; and the steady pulsing temperature rise ATN(0 C.), 
which is a function of the volume and heat transfer charac- 
teristics of the PEF treatment cell. Each time a pulse is 
applied to the pulsing medium, the temperature will jump. 
The magnitude of the temperature jump is proportional to 
the power density Wp given by Eq. 12, and can be expressed 
as: 
AT,(" C . ) = T ~ Z l ~ p m P p x C p >  (14) 
where ATj is the temperature jump (" C.), -cp is the electric 
field pulse length (with a typical range for cell isolations 
involving hematopoietic cells of about for example 2-20 
p), E is the electric field strength (with a typical range for 
cell isolations involving hematopoietic cells of about for 
example 0.5-5 kV/cm), $pm is the density of the pulsing 
medium (typically-1 g/cm3), pps is the resistivity of the 
pulsing suspension (with a typical range for cell isolations 
involving hematopoietic cells of about for example 7&500 
Q-cm), and cp is the specific heat of the pulsing medium 
(typically-4.19 Jig" C.). Under the most extreme conditions 
presented in Table 4, and listed in parenthesis directly above, 
the maximum temperature jump per electric field pulse will 
be ATj-0.86" C. The steady temperature rise is a function of 
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the heat input per pulse, the number of pulses per unit time 
(frequency), and the heat transfer rate of the PEF treatment 
cell tending to remove heat from the treatment volume. One 
dimensional conduction heat transfer considerations may be 
s applied for the static PEF treatment cell embodiment to 
determine the steady pulsing, time average temperature rise 
at the midplane between the electrodes imparting the electric 
field to the treatment volume relative to the temperature of 
the bounding electrodes. This formulation assumes that 
i o  convective transport driven by temperature induced density 
gradients are of negligible importance. Equation 14a below 
(see Holman J P. Heat Transfev, 5th Ed., McGraw-Hill, Inc., 
New York, 1981, p. 35) describes the average temperature 
rise for one dimensional steady pulsing volumetric heat 
IS deposition by PEFs into a treatment volume bounded by two 
plane electrodes. 
AT'I,,",=P 218K (144 
Where q is the volumetric heat deposition rate given by: 
20 
q=F5FZIPpx (14b) 
And where w is the separation distance between the 
electrodes, K is the thermal conductivity of the pulsing 
2s medium, F is the pulse repetition frequency, -cp is the electric 
field pulse length, E is the strength of the imposed electric 
field, and p 
is the resistivity of the pulsing medium. 
Equations 14a and 14b indicate that the mid-plane tem- 
30 perature increases as the square of the electrode separation 
distance, linearly with pulse repetition frequency, the square 
of electric field strength, and inversely proportional to the 
resistivity of the pulsing medium. Since the average mid- 
plane temperature rise given by Eq.'s 14a and 14b, which 
3s constitutes the maximum average temperature rise in the 
PEF treatment volume, is inversely proportional to the 
resistivity of the pulsing medium, an increase in pulse 
repetition frequency by a factor of ten can be realized while 
maintaining the same midplane temperature rise by increas- 
40 ing the pulsing medium resistivity by a factor of ten. This 
can be accomplished by decreasing the ionic strength of the 
pulsing medium to 10% of standard physiological ionic 
strength by the methods described previously. The tempera- 
ture jump given by Eq. 14 in response to the application of 
4s each electric field pulse can be imagined to be superimposed 
on the average steady pulsing temperature rise ATCl,,,, as a 
periodic temperature spike with an exponential decay and a 
frequency corresponding to electric field pulse repetition 
frequency. 
For illustrative purposes, if the electrode spacing is 0.318 
cm and using the most extreme conditions presented in Table 
4, which gave a maximum temperature jump per electric 
field pulse of AT=0.86" C., the steady pulsing temperature 
rise at the midplane between the two electrodes will be 
ss ATcl,ave(o C.)=5.16 F.(Hz). Thus, if the electrodes are main- 
tained at a temperature of 25" C. and one wishes not to 
exceed a midplane peak temperature no greater than 37" C., 
then the average midplane temperature cannot exceed ATcl, 
ave=37-25-ATj, which is ATCl,,,,=11.14" C., which con- 
60 strains the pulse repetition frequency to be no greater than 
F=11.14/5.16=2.16 Hz. If the ionic strength of the pulsing 
medium was reduced by a factor of ten, the pulsing medium 
resistivity would increase by a factor of ten, which would 
allow operating at a pulse repetition frequency of 21.6 Hz 
For illustrative purposes, assuming a worst-case heating 
situation by neglecting any PEF treatment volume heat 
SO 
65 for which ATCl,,,, would remain at 11.14' C. 
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removal effects, the total electric field exposure time 
(t=N,T,, where N, is the number of applied electric field 
pulses) that may be applied without exceeding a predefined 
pulsing medium temperature rise can be expressed as: 
~=@pmPpxcpATmaxIE2> (15) 
where AT,, is the maximum predefined allowable tem- 
perature rise (" C.). For example, if pulsing is initiated with 
a PEF treatment cell pulsing medium temperature of 25" C. 
and we wish not to exceed a final pulsing medium tempera- 
ture of 37" C., then the predefined maximum allowable 
temperature rise is AT,,,=12" C. Based on AT,,,, and the 
strength of the applied electric field the allowable total 
electric field exposure time for a given cell suspension in a 
PEF treatment cell can be determined by Eq. 15. Eq. 15 also 
shows that if a low ionic strength pulsing medium is used, 
the allowable electric field exposure time calculated for a 
given ATrnm is directly proportional to the decrease in ionic 
strength; for example, reducing the ionic strength by a factor 
of ten would increase the allowable exposure time by about 
a factor of ten. Furthermore, since under low ionic strength 
conditions, the energy transferred to the PEF treatment 
volume is reduced, for a given desired total exposure time, 
the pulse frequency may be increased without exceeding the 
predefined maximum temperature rise, thus allowing for a 
more rapid isolation or inactivation. Accordingly, the inven- 
tive PEF strategy can be a very rapid approach to cell 
purging and cell isolation. 
For a single- or multi-pass flow-through PEF treatment 
cell embodiment of the invention, Eq. 15 can be manipulated 
to a form that describes the temperature rise of a fluid 
element of the pulsing medium as it traverses from the inlet 
to the exit of the PEF treatment volume. This formulation 
represents an upper bound on the temperature rise since it 
neglects heat transfer to the bounding electrodes as the fluid 
element passes through the PEF treatment volume. If N, is 
the number of electric field pulses applied during the resi- 
dence time of the pulsing medium in the PEF treatment 
volume and T, is the duration of each of the electric field 
pulses, then the total electric field exposure time is t=Np-cp 
and the resulting temperature rise is given by Eq. 15a below: 
"Trex=~E21@pmPp,cp (is4 
As illustrated above for the static PEF treatment cell 
embodiment, reduction of the ionic strength of the pulsing 
medium, which results in an increase in the resistivity of the 
pulsing medium, can allow a corresponding increase in the 
number of pulses that can be applied during the residence 
time of the pulsing medium in the PEF treatment volume. 
Thus, for the flow-through PEF treatment cell embodiment, 
it can be beneficial to use the lowest ionic strength pulsing 
medium allowable in order to maximize the number of 
pulses that may be applied in a single pass without exceed- 
ing the temperature rise limitations beyond which thermal 
effects impact cell viability. The relationships given above 
provide guidance to the skilled practitioner or selecting 
reasonable pulse repetition frequencies that are appropriate, 
for a specific pulsing medium and electric field pulse inten- 
sity and duration, for inactivating selected cells from a cell 
suspension having a maximum allowable temperature rise. 
Another previously mentioned factor that can influence 
the way in which an applied electric field interacts with a cell 
suspension, and the selectivity of an applied electric field at 
inactivating cells based on a critical electroporation 
threshold, is the shape and orientation of cells within the 
field. This factor is important for any cell inactivation 
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involving non-spherical shaped cells. A problem arises with 
such samples because non-spherical cells, in a given sample, 
are typically randomly aligned with respect to the electric 
field direction. While such a random alignment is not a 
s problem for hematopoietic stem cells or other essentially 
spherical cells, random orientation can reduce the 
effectiveness, especially for cells with large aspect ratios, of 
cell inactivation with applied electric fields. Eq. 1 shows that 
the transmembrane voltage, V,, that results from an applied 
i o  electric field E is directly proportional to the projected 
length, 1, of the cell in the electric field direction. Thus, for 
cells with large aspect ratios, 1 can be highly variable 
depending on the orientation of the cell. Since it is typically 
desirable to apply an essentially time-invariant transmem- 
is brane voltage for a predetermined length of time in order to 
obtain more easily predictable and controllable poration 
results, it is therefore desirable to align cells that are not 
substantially spherical so that they have a more consistent 
and predictable orientation with respect to the electric field 
20 direction. For embodiments of the invention where it is 
desired to align the axes of cylindrical or oval shaped cells 
to achieve maximum PEF inactivation efficiency, an AC 
field can be applied across the sample to accomplish this 
function. The AC field is preferably selected to provide an 
zs essentially uniform oscillating electric field during the PEF 
treatment period, and has a magnitude selected to be suffi- 
cient to align the cells with their long dimensions parallel to 
the PEF field direction for optimum size selectivity by the 
PEF field, without porating the cells or unduly overheating 
30 the pulsing medium. The theoretical treatment of this cell 
alignment technique is discussed in detail by Lynch (Lynch 
P T and Davey M R. Electrical Manipulation of Cells, 
Chapman and Hall, New York, Chapter 4, 1996), herein 
incorporated by reference. 
Some preferred embodiments of the invention include the 
use of an applied electric field for cell inactivation that is a 
bipolar electric field. A"bipo1ar electric field" as used herein 
refers to an electric field that is pulsed or otherwise applied 
to a sample so that the average current across the sample 
40 over the total treatment time is essentially zero. The use of 
bipolar electric fields in the context of the present invention 
provides several advantages over non-bipolar fields. When 
an electric field is applied across a sample, particularly a 
blood sample, electrochemical reactions can occur which 
4s can produce free radicals, other deleterious compounds, and 
species that can shift suspension pH and/or generate 
bubbles. Such electrochemical effects are, as previously 
indicated, undesirable. Within the context of the present 
invention, the inventors have found that undesirable elec- 
SO trochemical effects can be reduced or eliminated by utilizing 
a bipolar electric field pulsed so that the average current 
across the sample over the treatment time is essentially zero. 
Because the application of the bipolar electric field involves 
essentially equal current flows across the sample for each 
ss applied polarity, the reversible electrochemical reactions 
induced by the applied electric field component having a 
first polarity, can be substantially reversed by the applied 
electric field component having the opposite polarity, thus 
yielding a situation characterized by no net electrochemical 
60 reaction over the treatment time. 
There are a variety of ways to apply a bipolar electric field 
to the sample as apparent to one skilled in the electrical 
engineering arts. For some embodiments, the pulses across 
the sample are of essentially equal magnitude, duration, and 
65 number, but alternate pulses are of opposite polarity, while 
for other embodiments, the pulse having a first polarity may 
be of greater magnitude but shorter duration while the pulse 
3s 
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of the reverse polarity is of lower magnitude and longer least 50%, more preferably at least 90%, and most prefer- 
duration, so that the total average current flow is essentially ably at least 95%, while conversely, “substantially non- 
zero. In another embodiment, an electric field pulse having viable” as used herein indicates that at least about 25% of the 
a first polarity is utilized together with a DC current having cells in the population are non-viable, preferably at least 
an opposite polarity selected so that the magnitude and s 75%, more preferably a least 90%, more preferably at least 
duration of each is selected to yield an essentially zero net 95%, and most preferably essentially all of the cells in the 
current in order to achieve no net electrochemical reaction population are non-viable. For applications where the dif- 
within the sample. In yet another embodiment for creating a ference in characteristic size of the desired cell type and the 
desired bipolar electric field, the pulse used to create the PEF undesired cell type is small, a variety of strategies can be 
field may also be utilized to charge a suitable capacitor. i o  utilized to improve the performance of the PEF isolation 
When the original PEF pulse terminates, the capacitor then protocol. One method is to remove the cells that are close in 
discharges back through the solution containing the cells at size to the desired cells by performing a preliminary cell 
a rate determined in part by a resistance in the discharge path separation step that separates cells on some basis other than 
to produce the desired bipolar field. a difference in size. Depending upon the particular 
In addition to reducing undesired electrochemical is application, suitable cell separation methods include but are 
reactions, bipolar PEFs can provide an additional advantage not limited to: flow cytometry; affinity cell chromatography; 
in the selective inactivationflysing of larger cells. The addi- and centrifugation. 
tional advantage lies in that the first pulse component having For example, in an application involving the isolation of 
a first polarity results in a charge across the membrane of the hematopoietic stem cells from other blood or bone marrow 
cell which remains for some period of time after the first 20 cells, both red blood cells (about 7 pm diameter) and resting 
pulse component terminates. If a second pulse component lymphocytes (about 7 pm diameter) are dimensionally the 
having an opposite polarity is applied across the cell during closest to the stem cell (about 6 pm diameter). Because the 
this time, the voltage across the cell can be effectively number of red blood cells is much greater than the number 
doubled for a short period of time. of all of the nucleated cells combined, and because the red 
This doubling effect is greater for larger cells than for zs cells have a higher density than the nucleated cells, they are 
smaller cells because of the larger membrane charging time typically separated from a sample by density gradient 
scale for larger cells (see Eq. 9). This effect can potentially centrifugation, using for example a Ficoll-Paque single 
enhance size-selective destruction of the larger cells, thereby gradient having a density of 1.07 g/cm3 (which will also 
enhancing the cell selectivity of the invention for certain remove polymorphonuclear leukocytes such as neutrophils), 
applications. 30 before PEF application. If the size selectivity of the PEF 
Temperature may also be utilized to enhance cell inacti- isolation for a particular embodiment is not sufficient to 
vation by the inventive methods. In general, biological cells select stem cells over the resting lymphocytes with the 
are less capable of repairing membrane damage at sub- desired level of purity, the resting lymphocytes, or other 
physiological temperatures. This behavior can be utilized to small cells, can be removed from the pulsing medium prior 
increase inactivation of cells in response to an applied 3s to PEF treatment. This can be achieved, by a variety of cell 
electric field. For example, in one embodiment the cells are separation methods known in the art including CD34 tar- 
subjected to a PEF in a solution that is maintained within a geted antibody affinity binding techniques that are selective 
physiological range of temperatures (for most mammalian for CD34- cells, such as hematopoietic precursor cells 
cells, approximately 33-39’ C.), the porated cells are then including some stem cells. An alternative is to add an agent 
resuspended in a solution at a lower temperature, for 40 to the cell suspension that can preferentially modify 
example room temperature (approximately 25” C.) or lower, (increase or decrease) the critical electroporation threshold 
but above the freezing temperature of the suspension. The of a subset of the cells to make them more or less susceptible 
lower temperature solution delays repair of porated mem- to inactivation by electric fields. For example in one 
branes and thus can increase the degree of cell inactivation embodiment, the small resting cells, such as resting 
by colloidal osmotic lysis. 4s lymphocytes, may be eliminated by activating the resting 
Alternatively, since cell repair (i.e. the closing of pores in lymphocytes using an agent that forces the resting lympho- 
a porated cell) will not take place when the cell temperature cytes into their active state so as to achieve their mature size 
is dropped much below body temperature, the PEF exposure (typically about 12 pm) where they can be more easily 
itself can be performed at a lower temperature, thereby inactivated without adversely affecting the stem cell popu- 
permitting irreversible poration to occur at an electric field SO lation. A variety of suitable activating agents are known in 
strength that can be lower than that which would otherwise the art including protein agents, such as cytokines, 
be required. In addition, utilizing a lower PEF subjecting lymphokines, chemokines, anti-cell surface marker 
temperature for any given applied electric field strength can antibodies, and cell receptor antagonists. Other suitable 
improve the kill rate (i.e. reduce the surviving fraction) from stimulants include lectins, such as Phaseolus vulgaris lectin 
that suggested by Eq. 8 as determined for the same given ss (PHA), and concanavalin A. As specific examples, mono- 
field strength but a higher PEF subjecting temperature. clonal anti-CD40 antibody, CD40 ligand, or interleukin-4 
For embodiments of the invention involving applications (IL-4) can efficiently activate resting B-cells (see Valle A, 
where it is desired to selectively inactivate one or more cell Zuber C E, Deffrance T, Djsou, et al., Activation of human 
types having a characteristic size greater than a predeter- B lymphocytes through CD40 and Interleukin 4. Euv J 
mined value while simultaneously leaving substantially 60 Zrnrnuno 19: 1463-1467, 1991. Banchereau J, de Paoli P, 
viable another desired cell type, or group of cell types, Valle A, Garcia E, et al., Long term human B cell lines 
having a characteristic size below the predetermined value, dependent on Interleukin 4 and anti-CD40. Science 
the greater the difference between the predetermined value 251:70-72. 1991. both incorporated herein by reference), 
of size and the characteristic size of the desired cells, in while interleukin-2 (IL-2) and concanavalin Acan efficiently 
general, the easier and more selective the isolation. “Sub- 65 activate T-cells (Berger S L, Lymphocytes as resting cells. 
stantially viable” as used herein indicates that at least about Methods in Enzymology. (eds) Jakoby W and Pastan I. 
10% of the cells in the population are viable, preferably at Academic Press. Vol LVIII:486-494, 1979. Waxman J and 
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Balkwill. (eds) Znterleukin-2. Blackwell Science ing upon the surface density of the beads attached to the cell. 
Publications, Oxford, 1992. both incorporated herein by If the surface density of the attached beads is very high, such 
reference). that an almost continuous layer of metallic beads exists on 
Another factor that can affect the performance of selective the surface of the cell, then the resulting metallic structure 
cell inactivation by electric fields on the the basis of a s will behave as a Faraday cage, which will shield the cell 
difference in a characteristic electroporation threshold based from the effects of the imposed electric fields. If the surface 
on cell size is a concurrent difference in the dielectric density of the beads on the cells is low, however, then the 
membrane breakdown voltage, for example, due to a differ- each bead will behave as an antenna, which can make the 
ence in the effective membrane thickness, between cell effective size of the cell larger, thereby making the cells 
types. In such cases, it can be advantageous to add an agent i o  more susceptible to the lethal effects of the imposed electric 
to the cell suspension, prior to or concurrently with electric fields than implied by the original size of the cell. Thus, 
field application, that can modify (increase or decrease) the agents, such as antibody coated metallic beads, can be used 
dielectric membrane breakdown voltage of one or more cell to alter the electroporation thresholds of specific cells, 
types. For example, for applications where a larger, unde- thereby enhancing PEF selection or inactivation character- 
sirable cell type possesses a thicker effective membrane is istics. 
thickness than a smaller desired cell type, as previously A typical stem cell, shown in FIG. 2a, also possess a 
discussed, the larger cell having the thicker effective mem- unique morphology that can make them less susceptible to 
brane thickness will typically have a higher critical dielectric poration by electric fields than their size would suggest. 
membrane breakdown voltage and thus require a larger Morphologically, stem cells are typically small in size (-6 
electric field strength for inactivation than a comparably 20 pm in diameter for hematopoietic stem cells) with a faint 
sized cell having a thinner membrane. Depending on the halo of cytoplasm 72 between the nuclear sack 74 sur- 
difference in characteristic size and effective membrane rounded by nuclear membrane 73, and outer (plasma) mem- 
thickness between the two cell types, the ability of the brane 71. The next larger nucleated hematopoietic cells, 
electric field to selectively porate the larger cells while not resting lymphocytes (-7-8 pm in diameter), typically have 
affecting the smaller cells can be diminished or eliminated. zs a much larger gap between their nuclear and outer mem- 
Aspecific example of an application where this phenomenon branes. The arrangement of the stem cell’s nuclear 73 and 
may arise is in the use of PEFs for selectively inactivating outer membranes 71 being separated by a very small dis- 
certain tumor cells from tissue samples or hematopoietic cell tance can cause the nuclear 73 and outer membrane 71 to 
suspensions. A variety of tumor cells, for example many become electrically coupled and to charge together as one 
epithelial tumor cells, have associated with their plasma 30 effective dielectric layer of thickness approximately equal to 
membrane a relatively thick layer of mucopolysaccharide, the sum of the thicknesses of the nuclear and outer mem- 
known as the glycocalyx, that can increase the effective branes. Provided the electric field pulse length is small 
thickness of the membrane dielectric layer making the cells compared to the discharge time scale of the nuclear 
less susceptible to the PEF. For applications where this membrane, electric field strengths considerably greater than 
phenomenon is an important consideration, e.g. when cell 3s the value implied by the diameter of the stem cell and the 
kills are substantially less than would be predicted based on critical transmembrane voltage, V, for the outer membrane 
cell size alone, the performance of the PEF method can be 71 will be needed to form temporary or irreversible pores in 
improved by removing the glycocalyx layer prior to sub- stem cells. Specifically, for PEF pulse durations less than the 
jecting the cell suspension to the PEF treatment. Agents that characteristic discharge time scale of the nuclear membrane 
can be used for effectively reducing or eliminating the 40 73, the critical electric field required for the onset of poration 
glycocalyx layer on cell membranes include enzymes such would be: 
as hyaluronidase, collagenase, pronase, elastase, and trypsin 
E=~~,-EXt~,+t,,)it,, (16) (Gmenert D C, Basbaum C B, and Widdicombe J H. 
Long-term culture of normal and cystic fibrosis cells grown where Ecoup is the required electric field strength to porate 
under serum-free conditions, Zn vltro Cell. Dev. Biol. 26, 4s the cell for electrically coupled nuclear 73 and outer 71 
411-418, 1990. Lechner J F, Babcock M S, Marnell M. membranes, E, is the critical field strength as calculated 
Narayan K S, and Kaighn M E. Normal human prostate from Eq. 7, to, is the effective thickness of the outer 
epithelial cell cultures, Methods in Cell Biology, 21B, membrane 71, and t, is the effective thickness of the 
195-225, 1980. Stamfer M R. Isolation and growth of nuclear membrane 73. 
human mammary epithelial cells, Journal of Tissue Culture SO FIG. 2b illustrates electrically the reasons the nuclear and 
Methods, 9, 107-115, 1985.). Alternatively, an agent that outer membranes of the stem cell can charge as one mem- 
preferentially increases the dielectric membrane breakdown brane when the electric field pulse duration is small com- 
voltage of a desired cell type could be used, in addition to pared to the discharge time scale of the nuclear membrane. 
or instead of the above mentioned agents, in some embodi- The poles 81, 82 of the cell are defined as those two points 
ments to make the cells less susceptible to inactivation by ss on the surface of the cell which are closest to the electrodes 
electric fields. imposing the electric field. The membrane gap is defined as 
In some embodiments, where it is desired to alter the the smallest distance between the nuclear and outer mem- 
apparent membrane breakdown voltage or characteristic size branes. The pole-to-pole membrane gap resistance 80 is the 
of one or more subpopulations of cells in a heterogeneous resistance in the membrane gap between opposite poles of 
population of cells, for example when the electroporation 60 the cell. The membrane gap resistance 77 is the gap resis- 
thresholds of desirable and undesirable cellular subsets are tance between the inner and outer membranes. When the 
comparable, such alterations can be effected by attaching membrane gap is very small, the membrane gap resistance 
material to cellular subsets using antibodies that have immu- 77 will be much less than pole-to-pole membrane gap 
nospecificity for the cells, especially monoclonal antibodies. resistance 80. This is typically the case for the stem cell. 
For example, metallic beads coated with a monoclonal 65 Under these conditions the nuclear and outer membranes 
antibody that can bind the bead to a specific cell surface will charge together as one membrane of thickness approxi- 
antigen can produce two distinctly different effects depend- mately equal to the sum of the thicknesses of the nuclear and 
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outer membranes. When the gap is significant, which will be selected viable cells are to be expanded, there may be no 
the case for most other cells in the blood and immune need to remove the post-PEF non-viable cells and debris, 
system, the pole-to-pole membrane gap resistance 80 is less since the expansion process can produce a post-expansion 
than the membrane gap resistance 77, and the nuclear population of viable cells that will render insignificant the 
membrane does not participate significantly in electric field s relatively small numbers of inactivated cells and residual 
effects, so that just the outer membrane charges. If Rpp is cellular debris, or the debris will simply decompose during 
taken as the pole-to-pole membrane gap resistance 80 and the expansion culture. 
Cpp is the capacitance of the dual membrane system, then the FIG. 3 presents a flow chart summarizing the steps of a 
discharge time scale of the nuclear membrane will be no typical PEF cell isolation strategy according to the inven- 
greater than zfic,,<RppCpp. Provided the electric field pulse is i o  tion. It should be reemphasized that for any given cell 
significantly less than zfic,,, the nuclear and outer membranes suspension and desired cell isolation or inactivation, the PEF 
will behave electrically as one membrane of thickness equal parameter values for optimal performance must be selected 
to the sum of the nuclear and outer membrane thicknesses based on routine experimentation and optimization with 
(see Eq. 16) and during this time, electric field strengths guidance from the theoretical development presented previ- 
much greater than implied by the diameter of the stem cell is ously. The general procedures described below may be 
(see Eq. 7) will be required to form irreversible pores. This employed both during screening tests to determine optimal 
effect can enhance the ability to isolate stem cells utilizing PEF parameters for cell isolation, and during actual cell 
the PEF methods of this invention and can reduce the need selections with predetermined optimal parameters. 
to activate cells that arc close in size to the stem cells in Initially, before the beginning of the procedure, PEF 
order to increase the difference in characteristic size. 20 operating parameters (e.g. electric field strength, total expo- 
While the discussion above has been with respect to the sure time, pulse duration and frequency, etc.) are selected as 
poration of larger cells to isolate or segregate stem cells described previously based, in part, upon a difference in a 
which typically have a smaller size, there are also applica- characteristic electroporation threshold difference between 
tions where it may be desirable to porate the stem cells. desired and undesired cells (determines choice of electric 
Heretofore, an effective technique for electroporating stem zs field strength) and a desired degree of cell inactivation 
cells has not existed. Poration of stem cells can be achieved (determines choice of exposure time). The first step 61 of the 
according to the present invention by initially using the PEF procedure 60 is to prepare the cell suspension. The cell 
method to isolate stem cells, and subjecting the isolated stem suspension is prepared by uniformly dispersing and sus- 
cells to an electric field of appropriate magnitude for porat- pending cells in a physiologically compatible, conductive 
ing the stem cells. For example, if the electric field pulse 30 medium. In some cases, e.g. blood, the sample to be treated 
duration, zp, being utilized is less than zfic,,, then the appro- may already be suspended in a suitable medium, in other 
priate magnitude would be determined by employing Eq. 16 cases, e.g. cells from solid tissue or organs, the cells may 
in combination with Eq. 7; however, if the pulse duration is need to be dispersed and resuspended in a suitable medium. 
longer than z,, then the appropriate magnitude would be The viability, concentration and identity of the cells present 
determined by employing Eq. 7. The objective in porating 3s in the pre-PEF treated suspension can be determined by a 
stem cells can be reversible, non-lethal poration or irrevers- variety of methods known in the art. Viability, for example, 
ible poration to lyse or kill the cells. One embodiment of the for many cells, such as mammalian cells, can be determined 
present inventive methods can enable the temporary, revers- by trypan blue dye exclusion. Concentration may be deter- 
ible poration of the stem cells to allow, for example, genetic mined by manual or automated cell counting techniques, for 
material to enter the stem cells, producing genetic mutations 40 example manual counting with a hemacytometer, or auto- 
or recombinations for gene therapy. The inventive stem cell mated counting by light scattering techniques. Individual 
transfection technique may be preferable to many currently cell types can be enumerated and marked for further tracking 
employed techniques, such as using viral transfection, since by standard immunophenotyping techniques known in the 
the PEF poration technique can enable the genetic material art, such as by using cell-specific dyes or dye-labeled 
to enter a larger percentage of the stem cells and can result 4s antibodies (e.g. fluorescently labeled antibodies) that have 
in a higher survival rate for the mutated stem cells. Such specificity for certain cell surface antigens specific to certain 
mutated stem cells can, for example, be utilized in a variety cell types. The labeled cells can then be quantified by 
of gene therapy techniques, for cloning, or to provide standard techniques, for example, fluorescence microscopy 
immunity against specific adverse biological agents such as or flow cytometry. 
viruses, bacteria, and various toxins. The second step 62 of the procedure 60 includes various 
Since a variety of known methods exist for extracting optional pre-treatment methods, or pre-PEF cell separations, 
viable cells from mixtures containing viableidead cells and used to enhance the performance of the PEF treatment. A 
cellular debris, selective inactivation of cells by the methods variety of such methods were discussed previously and 
provided by the present invention represents a potentially include: isolation of a subpopulation of cells by cell sepa- 
important step toward achieving high purity isolation. PEF ss ration methods such as centrifugation, for example, density 
cell inactivation can, via post-PEF spontaneous cell lysis gradient centrifugation; osmotic cell lysis of red blood cells; 
(colloidal osmotic lysis), transform the PEF inactivated cells cell affinity chromatography; fluorescence activated cell 
into ghost membranes and free nuclei dispersed in the sorting (FACS); etc. Other treatments that can be employed 
cellular suspension. Single or multiple gradient centrifuga- at this step include treatments designed to enhance a differ- 
tion techniques can then be used to separate the viable cells, 60 ence in characteristic electroporation threshold, such as: 
and, if desired, any residual intact non-viable cells, from the hypotonic swelling of the cells; treatment with an agent to 
cellular debris composed primarily of ghost membranes and remove a glycocalyx layer from one or more cell types to 
free nuclei. Viable cells can also be extracted from the reduce the effective membrane thickness; treating the cell 
PEF-treated mixture of viableidead cells and cellular debris suspension with an activating agent to increase the charac- 
by using cell sorting, e.g. FACS or flow cytometry, or 65 teristic size of one or more cell types, etc. For applications 
antibody binding strategies that are commercially available involving the isolation of hematopoietic stem cells from 
for a variety of cell types. Alternatively, if the population of blood or bone marrow, typically during this step, mono- 
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nuclear cells are purified from the sample from step 1 by cells from the PEF isolated subpopulation, which sub- 
using a standard Ficoll-Paque density gradient centrifuga- subpopulation may not be distinct with respect to a critical 
tion technique, followed by ACK (product 10-548, electroporation threshold. Such a secondary separation is 
BioWhittaker, Walkersville, Md.) lysis of residual erythro- potentially useful, for example, for applications where it is 
cytes. The mononuclear cells are then washed and resus- s desirable to separate a particular type of progenitor cell from 
pended in an appropriate pulsing buffer. Optionally, an 
activating agent, such as those mentioned previously, may 
be added to the suspension to activate resting lymphocytes, 
or, if tumor cells having a thick glycocalyx layer are present, 
an enzyme may be added to at least partially remove this 
layer. 
The third step 63 of the method 60 involves subjecting the 
cell suspension to the pulsed electric field. Electric field 
strengths and durations may be selected for this step that are 
sufficient to cause irreversible aoration and inactivation of 
a PEF isolated stem cell suspension. As previously 
discussed, preferred stem cell suspensions isolated by PEF 
can contain a variety of different lineage committed colony 
forming cells in addition to the pluripotent cells. One or 
i o  more of these cell sub-types may be isolated by, for example, 
FACS by utilizing one or more labeled antibodies with 
immunospecificity to cell surface markers present on par- 
ticular cell sub-types. 
The final optional seventh step 67 comprises any treat- 
is ments that are aerformed on or usinn the PEF treated cell a 
the porated cells, or alternatively, that are sufficient to suspensions. Such treatments can include, for example, 
reversibly porate but not inactivate porated cells. For some expansion and/or differentiation of the selected cells by in 
purposes, the PEF treated cell suspension produced during vitro cell culture techniques, transfection or other genetic 
this step is in a final, usable form; however, for many modification of selected cells, etc. For example for applica- 
applications, additional post-PEF steps are required or desir- 20 tions involving the isolation of stem cells, since the fraction 
able for attaining a final cell suspension. of stem cells present in a typical pre-treatment sample is 
The fourth step 64 of the method 60 is an optional step very small (about 1:106 in bone marrow aspirate), depending 
performed to inactivate cells that are porated but not inac- on the volume of sample processed, the final quantity of 
tivated in the previous step 63. This step 64 is typically isolated stem cells may not be sufficient to engraft a patient 
employed for embodiments where the PEF parameters cho- zs (typically about lo6 CD34’ cellskg body weight are 
sen in step 63 are sufficient to porate but not inactivate the required). In such cases, the quantity of stem cells can be 
undesired cells; however, the step may also be employed for amplified through standard stem cell amplification and 
embodiments utilizing PEF conditions selected for inacti- expansion techniques (Zandstra, A. J., et al. “Advances in 
vation in order to, for example, increase the total fraction of hematopoietic stem cell culture,” Cuvv Opin Biotechnol 
cells inactivated, speed up the inactivation process, or physi- 30 9:146-151(1998)). Cell culture techniques can also be 
cally disrupt the structure of the inactivated cells by irre- employed to activate the isolated stem cells to differentiate 
versible lysis. As previously discussed, the methods of this along desired lineage paths, thus increasing the number of 
step typically involve resuspending the PEF treated cells in committed progenitor cells reinfused into a patient. An 
an inactivation medium, or adding one or more supplemen- additional post-PEF isolation treatment that can optionally 
tal agents to the PEF medium to create an inactivation 3s be performed on the isolated stem cells, for example for 
medium in situ, designed to accelerate colloidal osmotic gene therapy applications, is reversible poration and trans- 
lysis, prevent cell membrane repair, or both. As previously fection of the cells with genetic material using PEFs to 
discussed, the inactivation medium for use in this step electroporate the stem cells. 
typically will have one or more of the following properties: In most applications, and especially when screening to 
a higher ionic strength than the pulsing medium; a higher 40 determine optimal PEF parameters, it is desirable to char- 
osmolality than the pulsing medium; a lower temperature 
than the pulsing medium; or an agent (e.g. Ca++) that 
specifically promotes colloidal osmotic lysis of porated 
cells. 
The fifth step 65 is an optional step performed to remove 
inactivated cells and cellular debris from the suspension 
containing viable PEF isolated cells. This step can be 
performed by a variety of techniques apparent to the skilled 
artisan, including, but not limited to centrifugation, 
filtration. and adsorution. In some embodiments. suitable 
acterize the post-PEF treatment cell suspension with regard 
to cell quantity, cell viability, and cell identity in order to 
evaluate performance. The techniques described for charac- 
terizing the pre-treatment suspensions can also be employed 
4s to characterize the post-treatment populations. From com- 
parison of the pre- and post-treatment cell suspensions, 
yield, selectivity, enrichment, and depletion determinations 
can be inferred. The inventors have found that for analyzing 
post-PEF suspensions of hematopoietic cells, an effective 
SO and convenient method to simultaneouslv determine cell 
agents may be added in order to break up or reduce cellular viability, cell apoptosis, and cell concentration, and cell 
debris, such agents including, for example DNase, trypsin, identity, is to stain the post-PEF cells obtained after the third 
or other enzymes. For applications involving hematopoietic step 63 or the fifth step 65 above with a combination of 
cell isolations, after PEF treatment, the stem cell enriched propidium iodide, Annexin-V, and fluorescently labeled 
suspension is typically subjected to a Ficoll-Paque gradient ss antibodies specific to CD3, CD14, CD19, CD45, CD34, and 
density centrifugation to remove inactivated cells and cel- CD38 cell surface markers. These cell specific fluorescently 
lular debris. labeled markers allow enumeration of lymphocytes (CD3+, 
For selected applications, it may be desirable to further CD45+), monocytes (CD14+, CD45+), primitive progenitor 
purify, isolate or treat a subpopulation of cells from the PEF cells (CD34+), and certain hematopoietic stem cells 
treated cell suspension. Such secondary, or supplemental 60 (CD34+, CD38-). The viability stain propidium iodide is a 
cell separation or other treatments comprise an optional DNA stain. Thus for cells with disrupted membranes, yet 
sixth step 66. Any of the previously mentioned cell separa- still containing a nucleus, this dye will stain non-viable cells. 
tion techniques can potentially be employed for this step. In Annexin-V, however, stains phosphatidylserine (PS) which 
some cases, the secondary purification may be used to migrates from the inside to the outside of the plasma 
further enrich or purify the subpopulation initially isolated 65 membrane during normal apoptosis. Thus it is normally used 
by PEF treatment, while in other cases, the secondary as an indicator of apoptotic, not yet non-viable cells. 
isolation may involve separating a sub-subpopulation of Whether or not the PS migrates to the external surface of the 
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cell as a result of PEF treatment is unimportant. What is assembly 95 includes a PEF treatment cell 110 that is 
important is that should PEFs result in the discharge of the designed to physically mate with cathode 114 and anode 
nucleus from the cell, Annexin-V will stain the PS on the 112. FIG. 5 is a cross-sectional view of the PEF electrode 
inside of the plasma membrane, since this stain has access enclosure assembly 95 taken by slicing the PEF electrode 
to the inside of the cell due to membrane disruption. Thus, s enclosure assembly 95, as oriented in FIG. 4, into the plane 
ghost cells should have a bright Annexin-V fluorescence of the drawing. The PEF electrode enclosure assembly 95 
signature. Therefore, gating based on both PI and Annexin-v also includes an annular enclosure 122 that is sealingly 
ing for viable cells. Additional markers specific to cancer 113 and bottom plate 111 are connected to each other at 
i o  spaced intervals using a plurality of spacer rods 120 which cells can also be included for applications involving cancer cell purging. are transversed by a threaded rod 126 with threadingly While the above description in association with FIG. 3 is 
intended to illustrate some representative methods and strat- attached nuts 12' which may be tightened to 
be understood that the above description is only illustrative removed for 
and exemplary, and that the invention can be performed is assembly 95. Annular enclosure 122 circumscribes and 
otherwise than described above without departing from the defines an enclosed space 123 that may be evacuated via 
spirit and scope of the invention as presented in the evacuation port 125 or pressurized with a gas via pressur- 
appended claims. Also, the above description presents and ization port 124 in order to more thoroughly insulate the 
describes various methods and techniques that can for electrical components of the assembly. The treatment cell 
certain embodiments and applications be associated with the 20 110 and cathode 114 is supported by a fluid-cooled cathode 
invention; however, additional or substitute methods may be support rod 115 that includes cooling fluid channels 116 and 
used as apparent to the skilled artisan, and details and 117. The anode 112 also preferably includes fluid cooling 
descriptions that, in some cases, may be necessary to per- channels 118 and 119 to provide additional heat removal 
form the invention but that are known or available to those capacity from the treatment cell 110. The fluid cooling 
skilled in the art are not necessarily included or described zs channels are in fluid communication with forced circulation 
herein. cooling system 98 shown in FIG. 4. Forced circulation 
The inventive electric field cellidiscrete object isolation/ cooling system 98 is preferably sized and designed to 
inactivation methods can potentially be performed using a maintain the cathode 114 and anode 112 at a selected 
wide variety of electroporation equipment known in the art temperature controlled to +/-0.1 degrees C. over a tempera- 
(see for example: Gene Pulser 11, BioRad, CA, ECM-2001, 30 ture range of at least 4-50 degrees C. Heat removal and 
BTX, CA, Multiporator, Eppendorf, Ny; Electroporator 11, temperature control of the pulsing medium is effected by 
Invitrogen, CA, PA-4000, Cytopulse, MD). Although there conductive heat transfer from the medium to the temperature 
are numerous electroporation systems available, they are not controlled anode 112 and cathode 114. The PEF electrode 
ideally suited for cell selectioniinactivation discussed herein enclosure assembly 95 should be constructed with appro- 
because they have been designed for electroporation or 3s priate seals so that enclosed space 123 can be maintained 
electrofusion applications for which cell preservation is key, under high vacuum without significant leakage. The PEF 
not cell inactivation. They are also typically not capable of electrode enclosure assembly 95 can be constructed from a 
processing the number of cells appropriate for either variety of materials apparent to one of skill in the art. The 
research or clinical implementations of the cell selection/ anode assembly 112, and cathode 114, should be constructed 
inactivation strategies discussed herein, since they are lim- 40 from conducting materials such as metals. In one particular 
ited by the electric field pulse energies they can deliver. FIG. embodiment, the cathode 114 and anode 112 are constructed 
4 shows one embodiment of a batch system 85 including of copper. In some preferred embodiments, anode assembly 
elements useful for performing the inventive PEF methods. 112 is removable from bottom plate 111 to allow easy access 
The main components of the illustrated system are: an and removal of test cell 110 without the need to disassemble 
electric field pulse driver 101, which applies voltage pulses 4s the entire PEF electrode enclosure assembly 95. The top 113 
to the PEF electrode enclosure assembly 95 (which includes and bottom 111 plates can be constructed of any strong stiff 
the PEF treatment cell); a power supply 102, which can be material. Preferred plates are constructed from an insulating 
external or internal to the pulse driver; an optional oscillo- material such as a strong plastic, for example Lexan. Annu- 
scope 103 for electric field waveform monitoring; a trigger lar enclosure 122 is preferably constructed from a transpar- 
generator 104; and a control/data acquisition system 105, SO ent material such as plexiglass. 
preferably including a computer, for controlling the system The static test cell 110 is shown in exploded view in FIG. 
and gathering and processing data. The control/data acqui- 6. The test cell comprises an anode end block 131, which 
sition system 105, trigger generator 104, oscilloscope 103, mates to anode 112 via element 138, a cathode end block 
power supply 102, and pulse generator 101 are electrically 132, which mates to cathode 114 via element 144. Each end 
coupled via appropriate electrical connections 106, and ss block includes a plate 137, which is circular in the illustrated 
together comprise an electric field generating mechanism embodiment, and a plurality of holes 136 through which 
90. The pulse driver 101 of the generating mechanism 90 is connecting elements pass in order to assemble and seal the 
electrically coupled to the PEF electrode enclosure assembly treatment cell 110. The end blocks are in contact with plate 
95 via cathode connecting line 100 and anode connecting electrodes 133 and 134 which are in turn separated by the 
line 99. Also included in the overall system 85 is an optional 60 fluid containing annular spacer 135. Annular spacer 135 
forced circulation cooling system 98 which forces cooling includes a channel 139 that, when the treatment cell 110 is 
fluid through the PEF electrode enclosure assembly 95 assembled, provides a passage in fluid communication with 
through lines 96 and 97 to remove heat from the treatment an internal volume 140 defined by the annular wall 141 of 
cell that is generated by the electric field and for controlling the spacer 135 and the planar walls 142 of plate electrodes 
the temperature of the treatment cell. 65 133 and 134. In operation, the cell suspension to be treated 
The PEF electrode enclosure assembly 95 of system 85 is is inserted and removed from the treatment volume 140 via 
shown in greater detail in FIG. 5 .  The electrode enclosure channel 139. The treatment cell 110 is sized to provide a 
has been found by the investigators to give the best screen- mated to the top plate 113 and bottom plate 111, Top plate 
egies for performing the inventive cell isolations, it should connect the top and bottom plates, Or loosened and 
Of the PEF 
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treatment volume having a desired total volume. Small scale 
experimental systems typically have a treatment volume of 
about 1-5 ml, while large scale clinical devices preferably 
have a treatment of 0.1-1 liter. 
End blocks 131 and 132 can be constructed of any suitable 
conducting material. Preferred end blocks are constructed 
from metal. Particularly preferred end blocks are con- 
structed from copper and subsequently gold plated, or are 
constructed from tungsten. Annular spacer 135 is con- 
structed from an insulating material that is preferably bio- 
compatible. Apreferred material for constructing the annular 
spacer 135 is tempered glass (e.g. Pyrex@ glass). Electrodes 
133 and 134 can be constructed from any suitable conduct- 
ing material, with preferred electrodes being constructed 
from conducting materials that are biocompatible and which 
do not release toxic amounts of electro-catalyzed reaction 
products during application of the electric field to the 
sample. Particularly preferred electrodes 133 and 134 are 
constructed from graphite carbon. For embodiments utiliz- 
ing porous graphite electrodes 133 and 134, the electrodes 
are preferably degassed after introduction of a pulsing 
medium or cell suspension into test cell 110 so that bubbles 
are not released from the electrodes into the medium during 
application of the PEFs. Degassing can be accomplished by 
a variety of methods apparent to the skilled practitioner, for 
example the pulsing medium can be added to the assembled 
test cell 110 at sub-ambient temperature and subsequently 
heated to ambient or physiological temperature to release 
gas bubbles, or the pulsing medium can be added to an 
assembled treatment cell 110 maintained under vacuum 
during the adding step. A particularly preferred electrode 
arrangement that can reduce or eliminate the release of 
bubbles trapped in the porous matrix is constructed from 
graphite which is subsequently sealed with a sealing agent 
so that the surfaces 142 in contact with the pulsed suspen- 
sions are rendered essentially non-porous. In preferred 
embodiments, the porous matrix is sealed with a thin layer 
of pyrolytic carbon. The test cell 110 is also preferably 
constructed and arranged so that an essentially spatially 
uniform electric field is applied to the treatment volume 140. 
During use, it is important that the suspension undergoing 
treatment completely fill treatment volume 140 so that there 
is no meniscus that can distort the electric field distribution. 
Also, preferred treatment cells 110 are constructed and 
lapped to have very smooth mating surfaces on components 
131, 133, 135, 134, and 132, so that when assembled, the 
treatment cell 110 is fluid tight without the need for supple- 
mental seals, such as washers or O-rings. 
A schematic diagram of a preferred continuous flow PEF 
system 150 is illustrated in FIG. 7. The system includes a 
flow-through treatment cell 151 having two electrodes 152 
and 153 in fluid contact with a flowing suspension being 
treated that enters the treatment cell 151 through line 168 
and exits through line 169. The electrodes 152 and 153 are 
electrically coupled to a generating mechanism 90, which 
can be essentially identical in arrangement as that previously 
described. System 150 also includes pump 160 for pumping 
cell-free pulsing medium through the system, and pump 161 
for pumping a cell suspension through the system. Pumps 
160 and 161 pump fluid via lines 162 and 163 respectively, 
into line 164, which is in fluid communication with three- 
way valve 165. Three-way valve 165 can be set to direct the 
pumped fluid to the treatment cell 151 via line 168 or to a 
waste container 167 via line 166. Pulsing medium or treated 
suspension exiting the treatment cell 151 via lines 169 and 
172 can be controllably directed to a sample container 177 
via line 176 or a waste container 175 through adjustment of 
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three-way valve 173. Particularly preferred embodiments of 
system 150 also include a supplemental pump 170 which 
controllably pumps a desired substance into the stream of 
PEF treated cells via line 171. The desired substance can be 
s a variety of materials useful in the fourth step 64 through the 
sixth step 66 of the exemplary procedure 60 discussed 
previously in reference to FIG. 3. For example, the sub- 
stance supplied by pump 171 can be DNase or be Trypsin, 
added to inactivate released DNA and reduce cellular debris, 
i o  or a medium added to raise the ionic strength and/or osmo- 
lality of the suspension in order to accelerate or bring about 
inactivation through colloidal osmotic lysis. The system as 
arranged allows the treatment cell 151 to be initially primed 
with pulsing medium before addition of cell suspension, and 
IS also allows the treated suspension to be diverted to waste 
until optimal PEF conditions are established. Also optionally 
included in the system 150 but not shown are mechanisms 
downstream of the treatment cell 151 for removing inacti- 
vated cells or cellular debris, such as filters or flow cytom- 
20 eters. In addition, for some embodiments, it may be advan- 
tageous to provide a cooling system, such as system 98 in 
FIG. 4, to remove heat from the flow-through treatment cell 
151. 
The preferred flow-through treatment cell 151 includes 
zs graphite electrodes constructed from similar material as 
discussed for electrodes 133 and 134 previously. The elec- 
trodes can be enclosed in a flow chamber constructed of an 
insulating material such as a plastic, or preferably, Pyrex 
glass. The electrodes 152 and 153 are elongated in shape and 
30 are positioned so that their long axis is parallel to the 
direction of fluid flow and have extended planar surfaces 
154 and 155 in contact with the fluid in treatment volume 
178. The electrodes are preferably constructed and arranged 
so that the electric field applied to the fluid in treatment 
3s volume 178 is substantially spatially uniform and so that the 
electric field strength upstream and downstream of the main 
electric field treatment region (the region bounded by the 
portion of the electrodes 152 and 153 that have surfaces, 
which are in contact with the cell suspension during 
40 operation, that are essentially parallel to one another) essen- 
tially never exceeds the strength in the main electric field 
treatment region. In order to accomplish this, preferred 
electrodes include contoured regions 156 and 157 (scale 
exaggerated in the Fig.) adjacent the inlet and outlet regions 
4s of the test cell 151. Well established electrode profiles exist 
(e.g. Rogowski, Ernst, or Chang profiles) that can be imple- 
mented to obtain the purpose of contours 156 and 157. The 
treatment volume 178 of the test cell 151 is defined, for 
rectangularly shaped test cells, as the product of the length 
SO 179, the gap width 195, and the height h (into the plane of 
the figure and not shown) so that vfllwh, where vTv is the 
total volumetric capacity of treatment volume 178, 1 is the 
length of the test cell 151, and w is smallest gap width 195 
between electrodes 152 and 153. These dimensions are 
ss chosen for a particular application to yield a desired volu- 
metric throughput having a desired total treatment residence 
time in the treatment volume 178 and a shear rate below the 
value that can cause damage to the cells. For a test cell 
having an essentially uniform rectangular cross-section for 
60 flow, the average residence time z,, of fluid in the treatment 
volume vTv is: 
~,=v,lu=lwhlu (17) 
where u is the volumetric flow rate of the fluid. The 
6s maximum laminar shear rate r can be approximated by: 
r=Zu(w+h)/(wh)’ (18) 
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The treatment cell dimensions and throughput flow rate 
should be selected to provide a desired total exposure time 
t to the electric field for a given applied pulse duration, -cp, 
and pulse frequency F. For example, if the desired total 
treatment time is t, then the necessary pulse frequency would 
be: 
F=(ut)/(Zwh,) (19) 
For one exemplary embodiment of treatment 151, length 
179 is 37.3 mm, the gap width 195 is 8 mm, and the height 
(into the plane of the figure) is 4 mm. 
Startup and operation of the flow-through system 150 can 
proceed as follows. The system, in this exemplary 
embodiment, employs syringe pumps for pumps 160, 161, 
and 170. With pump 160 loaded with cell-free pulsing 
medium, pump 161 loaded with the cell suspension to be 
treated, and pump 170 loaded with pulsing medium supple- 
mented with DNase, three-way valve 165 is positioned to 
direct fluid to the treatment cell 151, and three-way valve 
173 is positioned to direct fluid to waste container 175, and 
the lines and treatment cell 151 is flooded with pulsing 
buffer by activating pump 160 in order to remove bubbles 
from the system. Next, pump 160 is stopped, three-way 
valve 165 is repositioned to direct fluid to waste container 
167, and pump 161 is activated to pump cell suspension to 
waste container 167 in order to remove any bubbles from 
line 163. Three-way valve 165 is then switched to direct the 
cell suspension to the treatment cell 151 and the generating 
mechanism 90 is activated to apply PEFs to the treatment 
volume 178. As soon as it is determined that the system is 
functioning properly, three-way valve 173 is positioned to 
direct the treated cell suspension into cell collection con- 
tainer 177. When a desired quantity of cell suspension has 
been processed, pump 161 is shut off and the generating 
mechanism 90 is switched off. Pump 170 may be operated 
as desired during PEF treatment to add DNase to the treated 
cell suspension to prevent coagulation of any cellular debris. 
The sequence of events just described is preferably com- 
puter controlled and pertinent PEF system data is automati- 
cally collected and stored by a data acquisition system. In 
alternate embodiments of flow through system 150, instead 
of passing through the treatment cell 151 only once, the cell 
suspension can be recycled back to the inlet of the treatment 
cell for a plurality of PEF treatments. Also in some 
embodiments, instead of supplying a pulsed electric field to 
the treatment volume 178, the field is maintained at an 
essentially constant value during the PEF subjecting step, 
and the average exposure time of the cells in the suspension 
is simply the average residence time of the cells in the 
treatment volume 178 determined by the suspension flow 
rate. 
Pulse driver 101 (see FIG. 4) for use in systems 85 and 
150 can be any suitable pulse driver known in the art that is 
capable of producing pulsed electric fields within the PEF 
treatment volume of sufficient magnitude and duration for 
inactivating discrete objects of interest. Preferred pulse 
generators are able to induce an electric field magnitude of 
at least about 5 kV/cm, more preferably at least about 10 
kV/cm, and most preferably at least 20 kV/cm in the 
treatment volume. Preferred pulse generators are able to 
supply an electric field pulse duration above a set point 
electric field strength of between about 2-20 ps at pulse 
frequencies between about 0 to 10 kHz. Preferred pulse 
drivers are able to produce a substantially rectangular pulse 
shape, as previously discussed, with rise and fall times not 
exceeding about 0.5 p. Preferred pulse driver mechanisms 
also include control circuitry to allow the maximum pulse 
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voltage to be controllable by the user and to terminate 
pulsing upon detection of an electrical short circuit or arc. 
While pulse drivers based on gas switches, such as thyra- 
trons and spark gaps, can be employed for use in the 
s invention, because of their typically superior durability and 
reliability, pulse drivers based on all-solid-state switch tech- 
nology are preferred. 
Design specifications for the pulse driver are determined 
from the required maximum applied electric field strength, 
i o  maximum required electric field pulse duration, the size of 
the treatment volume, and the electrical resistivity of the 
suspensions being treated. The pulse driver for use in a 
particular application must be designed to supply a maxi- 
mum pulse energy, e,(Joules/pulse), determined by: 
e,~,VrvEz/P,, (20) 
where -cp is the maximum pulse duration, v,is the treatment 
volume, E is the maximum required electric field strength, 
and pps is the resistivity of the sample being treated. For 
2o impedance matched conditions, the load voltage, V,, is 
one-half the maximum charge voltage of the pulse driver. 
The load voltage requirements of the pulse driver can be 
determined by: 
1s 
2s V ~ E W  (21) 
where E is the maximum required electric field strength, and 
w is the distance between the electrodes (see FIG. 7). The 
resistance load of the treatment cell which the pulse driver 
3o must be able to handle is determined by: 
R=p,,,wZ/v, (22) 
where R is the impedance load (Q), pps is the resistivity of 
the sample being treated, w is the distance between the 
FIG. 8 is a block diagram of one embodiment of a pulse 
driver system 180 for use in the inventive PEF systems. The 
pulse driver 180 produces the substantially rectangular bipo- 
lar pulse shown in FIG. 9. The bipolar rectangular pulse 
40 shown in FIG. 9 has short rise 201 and fall 202 times 
separated by flat regions 203 of substantially constant volt- 
age. The trailing opposite polarity segment 204 of the 
waveform serves to reduce and/or reverse electrochemical 
reactions that otherwise can produce hydrogen and chlorine 
4s bubbles, which can degrade performance and affect suspen- 
sion pH. In other embodiments, instead of supplying a 
bipolar pulse as shown in FIG. 9, the pulse generator may 
instead supply a unipolar pulse, as shown in FIG. 10, while 
simultaneously supplying a reverse polarity DC current 
SO properly matched to essentially equal the time-averaged 
current of the electrical field pulses. The pulse shape shown 
in FIG. 10 is not substantially rectangular in shape but is 
instead in the shape of a half sine-wave. As previously 
discussed, such pulse shapes will, in general, yield poorer 
ss electroporation threshold selectivity than more rectangularly 
shaped pulses. 
The pulse driver system in FIG. 8 that produces the 
waveform shape shown in FIG. 9 includes two pulse driver 
circuits 205 and 206, one 205 for a positive polarity voltage 
60 pulse, the other 206 for a trailing, negative polarity pulse. 
Each of the pulse drivers includes a DC power supply (182 
and 183), a storage capacitor 184, and a stack of integrated 
bipolar transistors (IGBTs) 185 and 187, which are solid 
state switches that apply the electrical energy stored in the 
65 storage capacitors 184 to the PEF treatment cell 191. The 
IGBTs each include a switch stack and gate trigger 186,188, 
and a diode 189, 190 on the output line. The IGBTs are 
3s electrodes, and v, is the treatment region volume. 
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stacked in series and parallel combinations to provide as a function of electric field strength, pulse duration, and 
enhanced voltage and current capabilities. Power is supplied total electric field exposure time. The examples given by 
to the pulse driver system from a source 181 of facility line Cases 1-5 were performed under non-optimized PEF con- 
power. Preferred pulse driver systems also include circuitry ditions. Thus, these results represent a lower end demon- 
193 for process control and circuitry 192 for system diag- s stration of the capability of the PEF cell selection strategy. 
nostics and data acquisition as known in the art. In preferred 
Methods and Materials embodiments, the electric field strength developed in the 
PEF treatment cell 191 is determined by circuitry 192 for The methods and materials for the five example cases are 
system diagnostics and data acquisition by use of a Cali- given together below and are broken into three categories: 
brated high voltage probeioscilloscope system. The current i o  cell preparations, cell assays, and PEF apparatus. 
wareform can be measured using a Pearson coil and is, in Cell Preparations 
preferred embodiments, recorded on the same oscilloscope Four cellular systems were used in the example cases: 
as the voltage waveform. The time integrated product of the peripheral blood mononuclear cells (PBMCs), mobilized 
current and voltage waveforms can then be used to deter- peripheral blood mononuclear cells (hereafter referred to as 
mine pulse energy. Pulse energy thus determined, together is peripheral blood progenitor cells, (PBPCs)), megakaryocyte 
with measurements of the pulse repetition frequency and the tumor cells (CMKs), and mammary gland breast tumor cells 
temperature of the electrodes in the treatment cell 191 can be (MCF-7s). 
used, together with a heat transfer mathematical model PBMCs were used in Cases 1 ,2 ,  and 4. The PBMCs were 
describing the heat transfer characteristics of the treatment obtained from healthy donors by harvesting approximately 
cell 191, to calculate the temperature evolution of the pulsed 20 60 ml of peripheral blood per test day by venipuncture 
suspension. Alternatively, the temperature of the pulsed through a 21 G, 1 inch needle (Beckton Dickinson, 305175) 
suspension can be directly measured in a plurality of loca- into a syringe (Beckton Dickinson, 309663) containing 1 ml 
tions within the treatment volume with suitable temperature Heparin (5000U, Elkins-Sinn, Inc., A-0400H). The PBMCs 
probes or thermocouples. Diagnostic 192 and control 193 cells were separated from the whole blood using standard 
systems also, in preferred embodiments, include one or more zs density gradient centrifugation techniques. Under sterile 
computer elements, for example integrated personal conditions, the blood was diluted with twice its volume with 
computers, to control system operation and perform data lxphosphate buffered saline (PBS, Mediatech, 21-031-CV) 
reduction and analysis. and then aliquoted ( 3 0 4 0  ml) into 50 ml conical centrifuge 
The function and advantage of these and other embodi- tubes. Ficoll-Paque (Pharmacia Biotech, 17-0840-03) was 
ments of the present invention will be more fully understood 30 slowly dispensed into the bottom of each centrifuge tube, 
from the examples below. The following examples are and the tubes were centrifuged (IEC, Centra GP8R, rotor no. 
intended to illustrate the operation of the present invention, 228) at 2000 RPM for 30 minutes with the brake off. The 
but not to exemplify the full scope of the invention. PBMCs at the density interface were collected by aspiration 
with a 5 ml pipet. The recovered PBMC layers were 
3s combined into a single 50 ml centrifuge tube. The resulting 
PBMC suspension was then diluted lox using PBS, aliquot- 
ting into as many 50 ml centrifuge tubes as required, 
The experimental examples that follow, presented as five followed by centrifugation at 1500 RPM for 5 minutes. The 
separate cases, demonstrate pulsed electric field cell-size supernatant was aspirated, and one pellet was resuspended 
selectivity, hematopoietic primitive progenitor cell 40 in 10 ml PBS. This 10 ml suspension was then used to 
enrichment, and tumor cell purging. Two PEF cell-size resuspend the pellets of all remaining tubes. PBS was then 
selection examples are presented (Cases 1 and 2). In Case 1 added to the resulting suspension, bringing the total volume 
PEFs were applied to a suspension of peripheral blood to 50 ml. This 50 ml suspension was centifuged at 1500 
mononuclear cells resulting in a step-wise reduction in size RPM for 5 minutes; the supernatant was aspirated; the pellet 
distribution of the PEF treated viable cells as a function of 4s was then resuspended in 20 ml IMDM (Sigma, I 2762) with 
electric field strength and total electric field exposure time. 10% fetal calf serum (FCS, Sigma, F 2442), and then 
In Case 2 PEFs were applied to a suspension of peripheral transferred to a flask and placed in an incubator at 37" C. 
blood mononuclear cells, illustrating lymphocyte enrich- overnight in preparation for PEF treatment the next day. The 
ment by selective inactivation of monocytes in PEF treated next morning the contents of the flask were transferred to a 
specimens as a function of electric field strength and electric SO 50 ml centrifuge tube. The flask was washed three times with 
field exposure time. Case 3 illustrates the enrichment of 10 ml PBS: these PBS wash volumes were added to the 50 
hematopoictic stem cells in PEF treated peripheral blood ml tube containing the bulk of the PBMC specimen. The 
progenitor cell specimens. In Case 3, PEFs were applied to resulting suspension was then centrifuged at 1500 RPM for 
mobilized peripheral blood specimens harvested from a 5 minutes; the supernatant was aspirated, and the cells were 
patient by leukopheresis. Case 3 illustrates the dependence ss suspended in the desired pulsing buffer. Pulsing and post- 
of stem cell enrichment on electric field strength for a fixed PEF treatment buffers are discussed in more detail in a 
electric field exposure time. Two cases are presented that subsequent section. 
illustrate PEF tumor cell purging (Cases 4 and 5). In Case 4, Cell preparation for Case 3 was identical to that for Cases 
PEFs were applied to a suspension of peripheral blood 1 and 2 with the following exceptions. The cells for Case 3 
mononuclear cells seeded with a megakaryocyte tumor cell 60 were obtained by leukopheresis from a cancer patient that 
line (CMK). This case illustrates the selective inactivation of had been administered granulocyte colony stimulating factor 
the tumor cells with simultaneous preservation of lympho- (G-CSF). More specifically, mobilization of the patient's 
cyte and monocyte cells as a function of electric field peripheral blood was effected by administering G-CSF (10 
strength and fixed total electric field exposure time. In Case pg per kg body weight per day) subcutaneously for 4-6 days, 
5 PEFs were applied to a suspension containing only mam- 65 with apheresis collections beginning on day 4 until 2 . 5 ~ 1 0 ~  
mary gland breast tumor cells (MCF-7). This case illustrates CD34+ cells per kg body weight were obtained. The result- 
the PEF inactivation characteristics of this breast tumor line ing cell suspension contained approximately 2x10' leuko- 
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cytes in approximately 2 ml PBS. This cell preparation was CMK culture medium at 37" C., 5% CO,. The CMK culture 
used, instead of the whole blood in the protocol described medium comprised lxRPMI 1640 medium, without 
above for obtaining PBMC preparations. Before suspending glutamine, supplemented with 2 mM L-glutamine (Fisher/ 
the PBPCs in the pulsing buffer, the resting lymphocyte Cellgro, MT-25-005-L1), 50 I.U./ml of penicillin, and 50 
population was activated to move these cells to their larger, s pgiml streptomycin (FisheriCellgro, MT-300-01-LI) and 
active state in order to improve for stem cell enrichment. To 20% FCS. The CMKs were split 1:lO every 3-4 days by 
activate the lymphocytes, the PBPC suspension, transferring about 2 ml of the cell suspension to a new 75 
interleukin-2 (IL-2, 50 IUlml, R n' D Systems) and PHA cm2 flask containing 18 ml of CMK culture medium. Excess 
(0.25 pgiml, Sigma) were added to a culture medium (20 ml, cells were frozen as previously described. On the morning of 
IMDM, 10% FCS) and incubated at 37" C. for 36 hours. i o  a PEF treatment experiment, the CMKs were transferred 
After activation (incubation), the suspension was centri- from the culture flasks to 50 ml Falcon tubes (Becton 
fuged at 1500 RPM for 5 minutes, the supernatant was Dickinson, 2098). As part of this transfer, the cells were 
aspirated, and the resulting pellet was resuspended in the passed through a separation filter (Miltenyi Biotec, Inc., 
desired pulsing buffer. 414-07) to remove large-scale debris. The cells were then 
For Case 4, PBMCs, prepared as described above for is washed in PBS and resuspended in the pulsing buffer in 
Cases 1,2 and 4, were seeded with a megakaryocyte tumor preparation for PEF treatment. 
cell line (CMK, Sat0 T. et al., Bv. J .  Huemutol. June; 1989 Pulsing Medium 
72(2): 184-90). For Case 5, a suspension containing only For Cases 1 and 2, IMDM was used as the medium in 
mammary gland tumor cells (MCF-7, ATCC no. HTB-22) which the PBMCs were suspended for PEF treatment. After 
was exposed to PEFs. Preparation of the MCF-7s for PEF 20 PEF treatment, the treated specimens were combined with 
treatment is described below with modifications to the an equal volume of IMDM. The resulting specimen 
procedure for the CMK line noted. MCF-7 (ATCC no. remained at room temperature until preparation for flow 
HTB-22) cells were thawed under the following conditions. cytometry analysis. 
Avial of cells was thawed at 37" C., then transferred to a 50 For Cases 3, 4, and 5, the cells were suspended in a low 
ml tube (Fisher, 14-959-49A) containing 30 ml of zs ionic strength medium (10% v/v PBS, 90% v/v isotonic 
IxIscove's medium without glutamine (IMDM, Fisher, sucrose solution). This low ionic strength pulsing medium 
MT15 016L,V) and centrifuged at 1500 RPM for five was formulated to be isotonic. After PEF treatment, the 
minutes at room temperature. The supernatant was discarded treated specimen was combined with an approximately 
and the pellet was resuspended in 20 ml of MCF-7 culture- equal volume of IMDM. The inactivation protocol using a 
medium and cultured at 37" C., 5% CO,. The MCF-7 culture 30 low ionic strength pulsing medium, followed by resuspen- 
medium used was IxDulbecco's modification of Eagle's sion in a higher ionic strength medium, was used in these 
medium, without glutamine, including 4.5 g/L glucose, and cases to investigate whether the combination would result in 
supplemented with 2 mM L-glutamine (FisheriCellgro. more extensive post-PEF fragmentation of PEF porated cells 
MT-25-005-L1), 50 I.U./ml of penicillin, and 50 pgiml by colloidal osmotic lysis. The low ionic strength pulsing 
streptomycin (FisheriCellgro, MT-300-01-LI) and 20% 3s buffer was formulated as follows. Twenty milliliters of 
FCS. The cells were split upon reaching confluence, typi- lxsterile PBS was combined with 180 ml of distilled/ 
cally every three to four days, as follows. Culture superna- deionized water. To this solution, 16.6 g of powdered 
tant was aspirated and replaced with 5-6 ml of trypsin (2.5 sucrose was added (Fisher, BP220-212). This solution was 
g/L 1:250 in HBSS without calcium or magnesium, Fisher/ then sterilized by passing it through a 0.2pm filter (Nalgene, 
Cellgro, 25-050-11). After incubation at room temperature 40 291-3320). The pH of the resulting solution was checked 
for 5 minutes, the flask was rinsed using 10 ml of using a Beckman a 4 0  pH meter and was found typically to 
IxDulbecco's Phosphate buffered saline without calcium or lie in the range 7.4-7.6. Prior to final preparation of the 
magnesium (PBS, FisheriCellgro, MT-21-031-CV) supple- cellular suspensions for pulsing, trypan blue exclusion using 
mented with 1% fetal calf serum (FCS, Sigma, T-2442). The phase contrast microscopy was employed to enumerate the 
rinse solution was then transferred to a 50 ml tube, and the 4s number of viable cells present in PBS suspensions of the 
volume was made up to 50 ml with PBS, supplemented with various cells. Given the number of cells desired in the 
1% FCS, before centrifuging the tube, as described above. cellular suspensions for pulsing, the trypan blue results were 
After centrifugation, the supernatant was discarded and the used to determine the volume of PBS cell suspension 
pellet was resuspended in 10 ml of MCF-7 culture medium. required to provide the desired number of cells, which 
Five milliliters of this suspension was transferred to one of SO volume was then centrifuged to pellet the cells. The pellet 
two 75 cm2 flasks, each containing 15 ml of MCF-7 culture- was then suspended in the required amount of pulsing buffer. 
medium, prior to reculture under the above described con- Cell Assays 
ditions. If there were more than two flasks to be split, then Pre- and post-PEF cell enumerations were performed 
the excess cells were frozen as follows. The cells were using both trypan blue exclusion, using a hemacytometer 
trypsinized and washed as previously described, and then ss (Fisher, 02-671-10) under phase contrast optical 
resuspended in 1 ml of freezing medium (10% DMSO, microscopy, and a wide variety of well established flow 
Fisher, D128-500, 90% FCS), per flask and transferred to cytometry protocols. Trypan blue exclusion was used pri- 
labeled cryovials (Fisher, 5000-1020) prior to transfer to a marily for determining the number of viable cells to suspend 
-70" C. freezer. MCF-7 PEF treatment commenced the in the pulsing medium for each experiment. Flow cytometry, 
morning after these cells achieved half-confluency in the 60 using a variety of viability and conjugate antibody fluores- 
culture flasks. On the morning of a PEF experiment, the cent stains, was used to enumerate pre- and post-PEF viable 
MCF-7s were trypsinized using the above protocol, the cell numbers, including lymphocytes (B- and T-cells), 
recovered cells were then washed using PBS, and the monocytes, primitive progenitor cells (including stem cells), 
centrifuge pellet was then suspended in pulsing buffer in and tumor cells (CMK and MCF-7). A Becton Dickinson 
preparation for PEF treatment. 65 FACScan flow cytometer was used to perform the analytical 
For the CMK line, the cell suspensions were thawed as assays. For Cases 1,2,3,  and 4, cell viability was determined 
previously described for the MCF-7 line and cultured in by flow cytometry using either propidium iodide (PI, 
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Molecular Probes, P-3566) or TO-PRO-3 (Molecular The control specimens served two purposes. First, a 
Probes, T-3605) DNA staining combined with light scatter comparison of the total viable cell counts, as provided by 
characteristics. Viable lymphocytes were identified as those flow cytometry, between the stock cell controls and treat- 
cells scoring low for the particular DNAviability stain used ment cell controls gave an indication of the fraction of cells 
(either PI or TO-PRO-3) while staining brightly for CD3 s lost simply by virtue of residence in the PEF treatment cells. 
(T-cells, Fisher, 0B9515-02 or -09) or CD19 (B-cells, Second, the cytometry counts from the treatment cell con- 
Fisher, Becton Dickinson, 340409 or 340364). Viable mono- trols for each cell type were used to normalize the cytometry 
cytes were identified as those cells scoring low for the DNA counts for each cell type for the PEF treated specimens. This 
viability stain used while staining brightly for either CDl lb  allowed for computation of the surviving percent for each 
(Becton Dickinson, 347557), CD13 (Fisher, 0B9555-02 or i o  cell type for each set of PEF conditions. To obtain consistent 
-09), or CD14 (Fisher, 0B9560-02 or -09) and CD45 and meaningful cytometry counts, the following general 
(leukocytes, Fisher, 0B9625-02 or -09). Viable hematopoi- procedure was followed. By virtue of the fact that the PEF 
etic stem cells were identified as those cells scoring low for treatment cells employed had a fixed volume, and that the 
the DNA viability stain used while staining brightly for stock cell suspension controls were prepared using a stock 
CD34)Fisher, 0B9595-02 or -09and dimly for CD38)Fisher, is cell specimen having the same volume as the PEF treatment 
0B9610-02 or -09. Viable CMK tumor cells were identified cells, all of the specimens prepared on a given test day had 
as those cells scoring low for the DNA viability stain used, the same number of input cells. When preparing the control 
staining dimly for CD14, and staining brightly for CD45, and PEF treated specimens for flow cytometry analysis, all 
while also being outside of the light scatter compartments cellular material present prior to PEF treatment was ulti- 
for lymphocytes and monocytes (light scatter gating). 20 mately contained in the aliquot the cytometer drew from 
For Case 5, involving the PEF inactivation characteristics when performing the flow cytometry assays. Thus, if the 
of MCF-7 tumor cells, viable MCF-7s were identified as volume of each cytometry aliquot was the same for all 
those cells scoring low for both the apoptotic membrane specimens on a given test day, then acquiring counts for a 
stain Annexin-V (Caltag, Annexin VVO1-3) and the DNA fixed acquisition time for all specimens would provide 
stain PI. Light scatter gating was also used to discriminate zs viable counts that could be compared across the specimens 
cells from cell debris that was smaller than the smallest of prepared on a given test day. Most importantly, the viable 
the MCF-7 cells. Both PI and Annexin-V viability stains counts for the treatment cell controls could then be used to 
were used for MCF-7 analysis based on the following normalize the viable counts for each PEF treated specimen, 
considerations. Propidium iodide is a DNA stain. Thus, for thereby providing the information needed to compute sur- 
cells with disrupted membranes, yet still containing a 30 viving percent for each PEF-exposed specimen. 
nucleus, this dye will stain non-viable cells Annexin-V, Flow Cytometry 
however, stains phosphatidylserine (PS) which migrates The following procedures were used during preparation of 
from the inside to the outside of the plasma membrane the control and PEF-treated specimens for flow cytometry 
during normal apoptosis. Thus, it is normally used as an analysis. 100 pl of DNase I (100 mg; 500 Kunitz-units per 
indicator of apoptotic, but still viable cells. Whether or not 3s mg solid, Sigma, DN-25) was added to each specimen to 
the PS migrates to the external surface of the cell as a result minimize coagulation by released DNA. The specimens 
of PEF treatment is unimportant. What is important is that were then vortexed and centrifuged for 6 minutes at 1500 
should PEFs result in the discharge of the nucleus from the RPM. The supernatant was aspirated and the pellet was 
cell, Annexin-V will stain the PS on the inside of the plasma washed with 5 ml PBS. When preparing for PI and 
membrane, since this stain has access to the inside of the cell 40 Annexin-V staining, the specimens were centrifuged again 
due to membrane disruption. Thus, ghost cells should have for 6 minutes at 1500 RPM; the supernatant was aspirated, 
a bright Annexin-V fluorescence signature. Therefore, gat- and 100 pl of lxcalcium buffer was added (Bender 
ing based on both PI and Annexin-V has been found by the MedSystems, BMS306BB), followed by addition of 150 pl 
inventors to give the best screening for viable MCF-7 cells. of propidium iodide (PE conjugate) and 5 pl of Annexin-V 
Test and Control Specimens 4s (FITC conjugate). These specimens were incubated at room 
On a given test day, both control specimens and PEF temperature for 15 minutes. Next, 300 pl of lxcalcium 
treated specimens were prepared. Two types of controls buffer was added, the sample vortexed, and then the speci- 
were prepared: 1) a stock cell control specimen and 2) a PEF mens analyzed under flow cytometry. PIiAnnexin-V staining 
test cell control specimen. Stock cell suspension refers to the was the only staining used for Case 5 where the PEF 
cellular suspension in pulsing medium from which fixed SO inactivation characteristics of MCF-7s (with no other cellu- 
volume aliquots were taken for loading into the PEF treat- lar species resent) is presented. PI staining, in conjunction 
ment cells. The stock cell suspension controls were prepared with other conjugate monoclonal antibody stain, was used 
by placing the same volume of stock cell suspension into a for Cases 1 and 2, where the inactivation of PBMCs is 
15 ml centrifuge tube as would be loaded into the PEF presented: Annexin-V viability staining was not used for 
treatment volume. An additional 5 ml of IMDM was then ss these cases (Cases 1 and 2). For Case 1 the specimens were 
added to the same tube. The PEF treatment cell controls also stained using the conjugate monoclonal antibodies CD3 
were prepared by loading a PEF treatment cell with the and CDl lb  in order to enumerate lymphocyte (T-cells) and 
appropriate volume of cell suspension and allowing it to monocyteigranulocyte cells, respectively. For Case 2, the 
stand at room temperature for the period of time it would specimens were also stained with the conjugate monoclonal 
normally take to treat a specimen with PEFs; however, 60 antibodies CD3 and CD13 in order to enumerate lymphocyte 
during this time, no PEFs were applied to the PEF treatment (T-cells) and monocyte cells, respectively. For Case 3, the 
cell control specimens. When the standing period expired, washed pellets were resuspended in 200 pl PBS, which was 
the specimen was removed from the PEF treatment cell and then aliquoted to two 100 pl specimens. The conjugate 
placed in a 15 ml centrifuge tube to which 5 ml of IMDM monoclonal antibody stains CD14 and CD45 were added to 
was added. The PEF treated specimens were handled in the 65 one of these aliquots for enumeration of lymphocyte and 
same way as the PEE treatment cell controls, except PEFs monocyte cells, respectively. The conjugate monoclonal 
were applied to the treated specimens. antibody stains CD34 and CD38 were added to the second 
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aliquot for enumeration of primitive progenitor cells variant is referred to as the Type B test cell (not shown) and 
(hematopoietic stem cells). Both aliquots were then incu- was similar to the Type A test cell previously described with 
bated at room temperature for 15 minutes. These aliquots the following differences. The type B test cell used tungsten 
were then washed with 2 ml PBS, centrifuged for 6 minutes electrodes, rather than graphite and the annular spacer was 
at 1500 RPM; the supernatant was then aspirated, and 500 s made of plexiglass that had four radial holes (1 mm I.D.), 
pl  of 1 pgiml TO-PRO-3 viability stain was added to the equally spaced around its perimeter, that penetrated from the 
tube. The resulting aliquots were then incubated for 15 outer surface through to the inner surface. A silicon washer, 
minutes at room temperature, vortexed, and analyzed under which had an outside diameter equal to the inside diameter 
flow cytometry. The staining for Case 4 was very similar to of the plexiglass spacer and which was approximately 0.05 
Case 3, except the specimens were not stained with the i o  mm thicker than the plexiglass annular spacer, was inserted 
CD34iCD38 conjugate monoclonal antibodies. Rather, these inside the plexiglass spacer during assembly of the Type B 
specimens were stained with the conjugate monoclonal test cell, which silicon washer ultimately formed the cir- 
antibodies CD3 and CD19 (in addition to CD14 and CD45) cumferential bounding wall of the PEF treatment volume. 
in order to enumerate T- and B-cells, respectively. Once the Type B test cells were assembled, they were loaded 
When analyzing Cases 1,  2, 4, and 5 under flow is and unloaded with cell suspension through the 1 mm 1.d. 
cytometry, approximately 100,000 cytometer events were holes using A 21 G hypodermic needles mated to 1 ml 
found to give adequate resolution of the cell types of interest syringes (21 G needles, Becton Dickinson, 305176; 1 ml 
(lymphocytes, monocytes, tumor cells). Due to their rare syringes, Becton Dickinson, 5602). 
frequency, however, 500,000-1,000,000 cytometer counts The internal dimensions of the test cells that were critical 
were required to identify the CD34+/CD38- stem cell 20 for the heat transfer and electric field strength calculations, 
population for Case 3. were as follows. For the Type Atest cells, the diameter of the 
PEF Apparatus cylindrical treatment volume was 4.45 cm, and the gap 
The apparatus used for the examples that follow was a between graphite electrodes, when the test cell is assembled, 
batch PEF treatment system, i.e., PEF treatment takes place was 3.2 mm, which yields a volume of 4.94 ml. For the Type 
in a fixed, static PEF treatment volume. The batch PEF zs B test cells, the diameter of the cylindrical treatment volume 
system is comprised of a batch PEF treatment cell, an was 1.91 cm, and the gap between graphite electrode was 2.5 
electrode enclosure assembly that holds the PEF treatment mm, which yields a volume of 0.72 ml. The parts making up 
volume during exposure to PEFs, an electric field pulse the test cells were fabricated using standard methods known 
generator that applies voltage pulses to the PEF treatment in the art. 
cell, and a computer control/data acquisition system. In general, electrochemical reactions take place in the 
The essential details of the PEF treatment cell used for the region near the electrode surfaces when a current is passed 
examples is illustrated in FIG. 6. The treatment volume is through the electrodes into an electrolyte solution. For the 
formed by stacking the end blocks 131, 132, graphite disk present application, were thousands of electric field pulses 
electrodes 133,134, and Pyrex annular spacer 135 as shown may be applied, gold is not a good electrode candidate. This 
in FIG. 6. This treatment cell has a sealless design, i.e., no 3s is because free chlorine ions can react with the gold, forming 
O-ring or gasket seals are employed to seal the PEF treat- a gold salt, which dissolves in the electrolyte. Tungsten is a 
ment volume 140, defined by the mating of the Pyrex reasonably inert electrode material, but it can react with free 
annular spacer and graphite disks. Rather, all mating sur- oxygen ions to form an oxide layer on the electrodes. Carbon 
faces were lapped to a waviness of no more than 2.5 pm over electrodes (graphite) are the preferred electrode material 
the diameter (8.26 cm) of the disks involved the assembly. 40 since graphite is substantially inert with respect to the ionic 
Furthermore, all mating surfaces were lapped to a number 4 species formed during PEF treatment. 
surface finish, which had an RMS variation in surface To demonstrate to the importance of controlling electro- 
deviations of +/-0.1 pm. The graphite disks were made of chemical reactions, separate experiments were performed 
ISO-63 graphite, which had an average pore size of 1 pm. where electric field pulses were applied to isotonic potas- 
The tolerances were chosen to arevent blood cells. which are 4s sium chloride solutions. Plumes of bubbles were observed to 
30 
typically greater than 5 pm, from finding their way into the 
interface regions of the mating treatment cell components, or 
penetrating into the pores of the graphite disk electrodes. 
Nylon screws were employed to hold the treatment cell 
assembly together. Since all internal surfaces of the treat- 
ment cell were either normal to the electric field direction 
(e.g. conducting surfaces) or were parallel to the electric 
field direction (e.g. insulating surfaces), the utilized treat- 
ment cell geometry provided very uniform electric field 
strength over the entire treatment volume. The end blocks of 
the treatment cell were made of gold coated copper. The gold 
be released from both the anode and cathode electrodes of 
the Type A test cell. Furthermore, after a thousand pulses, the 
pH of the solution shifted from 7.0 to 6.0. However, when 
a DC counter-current was driven through the test cell during 
SO pulsing, which had a current equal to and opposite of the 
time average of the primary electric field pulses, no bubble 
formation was detected and the swing in pH was undetect- 
able. These experiments illustrated the ability of using a 
reverse polarity current to control electrochemical reactions 
ss in unbuffered aqueous solutions having high (i.e. 
physiological) ionic strengths. Reverse polarity currents 
coating was included to minimize surface oxidation and to were not employed in the example cases to follow since the 
provide excellent electrical contact with the assembly that pulsing media used for those cases was typically of lower 
holds the treatment cells during PEF treatment. The pulsing ionic strength and included a buffer to counter the effects of 
suspension was loaded and unloaded from the PEF treatment 60 low concentrations of electrochemically produced products. 
cell through the radial channel 139 in the Pyrex annular Once the test cells were loaded with the desired cellular 
spacer by using a pipetting syringe (pipetting needles, suspension, the test cells were then mounted in an electrode/ 
Fisher, 14-825-16N); 10 ml disposable syringes, Fisher, enclosure assembly that supports the test cell when the PEFs 
14-823-2A). are applied to the test cell. The electrodeienclosure assembly 
The treatment cell just described was used for Cases 1 ,2 ,  65 used for the example cases following has essentially the 
3, and 4. It is referred to hereafter as the Type Atest cell. For same features as the assembly shown in FIG. 5 .  This 
Case 5, a variant of the Type A test cell was used. This assembly serves three purposes. First, it provides electrical 
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contact between the electric pulse generator and the PEF 
treatment cell. Second, it provides temperature control for 
the test cell. Third, it encloses the test cell during PEF 
treatment, thereby protecting personnel in close proximity to 
the system from high voltage components. With reference to 
FIG. 5,  the temperature of the test cells were controlled by 
contact with temperature-controlled cathode 114 and anode 
111 supports of the electrodeienclosure assembly 95. The 
temperature of the cathode and anode supports is controlled 
by circulating temperature controlled water through these 
structures using a heaterichiller system (Neslab, RTE-110). 
This system is capable of setting the temperature of the test 
cells to +/-0.2" C. over the range 0-50" C. After mounting 
the test cells in the electrodeienclosure assembly, the test 
cells were allowed to reach thermal equilibrium with the 
temperature of the cathode and anode structures in the 
electrodeienclosure assembly. 
The electric pulse generator system used for the examples 
consisted of an energy storage capacitor (3 kV, 500 pf, 
Maxwell, 38683), which was connected to an all-solid-state 
pulse driver designed and fabricated by the inventors for 
driving a CO, laser. The pulse driver (electric pulse 
generator) is referred to as the COLD-I. This driver switches 
the energy stored in the 500 pf capacitor via solid-state SCR 
switches to a 20:l saturable core transformer into an imped- 
ance matched load (-8Q). This driver, as presently 
configured, can deliver fixed duration voltage pulses (-5 ps 
duration) at voltages up to 8 kV. Under these conditions, the 
deliverable pulse energy is -80 J. The storage capacitor was 
charged via a Maxwell (1 kV, 5 kJis, CCDS 501P372-208) 
high voltage charging power supply. Normally, the voltage 
output of the COLD-I is to high for use for PEF cell 
selection. This was remedied by using a high power voltage 
divider circuit, which simply comprised two resistors in 
series connected to ground. This voltage divider circuit 
could attenuate the voltage pulses delivered to the PEF test 
cell by factors of 4-20 simply by changing the resistance of 
the two resisters in the circuit. 
APearson coil current transducer was used to monitor the 
current delivered to the PEF test cell. Asecond Pearson coil 
transducer measured the current through a precision 100Q 
resister connected across the PEF test cell. The voltage 
applied to the test cell was derived from the second Pearson 
coil transducer signal by multiplying it by 1OOQ. These 
current and voltage signals were displayed on a LeCroy 
oscilloscope (9410). FIG. 10 presents the voltage waveform 
produced by the COLD-I driver when applied to a Type A 
test cell containing a room temperature isotonic potassium 
chloride solution, which corresponds to imposing a 2.2 
kVicm electric field in this saline solution. 
An IBM personal computer clone was used for system 
control and data acquisition. During PEF treatment, a con- 
trol program was run that issued pulse driver trigger signals. 
The frequency and number of the trigger signals was set by 
the operator based on the PEF conditions desired. The 
magnitude of the voltage pulses delivered to the PEF test 
cell, however, was set by a dial associated with the Maxwell 
charging power supply. The output trigger signal from the 
PC control computer was delivered to an opto-isolator 
circuit, which prevented any electric noise from feeding 
back to the PC. The output of the opto-isolator circuit was 
delivered to an HP 214-B trigger generator, which, in turn, 
sent a 100 volt, 2 ps pulse to the COLD-I driver, which 
triggered the COLD-I, thereby applying the desired electric 
field pulse to the PEF test cell. 
Upon completion of a PEF treatment experimental trial, 
the voltage and current waveform data was downloaded 
from the oscilloscope to the PC computer via a GPIB 
interface. After the data was downloaded, post-processing 
computations were performed. More specifically, the fol- 
lowing quantities were computed: peak voltages and 
s currents, the resistance of the test cell, the full-width at 
half-maximum (FWHM) electric field pulse length, and the 
energy delivered to the test cell per electric field pulse. For 
the cases that follow, the electric field strengths quoted were 
those based on the peak voltage of the pulses delivered to the 
IO PEF test cell. Furthermore, the electric field pulse lengths 
quoted were the FWHM values. After computing the single 
pulse energy deposited to the test cell, the average midplane 
temperature rise in the PEF test cell and the temperature 
jump per electric field pulse for a given PEF treatment trial 
IS was computed. These temperatures, when quoted in the 
cases that follow, were derived using Eqs. 14, 14a, and 14b 
given earlier in the detailed description. 
Case 1. Step-Wise PEF Inactivation of PBMCs 
The ability of PEFs to selectively inactivate cells in a 
step-wise, size-dependent manner with increasing electric 
field strength and exposure time is demonstrated in this case. 
The stock cell suspension contained PBMCs suspended in 
IMDM at a concentration of 1 . 1 ~ 1 0 ~  cellsiml. The pulsing 
25 medium was of standard physiological ionic strength. The 
input cells and stock cell suspension were prepared as 
previously described. Type A test cells were used in the Case 
1 trials. Pulsed electric fields, having strengths in the range 
1.4-1.8 kVicm, were applied to the specimens. The total 
30 electric field exposure times were in the range of 0.18-5.97 
ms, and the electric field pulse length was about 5.75+/-0.2 
ps (FWHM). The total electric field exposure time was 
varied over the noted range by varying the number of 
applied electric field pulses over a range of 30-1000 pulses. 
35 The single pulse energy deposited to the test cell ranged 
from 0.54-0.88 Jipulse. The electric field pulses were 
applied at 1 Hz. The end blocks of the test cells were 
maintained at 35" C.+i-O.2" C. Based on Eqs. 14, 14a, and 
14b, the average midplane temperature varied over the range 
40 from about 35.2-35.4' C. and the temperature jump per 
electric field pulse varied over the range 0.03-0.04" C. One 
stock cell control specimen and one test cell control speci- 
men were prepared before commencing PEF treatments, and 
one test cell control specimen was prepared after all PEF 
45 treatments had been performed for the test day in question. 
The control and PEF treated specimens (about 5 ml each) 
were placed in 15 ml centrihge tubes after preparation, to 
which an approximately equal volume of IMDM was added 
as previously described. These specimens were then ana- 
so lyzed by flow cytometry for enumeration of viable cell types 
and numbers as also previously described. 
FIG. 11 presents total surviving percent of all viable cells, 
on the y-axis, as a function of total electric field exposure 
time, for three different electric field strengths. These results 
5s indicate that PEF lethality, expressed as surviving percent, 
increased with increasing electric field strength and total 
electric field exposure time as predicted by Eq. 8. Further, 
FIG. 11 indicates that the onset of significant cell inactiva- 
tion occurred at approximately 1.8 kVicm. This measured 
60 threshold strength is in reasonable agreement with the 
threshold strength for the resting lymphocytes given in Table 
2, which would be expected since the most abundant popu- 
lation of cells in the PBMC specimens were resting lym- 
phocytes. 
FIGS. 12a-12d show viability scatter plots that were 
derived from flow cytometry assays of the specimens for this 
case. The results given in these figures were generated for 
2o 
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specimens exposed to a fixed electric field strength of 1.8 
kV/cm. FIG 12a shows the scatter plot for the test cell 
control specimen, whereas FIGS. 12b, 12c, and 12d show 
the scatter plots for 30, 100, and 300 applied electric field 
pulses respectively. The y-axes in these figures show relative 
propidium iodide (PI) intensity, and the x-axes show forward 
scattered (FSC-H) light angles, which are proportional to 
cell size. High PI values are indicative of non-viable cells. 
High FSC-H values are large cells. Regions represented by 
R 1  and R2 in these figures correspond to viable cells. In FIG. 
12a, the viable cells in R 1  and R2 form a pattern that looks 
like a pan with a handle. It can be seen that as one scans from 
FIG 12a to 124  the handle (i.e. viable cells in R2) disap- 
pears. These figures also show that the fraction of cells that 
scored high for PI increased with increasing total electric 
field exposure time (total number of applied pulses). Thus, 
for a field strength of 1.8 kV/cm, FIGS. 12a-12d indicate 
that the applied PEFs were selectively killing the larger 
cells. 
FIGS. 13a-13c present CDllblCD3 flow cytometry scat- 
ter plots for the corresponding specimens shown in FIGS. 
12a-12d. FIG. 13a shows results for the control specimen. 
Relative intensity of CDl lb  staining is shown on the y-axes, 
and relative intensity of CD3 staining is shown on the 
x-axes. FIGS. 13b, 13c, and 13d correspond to PEF treated 
specimens that received 30, 100, and 300 electric field 
pulses of 1.8 kV/cm strength respectively. Cells scoring high 
for CDl lb  are predominately monocytes. Those scoring 
high for CD3 are predominately T-cells. Based on Table 2, 
the T-cells (a subset of lymphocytes) are typically about 7 
pm in size, whereas the monocytes are typically about 15 pm 
in size. The upper left quadrant of FIG. 13a displays a 
distinct monocyte population that diminishes significantly as 
one scans from FIG. 13a to FIG. 13b to FIG. 13c and finally 
to FIG. 13d. In contrast, however, the T-cell population 
(lower right quadrant) has not been reduced as significantly 
as the monocyte population. Thus, the 1.8 kV/cm PEFs have 
selectively depleted the monocyte cells while preserving a 
significant fraction of the T-cells. 
Case 2. PEF Enrichment of Lymphocytes over 
Monocytes 
The ability of PEFs to enrich a PBMC specimen in 
lymphocytes by selective inactivation of the larger mono- 
cytes was demonstrated in this case. The stock cell suspen- 
sion contained PBMCs suspended in IMDM at a concen- 
tration of 1 . 5 ~ 1 0 ~  cellsiml. The pulsing medium was of 
standard physiological ionic strength. The input cells and 
stock cell suspension were prepared as previously described. 
Type A test cells were used for the Case 2 trials. Pulsed 
electric fields, having strengths in the range 1.2-1.6 kV/cm, 
were applied to the specimens. The total electric field 
exposure times were in the range 0.15-5.70 ms, and the 
electric field pulse length was about 5.17+/-0.3ps (FWHM). 
The total electric field exposure time was varied over the 
noted range by varying the number of applied electric field 
pulses over a range of 3Ck1000 pulses. The single pulse 
energy deposited to the test cells ranged from 0.36-0.77 
Jipulse. The electric field pulses were applied at 1 Hz. The 
end blocks of the test cells were maintained at 35" C.+/-0.2" 
C. Based on Eqs. 14, 14a, and 14b, the average midplane 
temperature varied over the range 35.1-35.3' C. and the 
temperature jump per electric field pulse varied over the 
range 0.024.04" C. One stock cell control specimen and 
one test cell control specimen were prepared before com- 
mencing PEF treatments, and one test cell control specimen 
was prepared after all PEF treatments had been performed 
60 
for the test day in question. The control and PEF treated 
specimens (about 5 ml EACH) were placed in 15 ml 
centrifuge tubes after preparation, to which an approxi- 
mately equal volume of IMDM was added as previously 
s described. These specimens were then analyzed by flow 
cytometry for enumeration of viable cell types and numbers 
as also previously described. 
The data in FIG. 14 is presented in the same format as 
shown previously in FIG. 11. The results indicate that PEF 
10 lethality, inversely proportional to surviving percent, 
increased with increasing electric field strength and total 
electric field exposure time as predicted by Eq. 8. The results 
presented in this figure exhibit the same trends as the data 
presented FIG. 11 for Case 1. 
Using light scatter, viability stain gating, and CD3 and 
CD13 antibody fluorescence. viable lymphocyte and mono- 
cyte cells populations were enumerated independently. 
FIGS. 15a-15j present the results in forward scatter histo- 
gram format with relative numbers of cells on the y-axes and 
2o size on the x-axes. FIGS. 15a and 15fshow the monocyte 
(FIG. 1%) and lymphocyte (FIG. l5f) histograms for the 
control specimens. Similarly, FIGS. 1% and 15g, 1% and 
15h, 15d and 1 5 ,  and 1% and 15j show the monocyte and 
lymphocyte histograms, respectively within each pair of 
25 Figs., for an electric field strength of 1.4 kV/cm and total 
electric field exposure times of 0.15 ms (30 pulses, FIGS. 
15b and 15g), 0.33 ms (65 pulses, FIGS. 1% and 15h), 0.70 
ms (140 pulses, FIGS. 15d and E ) ,  1.50 ms (300 pulses, 
FIGS. 1% and 15).  The size difference between the mono- 
30 cytes and lymphocytes can be inferred by considering the 
location of the corresponding distributions on the forward 
scatter axis: the monocytes are farther to the right (i.e. 
larger) relative to the lymphocytes (compare FIGS. 15a and 
l5f for example). Progressively comparing corresponding 
35 pairs of Figs. for related PEF treatment conditions and 
increasing electric field exposure times (i.e. comparing 
FIGS. 1% and lSf, then FIGS. 15b and FIG. 15g, etc.), 
indicates that as total electric field exposure time increased, 
there was a large reduction in the number of monocytes, with 
40 only a minor reduction in the number of lymphocytes. (Note 
that the scale for the monocyte histograms changes from 
FIG. 1% to FIG. 15c, and again from FIGS. 15d to 1 5 ) .  
FIGS. 15 a-15j clearly demonstrate the size selective inac- 
tivation characteristics of PEFs for this cellular system. It is 
45 also noteworthy that the steepness of the tail on the right 
hand side of the lymphocyte distributions increases with 
increasing electric field exposure time an indication that the 
larger lymphocytes were inactivated before the smaller ones. 
The results for this case have been replotted in FIG. 16 as 
lymphocyte enrichment (y-axis) as a function of total elec- 
tric field exposure time (x-axis) for three different electric 
field strengths. Lymphocyte enrichment was defined as the 
ratio of lymphocytes to monocytes for the control specimen 
55 divided by this ratio for the PEF treated specimens. This 
figure clearly shows that lymphocyte enrichment increased 
with both electric field strength and total electric field 
exposure time. At a field strength of 1.6 kV/cm and a total 
electric field exposure time of -5 ms, essentially no mono- 
6o cytes were detected by flow cytometry thereby yielding an 
essentially infinite value for lymphocyte enrichment. 
Case 3. PEF Enrichment of Stem Cells in PBPC 
Preparations 
65 The ability of PEFs to enrich PBPC specimens for 
hematopoietic stem cells by selective inactivation of the 
larger cells present in heterogeneous PBPC mixtures was 
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demonstrated in this case. The stock cell suspension con- 
tained PBPCs suspended in a low ionic strength pulsing 
medium (10% viv PBS, 90% viv isotonic sucrose solution) 
at a concentration of 6 . 6 ~ 1 0 ~  cellsiml. The PBPCs were 
harvested from patients, by leukopheresis, that had received 5 
G-CSF treatments as Previously discussed. Prior to PEF 
treatment, the resting 1YmPhoCYtes in the PBPC Preparation 
were activated, as previously discussed, thereby stimulating 
these cells to their active state which nearly doubled their 
included PBMCs and CMK tumor cells suspended in a low 
ionic strength pulsing medium (10% viv PBS, 90% viv 
isotonic sucrose solution) at 2 . 5 ~ 1 0 ~  cellsiml. The CMK 
tumor cells represented about 14% of the total number of 
cells. The CM& are a megakaryocyte line whose size 
approximates epithelial tumor cell types. The PBMCs and 
CMKs were prepared as previously described. Type A test 
cells were used for the Case 4 trials. Pulsed electric fields, 
having strengths in the range 1.2-1.8 kVicm, were applied 
size. Type A test were for the Case PLllsed 10 to the specimens, The total electric field exposure time was 
3.6 ms (1000 applied pulses), and the electric field pulse 
were to the specimens' The length was 3.6 (FWHM), The single pulse energy depos- 
electric field pulse length was 5.30 ranged from 0.04-0.10 Jhulse, and the 
having strengths Of 1.7, 1.8, and 1.9 kVicm, 
exposure time was 5.30 ms (1000 applied pulses), and the 
pulse energy deposited in the test cells ranged from electric field pulses were applied at 1 Hz. The end blocks of 
0.11-0.15 ~ / ~ ~ l ~ ~ ,  The electric field pulses were applied at is the test cells were maintained at 35" C.+/-0.2" C. Based on 
about 350 c , + ~ - o , ~ o  c,Based on 14, 14a, and 14b, the varied from about 35.02-35.04' C. and the temperature 
average midplane temperature varied from about 35.0-35.1' jump Per electric field Pulse varied from about @0~2-0.005" 
C., and the temperature jump per electric field pulse varied c .  One stock cell control specimen and one test control 
from about 0.005-0.007" C. One stock cell control specimen 20 specimen were prepared before commencing PEF 
and one test cell control specimen were prepared before treatments, and one test cell control specimen was prepared 
commencing PEF treatments, and one test cell control after all PEF treatments had been performed. The controls 
specimen was prepared after all PEF treatments had been and PEF treated specimens (each about 5 ml) were placed in 
performed The controls and PEF treated specimens (each 15 ml centrifuge tubes after preparation, to which an 
about 5 ml) were Placed in 15 ml centrifuge tubes after 2s approximately equal volume of IMDM was added as pre- 
Preparation, to which an equal volume of IMDM was added viously described. The specimens were then analyzed by 
as Previously described. The specimens were then analyzed flow cytometry for cell identification and enumeration as 
by flow cytometry for cell identification and enumeration as previous~y described, FIGS, 18a-18f show the flow cytom- 
etry data from the analysis of the input cells for this case. previously described. 
(T0-PR0-3and CD34, and CD38 anti- 30 FIGS. 18a, 18c. and 18e are the light scatter plots (no 
body staining, viable primitive progenitor cells were enu- viability stain gating) for the CMK cells alone, the PBMCs 
merated in the control and PEF treated specimens. Hemato- alone, and the CMWBMC mixture, respectively, FIGS, 
poietic stem cells were identified as those viable cells that 18b, 18d, and lsf are viability stain histograms for the 
CMKs alone, the PBMCs alone, and the C M W B M C  scored low for the viability stain, high for the CD34 fluo- rescence marker, and low for the CD38 marker (i.e., CD34+/ 
CD38- or CD34 single positive cells), The results for this 35 mixture respectively. Cells staining for the viability stain 
bars in FIG, 17 correspond to the surviving percent of all ered dead. FIG. 18b indicates that the CMK cells had a 
cells in the suspension. The unshaded bars correspond to component (i.e. that Population above 10' on the x-axis) that 
stem cell enrichment, which was defined as the ratio of was either dead or represented cell debris. These dead cells 
viable stem cells to total viable cells in the PEF treated 40 Or debris showed UP in the light scatter Plot (FIG. 18a) as a 
specimens normalized by the Same ratio for the control band of dots that extend up and to the right from the origin. 
specimens. FIG. 17 shows that the total surviving percent of The viable CMK population appeared as a cluster of dots 
cells decreased with increasing electric field strength. that is centered vertically in FIG. 18a and slightly to the right 
However, stem cell enrichment increased with increasing of center horizontally. FIG. 18c indicates that were three 
electric field strength. In fact, at 1.9 kVicm, enrichment 45 clusters of dots for the PBMCs. The cluster near the origin 
approached 1 1%. Significantly, the enrichment increased represents fine cell debris. The next cluster to the right 
inversely ProPortional to the decrease in total surviving represents the lymphocyte population, and the cluster fur- 
Percent. This indicates that the stem cell Population was thest to the right represents the monocyte population. The 
being preserved and demonstrates the Of PEF's to lymphocyte, monocyte, and CMK clusters are evident in 
enrich PBPC specimens for stem cells. 
It be re-emphasized that these were FIGS. 19a-19f qualitatively illustrate the effect of apply- 
ing 1000 electric field pulses, each with a strength of 1.8 obtained under conditions that were not optimized for stem 
kVicm, to the C M W B M C  mixture. FIGS. 19a, 19b, and cell enrichment. More specifically, the electric field wave- form shape used for this case (see FIG. 10) was Gaussian in 
shape, rather than rectangular, and the length of the pulse (5 19' are a light scatter plot, CD14iCD45 bivariate plot, and 
was very short, A discussed previously, the electric field 55 TO-PRO-3 viability histogram, respectively for the control 
waveform shape is preferably rectangular (with very short specimen. 19d3 19e3 and 19f present the Same 'Orre- 
riseifall times and with an essentially constant field strength sPonding information as 1 9 a 2  19b2 and 19c 
between rise and fall) for obtaining optimal size respectively, for the specimen treated with 1000 electric field 
selectivity. Also, as discussed previously, short electric field Pulses, each having a strength Of 1.8 kVicm. As in l s e 3  
pulses, such as the 5 ps pulses used in the present case are 60 the lymphocyte, monocyte, and CMK PoPulations are evi- 
generally less effective for cell inactivation than pulse dent in 19a. region R1 (in 19a and 19d) 
durations greater than about 10 ps. enclose the CMK population. Bracketed region R3 (in FIG. 
19c and 19f> defines viable cells as judged by TO-PRO-3 
viability staining intensity. Scatter plots shown in FIGS. 19b 
65 (control) and 19e (PEF treated specimen) were gated on both 
R 1  and R3, so the cells appearing in these two figures 
represent viable cells in the R 1  light scatter compartment, 
(FWHM), The single ited to the test 
1 Hz. The end blocks of the test cells were maintained at Eqs. 14, 14a, and 14b, the average temperature 
Using 
case are presented in FIG, 17 in bar chart format, The shaded (T0-PR0-3with an intensity greater than lo' were 
50 FIG. 18e. 
Case 4. PEF Purging of CMK Tumor Cells in 
PBMCs 
This case demonstrates the ability of PEFs to purge 
PBMC suspensions of tumor cells. The stock cell suspension 
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which is dominated by the CMK tumor cells. The lower right 
quadrant of FIG. 19b shows a well defined CMKpopulation. 
The upper right quadrant, however, shows that the R 1  region 
19e 
than a standard physiological ionic strength medium as used 
for the results presented in FIGS. 11 and 14. 
As noted, the pulsing medium used for this case was a low 
ionic strength pulsing buffer (10% v/v PBS, 90% v/v iso- 
tonic Sucrose solution), This low ionic strength pulsing 
medium was used for two reasons, First, as previously 
discussed, application of PEFs to cells in a low ionic 
contained a number Of monocytes. 
shows that both the CMKs and monocytes were 
by Of 'Oo0 pulses Of 1.8 kVicm 
strength. However, the light scatter plot (FIG. 1 9 4  for the 
5 
PEF treated specimen indicates that the specimen still con- strength pulsing medium, followed by resuspension in a 
tained 
change in the T0-PR0-3 
'ymphocyte and monocyte popu1ations. The standard physiological strength buffer, can lead to more 
19c and 10 extensive fragmentation of the of the PEF porated cells, It 
was observed during PEF cell selection experiments that 
post-PEF specimens that were treated with PEFs in a low 
ionic strength pulsing medium, followed by resuspension in 
a higher ionic strength medium, included far fewer trypan 
histograms 
19f> indicates that Only the CMK population had 
been affected by PEF treatment (the 
19', which is missing in 
population, which was derived by 'Onsidering 
peak in 
19f corresponds to the CMK 
lSb). 
20a-20f examine the effect Of PEFs On the lYm- 15 blue stained cells than when treated with PEFs under con- 
PhocYte Population. FIGS. 2% 20b, and 2oC are light ditions where the pulsing buffer was of standard physiologi- 
scatter, CD3ICD19 bivariate plots, and TO-PRO-3 viability cal ionic strength, even though the reductions in viable cells 
histograms, respectively, for the control specimen. FIGS. were comparable. This result indicates that the combination 
20d, 20e, and 20f are the light scatter, CD3iCD19 bivariate of a low ionic strength pulsing buffer and a higher ionic 
plots, and TO-PRO-3 viability histograms, respectively, for 20 strength Post-PEF resuspension buffer led to greater frag- 
the specimen that was treated with 1 0  electric field Pulses, mentation of the PEF porated cells by colloidal osmotic cell 
each having a strength of 1.8 kvicm. In FIG. 20a and FIG. lysis than for conditions where the pulsing buffer was of 
20dj regions labeled R4, R6, and R7 correspond to the light standard physiological ionic strength. Secondly, a lower 
scatter that the lYmPhocYtes, ionic strength pulsing medium requires lower energy input 
monocytes, and CM&, respectively. The TO-PRO-3 viabil- 2s to achieve the Same electric field strengths, 
ity histograms in FIG. 20c and FIG. 20f were gated on R4, 
which means that only events in the lymphocyte compart- 
ments in the light scatter plots are displayed in FIG. 20c and 
FIG. 20f. FIGS. 20b and 20e are gated on R8 (the TO-PRO-3 The efficacy of PEF inactivation of breast tumor cells was 
viability ranges in either FIG. 20c or FIG. 2 0 4  and R4 (the 30 investigated in this case. The stock cell suspension contained 
lymphocyte compartment in either FIG. 20a and FIG. 204.  only breast tumor cells (MCF-7), which were suspended in 
Thus, FIG. 20b and FIG. 20e display only the viable cells a low ionic strength pulsing medium (10% viv PB5,90% viv 
from the lymphocyte light scatter compartments. The con- isotonic sucrose solution) at a total concentration of 1 . 2 ~ 1 0 ~  
jugate monoclonal antibody fluorescence marker CD3 stains cellsiml. The MCF-7s were prepared as previously 
T-cells, a subset of lymphocytes. The fluorescence marker 35 described. Type B test cells were used for the Case 5 
CD19 stains B-cells. Thus, the upper left quadrants in FIG. experiments. Pulsed electric fields, having field strengths in 
20b and FIG. 20e contain viable T-cells, whereas the lower the range of 1.Ck2.0 kVicm were applied to the specimens. 
right quadrants contain viable B-cells. Comparison of FIG. Two electric field pulse lengths were used for this case: 3.50 
20b and FIG. 20e indicates there was little difference in the and 5.25 ps (FWHM). The total electric field exposure time 
abundance of viable T- and B-cells for the control and PEF 40 was 3.5 ms (1000 applied pulses) for the shortest electric 
treated specimens. However, FIGS. 19b and 19e clearly field pulse length, whereas the total electric field exposure 
show that the CMK cells had been almost entirely elimi- time for the longest electric field pulse was 4.7 ms (900 
nated under the same PEF conditions. pulses). The slight reduction in pulse number for the longer 
FIG. 21 presents the full set of data collected for this case. pulse length experiments was included to keep the total 
In this figure, the surviving percents of the relevant cell 4s electric field exposure time for the longer pulse length 
types (y-axis) are presented as a function of electric field experiments, based on the pulse length at 95% of the peak 
strength (x-axis). Recall that the total electric field exposure electric field strength, approximately the same as for the 
time was constant for each field strength and was produced shorter pulse length experiments. The single pulse energy 
by applying 1000 electric field pulses. The total electric field deposited to the test cells was in the range of 0.003-0.020 
exposure time was 3.6 ms. This figure clearly shows that an so Jipulse. The electric field pulses were applied at 1 Hz. The 
without impacting the viability of the lymphocytes. Also, it C.+i-o.2" C. Based on Eqs. 14, 1% and 1% the average 
is evident that the monocytes were just beginning to be midplane temperature varied over the range from 
affected at 1.8 kVicm, since the monocyte surviving percent 35.01-35.04' C., and the temperature jump per electric field 
curve is beginning to decrease at this field strength. Com- ss pulse varied over the range 0 .001~ .007"  C. One stock cell 
paring the PBMC total surviving percent curves presented in control specimen and test cell control specimen were pre- 
FIGS. 11 and 14 with the lymphocyte surviving percent pared before commencing PEF treatments, and one test cell 
curve in FIG. 21, shows the lethal effects of PEFs occurs at control specimen was prepared after all PEF treatments had 
lower electric field strengths in FIGS. 11 and 14. As already been performed for each set of tests. The controls and PEF 
indicated, the results presented in these examples have been 60 treated specimens (each about 0.72 ml) were placed in 15 ml 
acquired under non-optimized conditions. The differences in centrifuge tubes, to which about 5 ml of IMDM was added 
PEF efficacy found by comparing FIGS. 11 and 14 with FIG. as previously described. These specimens were then ana- 
21 may be due to pulse length and pulsing medium ionic lyzed by flow cytometry for enumeration of viable MCF-~S,  
strength differences. The pulse length for the results in FIG. also as previously described. 
21 was approximately 30% shorter than for the results in 65 For this case, viable MCF-7s were identified as those cells 
FIGS. 11 and 14. Further, the results in FIG. 21 were that fluoresced dimly for both propidium iodide (PI) and 
obtained using a low ionic strength pulsing medium, rather Annexin-V stains. FIG. 22 presents results typical of PEF 
Case 5. PEF Inactivation Characteristics of Breast 
Tumor Cells 
almost 2-10g reduction in CM& was achieved at 1.8 kV/cm end blocks of the test cells were maintained at about 35" 
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inactivation experiments using the MCF-7 cell line. More digestion protocol involved resuspending the trypsinized 
specifically, this figure illustrates the combined effect of cells in a digestion solution (500 ugiml hyaluronidase, 
increasing electric field pulse length and exposure time, as Sigma, H4272 30 mg; 94 mM potassium phosphate 
well as electric field strength. The curve shown by the monobasic, Sigma, p8416; 6 mM Sodium Phosphate 
dashed line represents data obtained by applying 1000 5 dibasic, Sigma, S-5136) and incubating the solution for 30 
electric field pulses, each pulse having a 3.5 ps FWHM pulse minutes at 37" c .  Using standard techniques for mucin 
length. The curve shown by the solid line represents data staining under Optical microscopy it was found that this 
obtained by applying 900 electric field pulses, each pulse digestion protocol essentially entirely removed the extracel- 
having a 5.3 ps FWHM pulse length. Thus, the total electric lular mucin coats. 
field exposure time for the dashed curve was 3,5 ms, While the invention has been shown and described above 
whereas the total electric field exposure time for the solid with reference to various embodiments and 'pecific 
examples, it is to be understood that the invention is not curve was 4.7 ms. limited to the embodiments or examples described and that 
and exposure time resulted in increased tumor cell purging in the art in various additional ways and for various 
efficacy. Further, the 5.3 ps pulse length produced about a 15 additional purposes, 
2.3 log reduction in viable tumor cells. It is important to note What is claimed is: 
that the 2.3 log reduction shown may significantly under- 1. A suspension of cells obtained by practicing a method 
state the efficacy of the PEF process. Optical microscopy comprising the steps of  
indicated that the input cell population included clumps of a. providing a biological sample comprising a cell sus- 
agglomerated cells, each clump containing from about 3-10 20 pension having a given cell population of at least a first 
cells. Thus, the number of viable MCF-7 cells in the control and a second cell type, at least said first cell type being 
specimens, which were used to normalize the data for viable nucleated, wherein said first and second cell types have 
cells contained in the PEF-treated specimens, could be low a difference in at least one property affecting a char- 
by about a factor of 3-10. Thus, the surviving percents acteristic electroporation threshold; 
reported for the PEF-treated specimens could be high by a 25 b. increasing the proportion of viable cells in the cell 
factor of 3-10. In addition, application of PEFs to this cell suspension that are viable cells of said second cell type 
line had two effects: 1) the PEFs breakup the clumps of without exposing the cell population to exogenous 
aggregated cells, and 2) inactivation of the cells. The toxins by: 
breakup of cells was clearly observed by the increase in total i. subjecting the sample to electric field conditions 
events recorded by the cytometer. Total events were 30 sufficient to porate a substantial fraction of cells of 
observed to increase by at least a factor of two once PEFs said first cell type while maintaining substantially 
had been applied to a specimen. It is also believed the viable cells of said second cell type; and 
inflection points in the curves of FIG. 22 could be due to an ii. selectively inactivating at least 90% of the porated 
increase in cell numbers due to disaggregation by the PEFs, cells of said first cell type in the sample subjected to 
followed by subsequent inactivation. Significantly, some of 35 the electric field conditions in step (b)(i), while 
the cells in clumps will be shielded from the PEFs until such maintaining substantially viable cells of said second 
clumps are completely reduced to monodispersed cells. cell type in the sample subjected to the electric field 
Once monodispersed, they can then be inactivated by the conditions in step (b)(i). 
PEFs. Thus the presence of clumped cells in the cell 2. The cell suspension as in claim 1, wherein in step b the 
suspension before treatment would imply that not all of the 40 Proportion of viable cells in the cell suspension that are 
cells in the specimens experienced the Same effective elec- viable cells of said second cell type is increased without 
tric field exposure time. Thus, increasing the electric field exposing the cell Population to exogenous antibodies to cell 
pulse length, may be an effective way to lead to more surface markers. 
efficient PEF clump disaggregation, which, in turn, could 3. The cell suspension as in claim 1, wherein steps b(i) 
allow the use of lower field strengths and possibly shorter 45 and b(ii) are Performed simultaneously. 
exposure times to achieve inactivation of cells that tend to 4. The suspension as in claim 3, wherein said at least one 
clump, like the MCF-7 tumor cells, The MCF-7 tumor cell property affecting a characteristic electroporation threshold 
inactivation results presented here show that at least a 2.3 comprises cell size. 
log reduction in this breast cancer line was achieved at PEF 5 .  The suspension as in claim 4, wherein the electric field 
conditions which led to a 1 log enrichment of stem cells, SO conditions are sufficient to inactivate cells of the sample 
without significant loss of viable stem cells, in Case 3 having a characteristic size greater than a selected threshold 
presented above. size by causing irreversible poration of the cell membrane. 
6. The suspension as in claim 5,  wherein a substantial 
Case 6. Enzymatic Removal of a Glycocalyx fraction of the cells inactivated by said electric field condi- 
Membrane Layer ss tions undergo irreparable cell lysis during the inactivating 
A small fraction of the cells within a given epithelial cell step. 
line, such as the MCF-7 line, secrete a mucopolysaccharide 7. The cell suspension as in claim 1, wherein both said 
(mucin), which can coat the cell plasma membrane. This first and second cell types are nucleated. 
mucin coat can function to increase the effective thickness of 8. The suspension as in claim 1, wherein said at least one 
the membrane of these cells, which can, in turn, require 60 property affecting a characteristic electroporation threshold 
higher electric field strengths for their inactivation. The comprises cell size. 
inventors have experimentally determined, using standard 9. The suspension as in claim 1, wherein at least 99% of 
mucin stains and optical microscopy, that a fraction of the the porated cells of said first cell type are selectively 
MCF-7 cells have a mucin coat and that the coat can be inactivated in step (b)(ii). 
removed by enzyme digestion. To achieve this, the MCF-7s 65 10. The suspension as in claim 9, wherein at least 
were subjected to a hyaluronidase digestion protocol just 99.99999% of the porated cells of said first cell type are 
prior to their suspension in the pulsing medium. The mucin selectively inactivated in step (b)(ii). 
FIG. 22 clearly shows that increasing PEF Pulse length the teachings of this invention may be practiced by one 
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11. The suspension as in claim 10, wherein essentially all 
of the porated cells of said first cell type are selectively 
inactivated in step (b)(ii). 
18. The cell suspension as in claim 16, wherein said stem 
cells comprise at least one of the following: mesenchymal 
stem cells; embryonic stem cells; epithelial stem cells; gut 
12. A cell suspension comprising: stem cells; liver progenitor cells; endocrine progenitor cells; 
a plurality of biological cells suspended in a liquid 5 skin stem cells; or neural stem cells. 
including a first population of cells having a maximum 19. The cell suspension as in claim 16, wherein said stem 
characteristic size not more than a predetermined value cells include hematopoietic stem cells. 
that are substantially viable and a second population of 20. The cell suspension as in claim 19, further comprising 
nucleated cells having a maximum characteristic size at least one population of cells selected from the group 
greater than said predetermined value that are substan- 10 consisting of  colony forming cells for granulocytes and 
tially non-viable, said cell suspension being essentially macrophages (CFC-GM), colony forming cells for erythro- 
free of exogenous toxins and being obtained from a cytes (BFU-E), colony forming cells for eosinophils (CFC- 
precursor cell suspension comprising substantially Eo), multipotent colony forming cells (CFC-GEMM), and 
viable cells, which precursor cell suspension contains immature lymphoid precursor cells. 
as subpopulations said first and second populations of 15 21. The cell suspension as in claim 16, wherein said stem 
cells, said cell suspension being obtained by increasing cells include stem cells that are essentially free of cell 
the proportion of viable cells in said precursor cell surface CD34 markers. 
suspension that are viable cells of said first population 22. The cell suspension as in claim 12, wherein the cell 
of cells by: suspension is essentially free of exogenous antibodies to cell 
subjecting the precursor cell suspension to an electric 20 surface markers. 
23. The cell suspension as in claim 12, wherein said first 
population of cells is nucleated. 
24. The suspension as in claim 12, wherein a substantial 
fraction of the cells inactivated by said electric field undergo 
25. The suspension as in claim 12, wherein at least 99% 
of the cells of said second population are inactivated in the 
subjecting step. 
26. The suspension as in claim 25, wherein at least 
30 99.99999% of the cells of said second population are inac- 
tivated in the subjecting step. 
27. The suspension as in claim 26, wherein essentially all 
of the cells of said second population are inactivated in the 
subjecting step. 
field of a magnitude and duration sufficient to porate 
a substantial fraction of cells of said second cell 
population in the precursor suspension and inactivate 
at least 90% of cells of said second population 
porated by the electric field, while maintaining sub- 25 irreparable cell lysis during the subjecting step. 
stantially viable cells of said first population. 
13. The cell suspension as in claim 12, wherein said 
14. The cell suspension as in claim 13, wherein said 
15. The cell suspension as in claim 12, wherein said 
16. The cell suspension as in claim 12, wherein said first 
17. The cell suspension as in claim 16, wherein said stem 35 
biological cells are derived from an animal. 
animal is a human. 
second population of cells include cancer cells. 
population of cells include stem cells. 
cells include pluripotent stem cells. * * * * *  
